Nothing Special   »   [go: up one dir, main page]

EP0963443B1 - Molecules d'etiquetage massique, non volatiles et liberables - Google Patents

Molecules d'etiquetage massique, non volatiles et liberables Download PDF

Info

Publication number
EP0963443B1
EP0963443B1 EP97954072A EP97954072A EP0963443B1 EP 0963443 B1 EP0963443 B1 EP 0963443B1 EP 97954072 A EP97954072 A EP 97954072A EP 97954072 A EP97954072 A EP 97954072A EP 0963443 B1 EP0963443 B1 EP 0963443B1
Authority
EP
European Patent Office
Prior art keywords
mass
probe
nucleic acid
probes
label
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97954072A
Other languages
German (de)
English (en)
Other versions
EP0963443A4 (fr
EP0963443A1 (fr
Inventor
Joseph A. Montforte
Christopher H. Becker
Daniel J. Pollart
Thomas A. Shaler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sequenom Inc
Original Assignee
Sequenom Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequenom Inc filed Critical Sequenom Inc
Publication of EP0963443A1 publication Critical patent/EP0963443A1/fr
Publication of EP0963443A4 publication Critical patent/EP0963443A4/fr
Application granted granted Critical
Publication of EP0963443B1 publication Critical patent/EP0963443B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/932—Specified use of nanostructure for electronic or optoelectronic application
    • Y10S977/953—Detector using nanostructure
    • Y10S977/957—Of chemical property or presence
    • Y10S977/958—Of biomolecule property

Definitions

  • the present invention relates generally to the field of chemical analysis. More particularly, it concerns a new class of nonvolatile, releasable tag reagents for use in the detection and analysis of target molecules e.g ., mass spectrometry.
  • Chemical labels otherwise known as tags or signal groups, are widely used in chemical analysis. Among the types of molecules used are radioactive atoms, fluorescent reagents, luminescent reagents, metal-containing compounds, electron-absorbing substances and light absorbing compounds. Chemical signal groups can be combined with reactivity groups so that they might be covalently attached to the target, the substance being detected. In many cases, however, chemical moieties present on the target may interfere with the detection of the signal group or not allow for measurement of the signal group in an optimal detection environment.
  • the signal group may be the product of the degradation of the target or a derivative of the target (Bueht et . al., 1974; Senft, 1985; U.S. Patent 4,650,750; U.S. Patent 4,709,016; U.S. Patent 4,629,689).
  • Volatile releasable tag compounds that can be analyzed using various forms of electron-attachment mass spectrometry, often with gas chromatography-mass spectrometry (GC-MS), have been described (Wang et al., 1996; U.S. Patent 5,360,819; U.S. Patent 5,516,931).
  • Isotopic mass labels have also been described, such as using tin or sulfur isotopes, with various mass spectrometric sampling approaches (Arlinghaus et al. 1997; U.S. Patent 5,174,962). Jacobson et al. ( Gen. Analy. Techniques Appl. 8(8): 223-229 (1996) discloses use of isotopic labels (sulfur, tin and iron) for direct detection of oligonucleotides by mass spectrometry. Sloop et al. ( Bioconjugate Chem.
  • TESPA Trimethylstannyl propanoic acid
  • N-succinimidyl ester of TESPA for use as a mass label for oligonucleotides.
  • the isotopic labeling often limits the extent of multiplexing and provides a more complex analysis requirement.
  • U.S. Patent No. 4,775,619 discloses compounds that provide for the indirect detection of sample nucleic acids by interacting sample nucleic acids with a reagent polynucleotide containing a cleavable label, cleaving the label, and detecting the sample nucleic acid by detecting the label.
  • WO 94/21822 discloses compounds used in the methods of determining the sequence of a nucleic acid by cleaving nucleic acids with exonucleases to sequentially release individual nucleotides and identifying each nucleotide by mass spectrometry.Hayes F.J. (Dissertation Abstracts Internat.
  • Mass spectral analysis of signal groups involves none of the concerns related to radioactive signal groups, such as their short half-lives and their safety and disposal issues. Another key advantage to detection of signal groups via mass spectrometry is that it allows a great ability to multiplex, to detect for more than one signal group in a complex mixture, and therefore more than one target at a time. Brummel et al . (1994; 1996) have demonstrated the use of mass spectrometry in the direct analysis of combinatorial libraries of small peptides. However, use of this technology is limited to analysis of the entire reacting compound by mass spectrometry.
  • Nucleic acid hybridization probes are modified to contain fluorescent chromophores that when excited by light emit a unique color spectrum signature.
  • fluorescent chromophores that when excited by light emit a unique color spectrum signature.
  • four different chromophores can be multiplexed within a sample and individually detected with the aid of software deconvolution.
  • the practical upper limit for fluorescence multiplexing is likely to be around 10 different labels due to the broad overlapping spectrum produced by existing fluorescent chromophores.
  • nonvolatile releasable mass labels detectable over the usable range of a mass spectrometer, would represent a significant advantage by permitting the multiplexing of tens, hundreds and perhaps even thousands of different mass labels that can be used to uniquely identify each desired target.
  • compositions and methods relating to the use of release tag compounds for detection and analysis of target molecules It is, therefore, a goal of the present invention to provide compositions and methods relating to the use of release tag compounds for detection and analysis of target molecules.
  • the present invention relates to the use of nonvolatile, releasable tag compounds, containing releasable mass labels, in chemical analysis, and to the use of these reagents in conjunction with probes which react with or bind noncovalently to a molecule whose presence is to be detected.
  • the releasable tag reagents thus may indirectly detect target molecules, including biomolecular targets.
  • the mass label may be released from the probe following reaction with or binding of the probe to the target and detected by mass spectrometry. The mass value of the label identifies and characterizes the probe and, therefore; the target molecule.
  • a release tag compound comprising Rx, Re and M, wherein Rx is a reactive group, Re is a release group, and M is a mass label detectable by mass spectrometry.
  • Rx is a reactive group
  • Re is a release group
  • M is a mass label detectable by mass spectrometry.
  • the mass label may typically be a synthetic polymer or a biopolymer or some combination thereof.
  • the mass label may be a biopolymer comprising monomer units, wherein each monomer unit is separately and independently selected from the group consisting essentially of an amino acid, a nucleic acid, and a saccharide with amino acids and nucleic acids being preferred monomer units. Because each monomer unit may be separately and independently selected, biopolymer mass labels may be polynucleic acids, peptides, peptide nucleic acids, oligonucleotides, and so on.
  • nucleic acids refer to standard or naturally-occurring as well as modified/non-natural nucleic acids, often known as nucleic acid mimics.
  • nucleotides refer to both naturally-occurring and modified/nonnaturally-occurring nucleotides, including nucleoside tri, di, and monophosphates as well as monophosphate monomers present within polynucleic acid or oligonucleotide.
  • a nucleotide may also be a ribo; 2'-deoxy; 2', 3'-deoxy as well as a vast array of other nucleotide mimics that are well-known in the art.
  • Mimics include chain-terminating nucleotides, such as 3'-O-methyl, halogenated base or sugar substitutions; alternative sugar structures including nonsugar, alkyl ring structures; alternative bases including inosine; deaza-modified; chi, and psi, linker-modified; mass label-modified; phosphodiester modifications or replacements including phosphorothioate, methylphosphonate, boranophosphate, amide, ester, ether; and a basic or complete internucleotide replacements, including cleavage linkages such as photocleavable nitrophenyl moieties.
  • modifications are well known by those of skill in the art and based on fundamental principles as described Saenger (1983).
  • amino acid refers to naturally-occurring amino acid as well as any modified amino acid that may be synthesized or obtained by methods that are well known in the art.
  • the mass label may be a synthetic polymer, such as polyethylene glycol, polyvinyl phenol, polyproplene glycol, polymethyl methacrylate, and derivatives thereof.
  • Synthetic polymers may typically contain monomer units selected from the group consisting essentially of ethylene glycol, vinyl phenol, propylene glycol, methyl methacrylate, and derivatives thereof. More typically the mass label may be a polymer containing polyethylene glycol units.
  • the mass label is typically detectable by a method of mass spectrometry. While it is envisioned that any known mass spectrometry method may be used to detect the mass labels of the present invention, methods such as matrix-assisted laser-desorption ionization mass spectrometry, direct laser-desorption ionization mass spectrometry (with no matrix), electrospray ionization mass spectrometry, secondary neutral mass spectrometry, and secondary ion mass spectrometry are preferred.
  • the mass label has a molecular weight greater than about 500 Daltons, and is a nonvolatile (including involatile) mass label.
  • the term "reactive group” refers to a group capable of reacting with the molecule whose presence is to be detected.
  • the reactive group may be a biomolecule capable of specific molecular recognition.
  • Biomolecules capable of specific molecular recognition may typically be any molecule capable of specific binding interactions with unique molecules or classes of molecules, such as peptides or proteins.
  • polypeptides refer to molecules containing more than one amino acid (which include native and non-native amino acid monomers.
  • polypeptides includes peptides comprising 2 or more amino acids; native proteins; enzymes; gene products; antibodies; protein conjugates; mutant or polymorphic polypeptides; post-translationally modified proteins; genetically engineered gene products including products of chemical synthesis, in vitro translation, cell-based expression systems, including fast evolution systems involving vector shuffling, random or directed mutagenesis, and peptide sequence randomization.
  • polypeptides may be oligopeptides, antibodies, enzymes, receptors, regulatory proteins, nucleic acid-binding proteins, hormones, or protein product of a display method, such as a phage display method or a bacterial display method. More preferred polypeptide reactive groups are antibodies and enzymes.
  • product of a display method refers to any polypeptide resulting from the performance of a display method which are well known in the art. It is contemplated that any display method known in the art may be used to produce the polypeptides for use in conjunction with the present invention.
  • the reactive group may contain a nuclease blocking moiety.
  • nuclease blocking moieties serve to block the digestion of the oligonucleotide by the nuclease, such as an exonuclease.
  • Typical nuclease blocking moieties thus include phosphorathioate, alkylsilyldiester, boranophosphate, methylphosphonate, and peptide nucleic acid.
  • the mass label is linked, or attached, to the reactive group via a releasable attachment.
  • a releasable attachment typically occurs through the use of a release group which may be the linkage between the mass label and the reactive group or which may comprise a portion or all of the reactive group or which may be contained within the reactive group.
  • the release group may be any labile group providing for such a releasable attachment.
  • the release group may thus be a chemically cleavable linkage or labile chemical linkage.
  • Such linkages may typically be cleaved by methods that are well known to those of skill in the art, such as by acid, base, oxidation, reduction, heat, light, or metal ion catalyzed, displacement or elimination chemistry.
  • the chemically cleavable linkage comprises a modified base, a modified sugar, a disulfide bond, a chemically cleavable group incorporated into the phosphate backbone, or a chemically cleavable linker.
  • linkages are described in PCT WO 96/37630.
  • chemically cleavable linkers are moieties cleavable by, for example, acid, base, oxidation, reduction, heat, light, metal ion catalyzed, displacement or elimination chemistry.
  • Chemically cleavable groups that may be incorporated into the phosphate backbone are well known to those of skill in the art and may include dialkoxysilane, 3'-(S)-phosphorothioate, 5'-(S)-phosphorothioate, 3'-(N)-phosphoroamidate, or 5'-(N)-phosphoroamidate.
  • the chemically cleavable linkage may be a modified sugar, such as ribose.
  • the linkage may be a disulfide bond.
  • Re is contained within Rx.
  • the release of Re may be activated by a selective event.
  • the selective release is mediated by an enzyme such as an exonuclease specific for double-stranded or single-stranded DNA.
  • release groups encompassed by the invention also include groups or linkages cleavable by an enzyme.
  • Enzymatically-cleavable release groups include phosphodiester or amide linkages as well as restriction endonuclease recognition sites.
  • Preferred embodiments encompass release groups cleavable by nucleases. These nucleases may typically be an exonuclease or a restriction endonuclease. Typical exonucleases include exonucleases specific for both double-stranded and single-stranded polynucleic acids. Additionally, restriction endonucleases encompassed by certain embodiments include Type IIS and Type II restriction endonucleases.
  • the release group may be cleavable by a protease.
  • Typical proteases include endoproteinases.
  • mass-labeled probes are provided wherein at least one component is a nucleoside triphosphate. It is further contemplated that the labeled probes of the invention may include at least two unique mass-labels are incorporated.
  • the mass label of at least one member of the set may identify a specific sequence within the variable region.
  • the mass label for each member of the set may uniquely identify each different sequence within the variable region.
  • a combination of the mass labels of two or more release tag compounds may identify each different sequence within the variable region.
  • Methods of producing a mass-labeled probe comprising combining nucleoside or amino acid monomers with at least one mass-labeled monomer under conditions to allow for polymerization.
  • polymerization is mediated by an enzyme. Still further embodiments are provided wherein the polymerization is mediated by chemical synthesis.
  • the preferred synthetic methods to prepare the compound of the present invention are essentially those for standard peptide and DNA synthesis.
  • synthesis in the solid phase is preferred to allow for a wide variety of compounds to be produced using combinatorial methods.
  • Additional embodiments are provided for a method of producing a mass-labeled probe, comprising the steps of (a) combining nucleoside monomers with at least one activated nucleoside monomer under conditions to allow for polymerization; and (b) adding a releasable, nonvolatile mass unit to said activated nucleoside monomer.
  • the present invention also provides embodiments which provide a method for detecting a target molecule.
  • the method includes obtaining a plurality of probes, each probe including a reactive group, a release group and a mass label, as described. It is preferred that each probe within the plurality contains a unique mass-label.
  • unique mass label it is meant that each probe within the plurality will have a different mass label from all other probes in the plurality.
  • a plurality will generally be understood to include two or more probes.
  • the target molecule is contacted with the plurality of probes under conditions suitable to allow for the formation of probe: target molecule complexes.
  • the mass-label is released from the probe and the mass of the mass-label is determined. Typically, the mass is indicative of a specific target molecule. In this way, the target molecule can be identified according to the unique combination of mass-labels.
  • the invention provides a method for detecting a target molecule where the target molecule is amplified to produce an amplified target molecule.
  • the amplified target molecule is then hybridized with a probe such as those described hereinabove to produce probe: amplified target molecule complexes.
  • the mass label on the probe amplified target molecule complexes are then released and the mass of the mass label determined by mass spectrometry.
  • the target nucleic acid may be amplified by any method known by one of skill in the art, for example, polymerase chain reaction ("PCR"), with PCR being a preferred amplification method.
  • the amplification may include a functional group capable of being immobilized on a solid support, such as biotin or digoxigcnin. This functional group may be attached to an oligonucleotide primer incorporated into the amplified molecule during the amplification step or it may be attached to a nucleotide incorporated into the amplified target molecule during the amplification step.
  • the amplified target molecule is immobilized onto a solid support and any probe not part of a probe:amplified target molecule complex is removed by washing.
  • the nature of the recognition of the target molecule by the reactive group will depend on the identity of the target molecule and the reactive group. For purposes of exemplification and not limitation, this recognition may encompass the formation of a double-stranded duplex by hybridization where the reactive group and target molecule are oligonucleotides. The mass label may be released enzymatically or chemically.
  • useful enzymes for this embodiment will include nucleases, such as Type II and IIS restriction endonuclease and exonucleases.
  • the envisioned exonucleases may be specific for double-stranded DNA, such as exonuclease III, T4 endonuclease VII, lambda exonuclease, and DNA polymerase.
  • the release of the mass label may be triggered by the hybridization of the probe to the amplification product.
  • the probe would be single-stranded and capable of hybridizing to the target whose presence was to be detected.
  • the exonuclease may also be specific for single-stranded DNA.
  • Chemically cleavable linkages may comprise a modified base, a modified sugar, a disulfide bond, a chemically cleavable group incorporated into the phosphate backbone, or a chemically cleavable linker and are typically cleaved by acid, base, oxidation, reduction, heat, light, or metal ion catalyzed, displacement or elimination chemistry.
  • the reactive group further comprises a nucleotide or oligonucleotide added after hybridization to the amplification product, amplified target molecule or amplified nucleic acid molecule.
  • a nucleotide or oligonucleotide added after hybridization to the amplification product, amplified target molecule or amplified nucleic acid molecule.
  • These added nucleotides or oligonucleotides may optionally include a functional group capable of being immobilized on a solid support.
  • any probes having unbound reactive groups are removed prior to releasing the mass label of any probe belonging to a probe:amplified target molecule complex or probe:target molecule complex.
  • the reactive and release groups may be the same or the release group may be contained within the reactive group.
  • the probe may also comprise at least two unique mass labels.
  • each reactive group of the probe may be associated with a unique mass label or it may be associated with a unique set of mass labels.
  • a target molecule may be detected by the mass spectral detection of a particular mass label or a particular set of mass labels.
  • the set of mass labels may be attached to the same probe. Alternatively, each member of the set may be attached to a different probe.
  • the amplified nucleic acid product comprises a double-stranded molecule containing a mismatch, and an exonuclease-blocking functionality at the 3' ends of the strands.
  • this method may further comprise cleavage of at least one strand of the double-stranded molecule at the site of the mismatch; and selective releasing of the mass label.
  • Selective releasing of the mass label may typically be accomplished by digestion of the cleaved strand by a 3' to 5' exonuclease, such as exonuclease III.
  • selective releasing comprises to the releasing of a mass label from a probe which belongs to a probe:target molecule complex without releasing a mass label from a probe not belonging to such a complex without having to physically partition the two types of probes.
  • some embodiments may include both selective releasing and physical partitioning.
  • the described immobilization and washing techniques exemplify a method of physical partitioning.
  • the mismatch may be cleaved by an enzyme, such as mutHLS, T4 endonuclease VII, mutY DNA glycosylase, thymine mismatch DNA glycosylase, or endonuclease V.
  • the mismatch may also be cleaved by a chemical, such as OsO 4 , HONH 2 , or KMnO 4 .
  • the invention further provides a method for detecting a target molecule including the steps of: (a) obtaining a probe including a reactive group, a release group and a nonvolatile mass label; (b) contacting a target molecule with the probe to produce probe:target molecule complexes; (c) the selectively releasing the mass label from the probe:target molecule complexes to produce released mass labels; and (d) determining the mass of the released mass labels by mass spectrometry.
  • cleavage means that are inhibited by the presence of a double-stranded oligonucleotide at the said release group.
  • at said release group means that base pairing is maintained on both sides of the release group by at least one nucleotide.
  • contacting the probe with the target molecule typically results in the release group being present in a single-stranded region because one strand of the probe interacts with the target molecule, for example, by hybridizing to it.
  • Another aspect of the invention encompasses a method for multiplexing the detection of a target molecule including: (a) obtaining a plurality of probes, each probe including a reactive group, a release group and a mass label; (b) contacting the target molecule with the plurality of probes to produce probe:target molecule complexes; (c) releasing the mass label from any probe belonging to probe:target molecule complexes to produce released mass labels; and (d) determining the mass of any released mass label by mass spectrometry.
  • each reactive group recognizing a specific target molecule is associated with a unique set of mass labels. It may often be preferred that a plurality of target molecules with the plurality of probes.
  • the members of the set of mass labels may be attached to the same probe or to different probes. Additionally, the same mass label may be a member of sets identifying more than one reactive group. Thus, in this embodiment the set of mass labels, and not the individual mass label, is unique to a particular reactive group. In this embodiment, probes having a reactive group that identifies a particular target may vary in release group and mass label as well as in other respects.
  • Immobilization and washing techniques may be employed with this embodiment and it may be preferred in some embodiments to immobilize a plurality of target molecules onto the solid support at spaced locations and to then contact them with the mass-labeled probes.
  • Typical target molecules include a polynucleotide, an antigen, a ligand, a polypeptide, a carbohydrate, and a lipid.
  • mass label A could correspond to a reactive group composed of A'X 2 ...X N functionalities where A can be anywhere in the reactive group and only represents A' and may or may not be structurally related to A' in any way.
  • detecting mass label results in the detection of a target molecule that recognizes A', but does not necessarily identify anything else about the structure or composition of the target molecule.
  • the unique set of mass labels comprises a mass label that indicates the presence of a specified component within the reactive group. Further embodiments also include methods wherein the mass label indicates the presence of the specified component at a specified location within the reactive group.
  • a reactive group comprising n specified components may be associated with a unique set of mass labels having n members where n may typically be from 1 to 1000. Generally, mass labels are individually attached to the reactive group and are identified intact.
  • a reactive group comprising n specified components may also be associated with a unique set of mass labels having y members wherein n is less than y!/[x!(y-x)!]; and wherein x comprises the number of mass labels per reactive group.
  • a plurality of probes may each comprise a known reactive group having a known set of mass labels and the plurality of probes may be prepared by combinatorial synthesis.
  • the plurality of target molecules may also comprise a known chemical structure.
  • Also provided is a method of monitoring gene expression including (a) obtaining a plurality of probes, each including a reactive group, a release group and a mass label; (b) contacting a plurality of target nucleic acids with the plurality of probes to produce probe:target nucleic acid complexes; (c) selectively releasing the mass label from any probe belonging to a probe:target nucleic acid complexes to produce released mass labels; and (d) determining the mass of any released mass label by mass spectrometry.
  • the target nucleic acids may have sequences representative of the genes being expressed in a particular cell culture and are present in concentrations related to their mRNA abundance levels.
  • the target nucleic acids may typically comprise mRNA or first-strand cDNA as well as amplified nucleic acid products.
  • Such amplified nucleic acid products may be produced using PCR, rtPCR, LCR, Qbeta Replicase, SDA, CPR, TAS, NASBA, or multiple rounds of RNA transcription or some combination thereof.
  • Amplification may be used to selectively amplify a subset of the mBNA pool increasing detection signal for these gene products and reducing background from gene products outside of the amplified subset.
  • Another embodiment encompasses a method of monitoring gene expression including amplifying a subset of an mRNA pool to produce a plurality of amplified nucleic acid products; contacting a plurality of amplified nucleic acid products with a plurality of probes, each probe including a reactive group, a release group and a mass label to produce probe:amplified nucleic acid product complexes selectively releasing the mass label from any probe belonging to a probe:amplified nucleic acid produce complexes to produce released mass labels determining the mass of any released mass label by mass spectrometry.
  • one more probes or amplified nucleic acid products may be capable of being immobilized onto a solid support.
  • Another aspect of the invention is a method for detecting a target molecule, including contacting a target molecule with a probe including a reactive group, a release group and a nonvolatile mass label to produce probe:target molecule complexes; releasing the mass label from any probe belonging to a complex to produce released mass labels; selectively desorbing the released mass label from the mass spectral matrix such that the probes not belonging to probe:target molecule complexes do not desorb; and determining the mass of the released mass label by mass spectrometry.
  • the mass label should desorb more efficiently from the mass spectral matrix than the probe or the mass-labeled probe.
  • Preferred mass spectral matrices include 2,5-dihydroxybenzoic acid, sinapinic acid, or alpha-cyano-4-hydroxycinammic acid.
  • a method for detecting a target molecule includes amplifying one or more target nucleic acids to produce amplified nucleic acid products; incorporating one or more molecules including a reactive group, a release group and a nonvolatile mass label into the amplified nucleic acid product during the amplification process; selectively releasing the mass labels incorporated into the amplified nucleic products to produce released mass labels; and determining the mass of the released mass labels by mass spectrometry.
  • Incorporated molecules may be oligonucleotide primers and nucleoside triphosphates and the amplified nucleic acid products are produced using PCR, rtPCR, LCR, Qbeta Repiicase, SDA, CPR, TAS, NASBA, or multiple rounds of RNA transcription or some combination thereof.
  • One or more second molecules each including a functional group capable of being immobilized on a solid support, may also be incorporated into the amplified nucleic acid products. The functional group may also be used to bind the amplified nucleic acid products to a solid support, and separate incorporated mass labeled molecules from unincorporated mass labeled molecules.
  • the amplified nucleic acid products may also be preferable to separate the amplified nucleic acid products from the unincorporated mass labeled molecules, for example, by binding the amplified nucleic acid products to a solid support or by hybridizing the amplified nucleic acid products to a polynucleotide bound to solid support.
  • the bound polynucleotide may be an oligonucleotide, a polyribonucleotide, a plasmid, an M13, a cosmid, a P1 clone, a BAC or a YAC.
  • a plurality of these polynucleotides may also be immobilized onto the solid support at spaced locations.
  • Also provided is a method for detecting the presence of a target nucleic acid molecule comprising: obtaining a probe comprising a reactive group, a release group and a mass label; contacting the probe to a target nucleic acid molecule to produce probe:nucleic acid molecule complexes; mass modifying the probe:nucleic acid molecule complexes by attaching a nucleotide or oligonucleotide to the probe to produce mass modified mass labels; releasing the mass modified mass labels; and determining the mass of the mass-modified mass labels by mass spectrometry.
  • Another embodiment encompasses a method for detecting specific biomolecules in an enzyme-linked affinity assay comprising: obtaining a substrate; contacting a target molecule with an affinity ligand-enzyme conjugate to produce an affinity ligand-enzyme conjugate:target molecule complex; contacting the affinity ligand-enzyme conjugate:target molecule complex with the substrate to produce a mass modified product; and determining the mass of the mass modified product by mass spectrometry.
  • affinity ligands are groups, molecules, or moieties having an affinity for, or reacting with a particular target molecule, similar to the reactive groups employed with the mass label probes disclosed above.
  • the affinity ligand may be a biomolecule capable of specific molecular recognition, such as a polypeptide or polynucleic acid.
  • Preferred polypeptides include antibodies, enzymes, receptors, regulatory proteins, nucleic acid-binding proteins, hormones, and protein products of a display method, such as products of a phage display method or a bacterial display method.
  • the enzymes conjugated to these affinity ligands may be any enzyme that catalyze the conversion of the substrate to a product having a different mass, such as restriction endonucleases and proteases. Thus, the mass of the substrate has been modified in the production of the product by the enzyme.
  • Affinity ligand-enzyme conjugates are molecules where the affinity ligand and enzyme have been attached by the formation of covalent or noncovalent interactions, including hydrogen bonds.
  • the various endonucleases may be conjugated to the affinity ligand to form several affinity ligand-enzyme conjugates which are then contacted with the target molecule.
  • the substrate may be any molecule whose conversion to a mass-modified product is accomplished by the enzyme employed such as a polypeptide.
  • the enzyme employed such as a polypeptide.
  • it may therefore comprise a restriction site.
  • FIG. 1A and FIG. 1B show generalized examples of two mass-labeled building blocks for the preparation of mass-labeled polynucleotides, a mass-labeled nucleoside triphosphate (FIG. 1A) and a mass-labeled nucleoside phosphoramidite (FIG. 1B).
  • B refers to a base
  • R to an optional releasing linkage
  • M to a mass label.
  • Mass labels may also be added after polynucleotide synthesis via linker reagents.
  • FIG 2A and FIG. 2B show examples of a mass-labeled probe where the releasable group is contained within the reactive group and the released mass-label includes one or more monomers of the reactive group.
  • oligonucleotide primer that can be extended (Step A) by polymerase using nucleoside triphosphates, including deoxy and dideoxyribonucleotide or combinations thereof, or by ligase using oligonucleotides.
  • Ligase may be used to attach oligonucleotides to the 5' as well as the 3' end.
  • Nucleotides and oligonucleotides added as well as nucleotide monomers within the probe may optionally consist of modified nucleotides or non-natural, mimic nucleotides.
  • Step B a solid-phase binding group such as biotin
  • Step C a solid-phase binding group
  • the non-reactive group component of the mass label is indicated by Mx, where the x signifies that this component may have a single molecular mass or it may represent a combination of 2 or more molecules of defined mass.
  • the Mx component may be optionally contained fully within the reactive group and may be comprised of nucleotides or non-natural, mimic nucleotides. Determining the mass of the mass-label product provides the means for identifying the nucleotide composition and sequence of bases immediately adjacent to the probe.
  • FIG. 2B illustrates the specific case where the mass-labeled probe functions as a primer to detect a single nucleotide polymorphism.
  • Step A following hybridization to a template nucleic acid, a polymerase is used to add a single nucleotide chain terminator or mass-modified version thereof, selecting from the four possible bases.
  • the mass-labeled product is released (Step B) and analyzed by mass spectrometry (Step C).
  • the probe optionally comprises a solid-phase binding group that may be used to bind and wash the probe prior to the releasing step.
  • a T chain terminator is added increasing the mass of the mass-label product by 298 Da, indicating the presence of an A within the template at the targeted position.
  • FIG. 2C illustrates a different embodiment for the use of a mass-labeled probe in the determination of single nucleotide polymorphisms.
  • a mass-labeled probe is hybridized to a template and is extended by polymerase which incorporates a single chain-terminating nucleotide (Step A).
  • the chain terminating nucleotide is modified to contain a solid-phase binding group such as biotin (labeled B) that is used to capture the extended mass-labeled primer prior to release of the mass-label product (Step D).
  • the probe is being used to identify whether or not an A nucleotide is present in the position adjacent to where the probe hybridizes.
  • Step B Use of a washing step (Step C) prior to release (Step D) will remove any probes that have not incorporated T, removing their mass labels from the system. Only probes that were bound to the solid phase (Step B) will be detected in the mass spectrometer (Step E).
  • the mass label is indicated by Mx, where the x signifies that this component may have a single molecular mass or it may represent a combination of 2 or more molecules of defined mass.
  • the release group, Re may be placed in the linker connecting the mass label to the probe, or at any position within the backbone of the probe. This methodology may be extended to cases where a combination of nucleotides and chain-terminating nucleotides are used, as well as oligonucleotides, where particular components are selected to contain a solid-phase binding group.
  • FIG. 3A and FIG. 3B illustrate a generalized scheme to produce a mixture of nucleic acid probes each with a unique single or combination of mass labels (FIG. 3A) and, in particular, a generalized scheme to incorporate mass-labeled nucleotides or oligonucleotides into a polynucleotide sequence using DNA polymerase (Step A) or ligase (Step B) (FIG. 3B).
  • FIG. 3A illustrates a nucleic acid probe containing an invariant region and a variable region.
  • the invariant region which is optional, carries the same or near the same sequence for all probes within a family.
  • the variable region contains all possible sequences or some subset thereof. As an example, if the variable region is 4 nucleotides in length 256 different probes can be made, if the variable region is 6 nucleotides in length 4096 different probe can be made.
  • Associated with each probe sequence is a single or combination of mass labels. In either case, the mass labels chosen are unique to each sequence. In cases where combinations are used the mass labels (labeled M) may be single labels attached to different probes carrying the same sequence or multiple labels attached to a single probe, or some combination thereof.
  • FIG. 3B illustrates two embodiments where the mass-labeled family of probes may be used to screen a nucleic acid template.
  • the probes may be extended using either polymerase (Step A) or ligase (Step B).
  • Step A polymerase
  • Step B ligase
  • nucleotides or oligonucleotides may be used that carry additional mass labels (labeled M*) identifying the sequence of the nucleic acid product being added, therefore enlarging the total template sequence determined per probe hybridization event.
  • the template is bound to the solid phase.
  • the nucleotides or oligonucleotides added to the probe may contain a solid-phase binding group, enabling the isolation of the probe and attachment via solid-phase capture.
  • X-Y represents Watson-Crick base pairing in the variable region of the probe
  • N-M represents Watson-Crick base pairing in the added nucleotide or oligonucleotide sequence.
  • FIG. 4A, FIG. 4B, and FIG. 4C illustrate different combinatorial approaches to preparing mass labeled probes (FIG. 4A) , using mass-labeled probes to screen a vector insert (FIG. 4B) , and enzymatic methods, including transcription and PCR for the preparation of large mass-labeled polynucleotide probes (FIG. 4C) .
  • FIG. 4A describes an example of how combinatorial labels may be used to label a complex set of oligonucleotides.
  • the example describes a set of probes that have a variable region 4 nucleotides long comprising 256 possible sequence combinations. Variable regions shorter or longer are also possible.
  • C it is shown how a set of 16 different mass labels may be used to create a mass label signature that is unique for all 256 combinations.
  • Two different approaches may be used to creating the labeled probes, the first (A) being the use of 16 different phosphoramidites each containing a different mass label that are used according to the base and position of synthesis. This approach leads to a set of molecules each with 4 labels on them and is performed as a single reaction.
  • Variants are possible where the synthesis is split into multiple pots and standard phosphoramidite are used in some positions to reduce the number of labels per molecule.
  • the second combinatorial approach (B) is to presynthesize the 256 combinations in 16 different reactions prior to adding the mass labels, each of which is used to define one of the 4 bases in one of the 4 positions. Following oligonucleotide synthesis, each of the 16 different reactions is coupled to one of 16 different mass labels. The end product is that each probe in the pool contains only one specific mass label.
  • the second approach offers greater flexibility for the placement and type of the mass label since it is not coupled directly to the oligonucleotide synthesis.
  • the synthesis may optionally include an invariant synthetic region as shown in FIG. 4A.
  • the variable region may also include one or more discontinuous bases within the invariant region.
  • FIG. 4B describes how the combinatorially labeled probes may be used to screen polymorphic sequences that are adjacent to the insert sequences within cloning vectors (A), including cDNA and genomic clones.
  • A cloning vectors
  • the use of an invariant sequence within the probes allows the probes to be anchored at the junction between the known vector sequence and the unknown insert sequence with the invariant region of the probe hybridizing to the known sequence and the variable region selecting its complement in the unknown region (B).
  • Methods utilizing these probes include simple hybridization to one or both of the clone insert ends, nucleotide or oligonucleotide extensions as described in FIG. 3B, and use of the probes for primer extension to make a single copy of the insert or for purposes of amplification.
  • FIG. 4C illustrates two different methods for creating mass-labeled polynucleotide probes by either transcription (A) or PCR amplification (B).
  • Use of RNA transcription to synthesize mass-probes is limited to sequence regions that are downstream from a promoter sequence (labeled P). Typical synthetic procedures would utilize RNA polymerase and ribonucleoside triphosphates, including mass-labeled versions that may carry one or more mass labels.
  • Shown in (A) is a transcription vector carrying a transcription promoter and a clone insert sequence to be transcribed downstream.
  • the vector also carries one or more restriction sites (labeled R) that may optionally be cut to control the length of transcripts.
  • PCR amplification requires the use of two opposing primers to enable exponential amplification of the sequence located between them.
  • One or more mass labels may be placed on one or both of the primers or optionally incorporated through the use of mass-labeled nucleoside triphosphates.
  • FIG. 5A and FIG. 5B illustrate schemes for detecting mutations using mismatch specific techniques with enzymatically sythesized mass-labeled probes.
  • the methodology requires the cross hybridization of normal and mutant or polymorphic nucleic acid to form a double-stranded product containing a mismatch; enzymatic or chemical cleavage at the site of a mismatch; and cleavage induced digestion of the probe to release one or more mass labels.
  • a double-stranded mass-labeled nucleic acid probe is synthesized using PCR (A), the 3' ends of the product are blocked from exonuclease digestion (B), the PCR probe is hybridized to mutation carrying DNA (C) which leads to the formation of a base-pair mismatch, the mismatches are cleaved (D), the cleaved products are digested with a 3' to 5' exonuclease (E), the mass labels are released (F) and analyzed by mass spectrometry (G).
  • 3' exonuclease blocking groups include nucleotide mimics incorporated near the 3' end, such as nucleotides contains boranophosphates or phosphorothioates, or the use of 3' overhangs created during nested-set PCR or by template independent extension by terminal transferase in combination with a double-strand-specific 3' to 5' exonuclease, such as exonuclease III, that does not recognize or digest 3' overhangs.
  • mismatch specific cleavage agents for use in (D) include the chemical OsO 4 , KMnO 4 , and HONH 2 , and enzymes, such as mutHLS, T4 endonuclease VII, mutY DNA glycosylase, thymine mismatch DNA glycosylase, or endonuclease V. Methods using RNA or RNA/DNA hybrids are also possible.
  • FIG. 6A, FIG. 6B and FIG. 6C illustrate schemes for the synthesis of peptide-linked nucleoside triphosphates (FIG. 6A), an oligonucleotide with a linker molecule that contains a release group, a disulfide, and a terminal amino-modification for coupling a peptide of some other mass label component to the end (FIG. 6B), and a scheme for the synthesis of a peptide-linked nucleoside phosphoramidite (FIG. 6C).
  • FIG. 7A and FIG. 7B show the mass spectra of the unconjugated oligonucleotide (FIG. 7A) and the oligonucleotide-peptide conjugate (FIG. 7B) of Example 1D.
  • the spectrum of FIG. 7A contains in addition to the signal for the desired oligonucleotide at m/z 7052, signals showing the presence of two significant synthesis failures that correspond to one base and three bases less, and also signals of doubly charged ions for each of these.
  • the spectrum of FIG. 7B shows that the purified conjugate is of similar purity to the starting oligonucleotide.
  • FIG. 8A, FIG. 8B, FIG. 8C, and FIG. 8D show the mass spectra of a hybridized, mass-labeled probe and target in a buffer after Exonuclease III digestion (FIG. 8A), a hybridized, mass-labeled probe and target incubated with no Exonuclease III (FIG. 8B), of a mass-labeled probe in buffer incubated with Exonuclease III (FIG. 8C), of a mass-labeled probe incubated with Exonuclease III buffer in the presence of a non-complementary 36-mer target (FIG. 8D).
  • the mass label is released only in the presence of the exonuclease and a complementary target strand.
  • FIG. 9A, FIG. 9B and FIG. 9C compare solid support grid assays using a radioactively-labeled probe (FIG. 9A), fluorescently-labeled probes (FIG. 9B) and mass-labeled probes (FIG. 9C).
  • FIG. 9A describes the classical approach to probing nucleic acid samples arrayed on a spaced grid.
  • nucleic acid samples representing mRNA isolates, cDNA clones, genomic clones are arrayed on a nylon membrane or filter grid (A).
  • A a nylon membrane or filter grid
  • B radioactive probe
  • C the grid
  • the probe hybridizes to positions in the grid where the nucleic acid samples contain a length of sequence complementary to the probe.
  • the grid is exposed to X-ray film and the hybridization positions are identified (indicated by the A positions in the grid) (D).
  • FIG. 9B illustrates the extension of the process in FIG. 9A , to the use of fluorescently-labeled probes (B). Because of the different emission spectra of different fluorescent labels it is possible to multiplex a small number, e.g. 4 (labeled A, B, C, D), of differently labeled fluorescent probes and cross hybridize them to the grid (C). In the case where fluorescence is used, the grid may be composed on a glass plate, rather than a filter or membrane, to enable fluorescence scanning techniques.
  • FIG. 9C illustrates the use of mass-labeled probes (B) (labeled A-S) for hybridization against a gridded array of nucleic acid samples. Either single or combinatorial labeling techniques may be used to create a few to millions of different probes, all simultaneously hybridized against the array.
  • the grid (D) which may be a nylon membrane or some other conductive material may be scanned directly in the mass spectrometer following hybridization, wash, mass-label release, and matrix addition steps (C). Scanning each position of the grid in the mass spectrometer reveals one of the many possible mass-label signatures associated with each unique probe.
  • Typical examples of assays that would use this technology include the use of known gene-specific probes against gridded cDNA clones, mRNA, cDNA or amplified cDNA pools. Genomic probes, both known or unknown against gridded genomic clones, mRNA, cDNA, amplified cDNA against known gridded genes.
  • FIG. 10A and FIG. 10B compare library expression analysis using a fluorescence based system (FIG. 10A) and a mass-labeled system (FIG. 10B). Fluorescence labeling of pairs of cDNA pools derived from mRNA is used to cross compare the gene expression patterns between two different biological samples.
  • one cDNA pool is labeled with fluorescent tag A while the other pool is labeled with fluorescent tag B (A).
  • These pools have their concentrations normalized and are mixed (B).
  • the mixture of the pools is then hybridized against a gridded, reference array of known genes, typically arrayed as cDNA clones. Following hybridization the array is scanning fluorimetrically and the ratio of the two tags is measured for each location. For a given location if tag A is twice the intensity of tag B, it is determined that the gene, which is gridded to that location, is expressed as mRNA at twice the concentration for sample A than for sample B.
  • FIG. 10B expands the concept of competitively hybridizing cDNA pools beyond the 2 pool level.
  • releaseable mass labels provide the means for the preparation of many more pools (A) (labeled A-H), cross-competitive hybridization (B), and detection (C) of many more pools of expressed message all simultaneously.
  • FIG. 11 illustrates the basic principal of release of a mass label from a nucleic acid probe for analysis by mass spectrometry.
  • the mass label, M1 is released either chemically or enzymatically (A) and detected by mass spectrometry (B).
  • FIG. 12 illustrates selective release of mass labels following hybridization of a nucleic acid probe to a target DNA sequence.
  • Mass-labeled nucleic acid probes A
  • B complementary nucleic acid target
  • C complementary nucleic acid target
  • This complex is recognized by a double-strand-specific exonuclease and the probe is digested (D), releasing mass labels from the probe (E).
  • E For processive exonucleases the process will continue (F) until the entire probe is digested (G). The digestion is then analyzed by mass spectrometry and the released mass labels are detected (H).
  • Mass labels comprise at least one nucleotide when digested by an exonuclease.
  • FIG. 13 illustrates the separation of peptides A-G by MALDI mass spectrometry
  • A is angiotensin I
  • B is substance P
  • C is CGYGPKKKRKVGG (SEQ ID NO:2)
  • D is TCVEWLRRYLKN (SEQ ID NO:7)
  • E is CSRARKQAASIKVSADR (SEQ ID NO:8)
  • F is oxidized A-chain insulin
  • G is melittin.
  • FIG. 14 illustrates a schematic representation of a process by which a series of gene-specific mass-labeled nucleic acid probes are used to detect and quantify the amount of different targeted mRNAs within a given sample.
  • a starting pool of nucleic acid (A) that is the mRNA, cDNA copy of the mRNA, or some amplified multiplex of nucleic acid derived from the mRNA, is mixed with a set of message-specific mass-labeled nucleic acid probes (B) (probes with different mass labels labeled A-S).
  • the mixture is allowed to hybridize (C) wherein probes that find complementary messages in the pool form double-stranded complexes, wherein the concentrations of the gene-specific double-stranded complexes is proportional to the levels of mRNA present in the starting material.
  • C hybridize
  • the mixture is treated with a double-strand-specific nuclease, e.g. exonuclease III treatment, selectively releasing mass labels from probes that had hybridized (D).
  • the released mass labels (labeled A-S) are then analyzed by mass spectrometry (E), wherein the quantity of each mass label detected is proportional to the levels of mRNA present in the starting material.
  • the selective release step may optionally use double-stranded chemical release probes as well as solid phase capture methods to differentiate double-stranded probes from unhybridized single-stranded probes.
  • FIG. 15A and FIG. 15B shows two mass spectra.
  • an rtPCRTM reaction was performed using a pair of mass-labeled primers targeted at the mRNA for ribosomal protein L7.
  • the reaction mix was treated with the double-strand-specific exonuclease T7 gene 6 exonuclease. Only when a double-stranded PCRTM product is formed does the exonuclease digest the product and release the two mass labels, as indicated by two peaks in the spectrum.
  • a control was performed where a single-stranded, mass-labeled primer was incubated with T7 gene 6 exonuclease. No digestion occurred.
  • FIG. 16 illustrates the release of a series of seven different mass-labeled probes which were hybridized to seven different cDNA plasmids and then treated with exonuclease III. An aliquot of the double-strand-specific digestion was taken and analyzed by mass spectrometry. The mass spectrum is shown with the peaks corresponding to each mass label signal labeled A-G.
  • FIG. 17A and FIG. 17B shows two mass spectra from a SNP analysis using a mass-labeled primer and a biotinylated dideoxynucleoside triphosphate.
  • a complementary match is made between the polymorphic base on the template and the biotinylated dideoxynucleoside triphosphate.
  • the mass-labeled primer has been extended and therefore biotinylated, which allows it to be captured to a streptavidin-coated surface, washed and subsequently cleaved from the surface.
  • 17B shows a mass spectrum from a reaction in which the base at the polymorphic site is not a complementary match to the biotinylated dideoxynucleoside triphosphate present in the reaction. No extension of the primer occurred as evidenced by the absence of a mass spectrometric signal for the primer mass label. The unextended primer is not captured on the streptavidin-coated surface and is removed in the subsequent washes.
  • FIG. 18 shows a mass spectrum from a multiplex SNP analysis in which three differently mass-labeled primers for three different polymorphic sites are all simultaneously extended with a biotinylated dideoxynucleoside triphosphate.
  • the three extended primers are all capable of being captured on a streptavidin-coated surface, washed to remove unextended primers and then cleaved from the surface.
  • FIG. 19A and FIG. 19B shows two mass spectra from a SNP analysis in which the extension is carried out a few bases past the polymorphic site and for which biotin is incorporated through a biotinylated deoxynucleoside triphosphate.
  • the mixture of triphosphates in the reactions consists of deoxy-ATP, biotinylated-deoxy-CTP, and dideoxy-TTP.
  • the spectrum is from a reaction in which the polymorphic site on the template, located one base past the 3'-end of the primer, is a T. Since the polymorphic site is a complementary match to one of the deoxynucleoside triphosphates in the reaction, the primer is extended past the polymorphic site, and subsequently incorporates a biotinylated-dCTP before terminating chain extension with the dideoxynucleoside triphosphate.
  • the reaction whose spectrum is shown in FIG. 19B is one in which the polymorphic site on the template is A. Therefore a dideoxy-TTP is incorporated at the first base past the primer, and chain extension is terminated prior to incorporation of the biotinylated-dCTP, which results in a lack of signal in the mass spectrum.
  • FIG. 20A and FIG. 20B show two mass spectra from primer extension analyses in which a mixture of three primers, differing only in their 3'-end-bases and each containing unique mass labels, is extended with biotinylated dideoxynucleoside triphosphate.
  • the mass spectrum shows signal predominantly for the primer whose 3'-end base (primer A) is a perfect match for the template used in the reaction.
  • the spectrum in FIG. 20B is from a reaction in which the template is changed from the reaction in FIG. 20A in such a way that the 3'-end base matches to a different primer and gives predominantly signal from extension of primer E.
  • FIG. 21A and FIG. 21B show two mass spectra comparing the chemical cleavage rates for double-stranded versus single-stranded DNA.
  • a cleavable oligonucleotide containing a 5'-S-P bond is cleavable by AgNO3.
  • Two cleavage reactions are run. In the first reaction the cleavable oligonucleotide is hybridized to a complementary oligonucleotide to make it double-stranded prior to adding cleavage reagent.
  • the second reaction is performed on single-stranded oligonucleotide.
  • the mass spectrum in FIG. 21A shows the products from cleavage of double-stranded DNA.
  • the cleavage products are expected at masses of 6560 Da and 1470 Da, while the uncleaved oligonucleotide is seen at 8012 Da.
  • the spectrum of FIG. 21A indicates that only about 5% cleavage has occurred.
  • the spectrum in FIG. 21B, which is from cleavage of single-stranded oligonucleotide demonstrates that under the same conditions, cleavage is about 90% complete.
  • FIG. 22A and FIG. 22B show two mass spectra from a probe assay of a gene-specific RNA transcript. Two exonuclease III digestions reactions are run. In both reactions a mixture of two probes is present and the template consists of either RNA transcript or the DNA PCR-product template from which the RNA is transcribed. Only one of the probes is complementary to the RNA transcript the other probe is complementary to the opposite strand. Therefore if mass label signal is obtained from the DNA PCR product, signals for both probes are seen, while if the signal is obtained from RNA transcript, only one signal is seen.
  • the mass spectrum shows the resulting released mass label for the reaction in which RNA transcript is present. Since only one signal is seen, the signal must come from digestion of the probe hybridized to the RNA transcript.
  • the second reaction contains a 100-fold greater amount of DNA PCR product than is present in the first reaction, and no RNA transcript.
  • FIG. 22B shows the mass spectrum resulting from the second reaction. The presence of signals from both probes confirms the fact that the signal in FIG. 22A comes from RNA-hybridized probe.
  • FIG. 23A, FIG. 23B, FIG. 23C, and FIG. 23D show a set of four mass spectra which compare the analyte selectivity of two different matrices for MALDI.
  • the samples used for the comparison are equimolar mixtures of a nucleotidylated peptide and an oligonucleotide obtained by a selective chemical cleavage of an oligonucleotide-peptide conjugate.
  • FIGS. 23A and 23B compare spectra of the same sample obtained with 2,5-dihydroxybenzoic acid matrix (FIG. 23A) and with 3-HPA matrix (FIG. 23B).
  • the peptide signal predominates in FIG.
  • FIG. 23A while the oligonucleotide predominates in spectrum FIG. 23B due to differing desorption selectivities or efficiencies of the matrices for the peptide and the oligopeptide.
  • the spectra in FIG. 23C and 23D make the same comparison with a different sample showing that the ionization selectivity is general.
  • FIG. 24 illustrates the use of a double-stranded, mass-labeled nucleic acid probe for detecting and quantifying the presence of a nucleic acid target sequence.
  • Contained within the double-stranded probe is a chemical cleavage group that, under proper conditions, only cleaves when the nucleic acid probe is single-stranded.
  • Examples of chemical cleavage groups that demonstrate enhanced cleavage rates when single stranded include chemically labile nucleic acid backbone modifications such as 5'-(S)-phosphorothioate, 3'-(S)-phosphorothioate, 5'-(N)-phosphoramidate, 3'-(N)-phosphoramidate, and ribose.
  • Probing of a nucleic acid target sequence involves combining the double-stranded probe (A) with the single-stranded target (B) and allowing them to denature and anneal under equilibrium conditions (C).
  • the probe strand containing the mass label and single-strand-specific release group (labeled Re) is homologous to the target nucleic acid; the complementary strand is also complementary to the target.
  • the other products of this equilibrium event are the mass-labeled, cleavable strand in single-stranded form (D), and the complementary strand annealed to the target (E).
  • the amount of complementary strand released from the mass-labeled strand and annealed to the target is proportional to the concentration of the target nucleic acid.
  • the probes are treated with a single-strand-specific chemical cleaving agent (F) yielding cleaved single-stranded probe (G) and detected and quantitated by mass spectrometry (H).
  • F single-strand-specific chemical cleaving agent
  • G cleaved single-stranded probe
  • H mass spectrometry
  • the mass label may be wholely or only partially contained within the nucleic acid probe or reactive group and may include the use of nucleic acid mimics.
  • FIG. 25 illustrates the use of mass-labeled substrates in enzyme-linked affinity assays.
  • the target molecule labeled T
  • A protein
  • B nucleic acid
  • an antibody labeled Ab
  • E enzyme
  • the enzyme recognizes a mass-label substrate (labeled MX) and converts it to product which in this example is a cleavage event to form two products (labeled M and X) which are then analyzed by mass spectrometry.
  • the primary requirement is that the enzyme modify the mass of the substrate when it is converted to product by either adding or removing chemical moieties from the substrate.
  • the antibody has been replaced by a nucleic acid probe that is then conjugated to the signal producing enzyme.
  • the assay is extremely generalizable and one skilled in the art would be able to identify a variety of combinations of probe and target, as well as enzymes and mass-label substrates that may be used.
  • FIG. 26 illustrates two examples of mass-label substrates for use in enzyme-linked affinity assays. Specifically illustrated are two examples, (A) a double-stranded oligonucleotide containing a restriction endonuclease site (labeled R), and (B) a polypeptide containing a specific proteolytic linkage.
  • A a double-stranded oligonucleotide containing a restriction endonuclease site
  • B a polypeptide containing a specific proteolytic linkage.
  • A a double-stranded oligonucleotide containing a restriction endonuclease site
  • B a polypeptide containing a specific proteolytic linkage.
  • the mass label may be wholely or only partially contained within the nucleic acid or polypeptide substrate and may include the use of nucleic acid mimics or non-natural amino acids.
  • the present invention is directed to the composition and use of releasable, nonvolatile mass labels for chemical analysis.
  • the mass labels will be detectable by mass spectrometry.
  • the present invention also describes novel methods utilizing mass labels of any form.
  • nonvolatile refers to a molecule which when present in its pure, neat form and heated, does not sublimate intact to any significant extent. Also included in the definition of nonvolatile compounds are compounds which when present in their pure, neat form cannot be practically analyzed by mass spectrometry when conventional gas chromatography is employed in the sampling process.
  • An advantage of using nonvolatile mass labels versus volatile mass labels is that the sample mixtures are thereby easily physically stable after release.
  • the mass labels described may be attached to a probe molecule that can specifically interact with the intended target. In some cases, a special release group may be included to chemically link the mass label to the probe.
  • the compounds of the present invention are useful for detecting a wide variety of biomolecular interactions. Representative examples include identification of gene sequences, identification of non-coding nucleotide sequences, identification of mutations within a gene or protein sequence, detection of metals, detection of toxins, detection of receptors on an organism or a cell, characterization of antibody-antigen interactions, enzyme-substrate interactions and characterization of ligand interactions.
  • Mass label is a term that can be used synonomously with tag or signal.
  • Examples of the types of mass labels for the present invention include a repertoire of compounds, preferably ones that share similar mass spectrometric desorption properties and have similar or identical coupling chemistries in order to streamline synthesis of multiple mass label variants.
  • a mass label of the present invention is detectable by mass spectrometry.
  • Representative types of mass spectrometric techniques include matrix-assisted laser desorption ionization, direct laser-desorption, electrospray ionization, secondary neutral, and secondary ion mass spectrometry, with laser-desorption ionization being preferred.
  • the dynamic range of mass spectral measurements can generally be extended by use of a logarithmic amplifier and/or variable attenuation in the processing and analysis of the signal.
  • An example of a peptide mixture separated by mass spectrometry is shown in FIG. 13.
  • Mass labels may include a vast array of different types of compounds including biopolymers and synthetic polymers.
  • Representative biological monomer units that may be used as mass labels, either singly or in polymeric form, include amino acids, non-natural amino acids, nucleic acids, saccharides, carbohydrates, peptide mimics and nucleic acid mimics.
  • Preferred amino acids include those with simple aliphatic side chains ( e.g.
  • glycine alanine, valine, leucine and isoleucine
  • amino acids with aromatic side chains e.g ., phenylalanine, tryptophan, tyrosine, and histidine
  • amino acids with oxygen and sulfur containing side chains e.g ., serine, threonine, methionine and cysteine
  • amino acids with side chains containing carboxylic or amide groups e.g ., aspartic acid, glutamic acid, asparagine and glutamine
  • amino acids with side chains containing strongly basic groups e.g. , lysine and arginine
  • amino acid derivative as used herein is any compound that contains within its structure the basic amino acid core of an ⁇ amino-substituted carboxylic acid, with representative examples including but not limited to azaserine, fluoroalanine, GABA, ornithine, norleucine and cycloserine.
  • Peptides derived from the above described amino acids can also be used as monomer units. Representative examples include both naturally occurring and synthetic peptides with molecular weight above about 500 Daltons, with peptides from about 500-5000 Daltons being preferred.
  • Representative examples of saccharides include ribose, arabinose, xylose, glucose, galactose and other sugar derivatives composed of chains from 2-7 carbons.
  • Representative polysaccharides include combinations of the saccharide units listed above linked via a glycosidic bond. The sequence of the polymeric units within any one mass label is not critical; the total mass is the key feature of the label.
  • the monomer units according to the present invention also may be composed of nucleobase compounds.
  • nucleobase refers to any moiety that includes within its structure a purine, a pyrimidine, a nucleic acid, nucleoside, nucleotide or derivative of any of these, such as a protected nucleobase, purine analog, pyrimidine analog, folinic acid analog, methyl phosphonate derivatives, phosphotriester derivatives, borano phosphate derivatives or phosphorothioate derivatives.
  • Mass labels according to the present invention may also include any organic or inorganic polymer that has a defined mass value, remains water soluble during bioassays and is detectable by mass spectrometry.
  • Representative synthetic monomer units that may be used as mass units in polymeric form include polyethylene glycols, polyvinyl phenols, polymethyl methacrylates, polypropylene glycol, polypyroles, and derivatives thereof.
  • a wide variety of polymers would be readily available to one of skill in the art based on references such as Allcock et al. (1981) which describes the properties of many additional polymers contemplated for use in the present invention.
  • the polymers may be composed of a single type of monomer unit or combinations of monomer units to create a mixed polymer. The sequence of the polymeric units within any one mass label is not critical; the total mass is the key feature of the label.
  • nonvolatile mass labels having mass below about 500 Da usually significant ionic character is required; representative examples include polyethylene glycol oligomers of quaternary ammonium salts (e.g ., R-(O-CH 2 -CH 2 ) n -N(CH 3 ) 3 + • Cl - ) and polyethylene glycol oligomers of carboxylic acids and salts ( e.g ., R-(O-CH 2 -CH 2 ) n -CO 2 - • Na + ).
  • polyethylene glycol oligomers of quaternary ammonium salts e.g ., R-(O-CH 2 -CH 2 ) n -N(CH 3 ) 3 + • Cl -
  • polyethylene glycol oligomers of carboxylic acids and salts e.g ., R-(O-CH 2 -CH 2 ) n -CO 2 - • Na + .
  • involatile mass labels typically include small oligomers of polyethylene glycol and small peptides (natural or modified) less than about 500 Da in molecular weight. In these instances, as for all of the cases considered herein, mass analysis is not by electron attachment.
  • Mass labels of the present invention may also include a variety of nonvolatile and involatile organic compounds which are nonpolymeric.
  • Representative examples of nonvolatile organic compounds include heme groups, dyes, organometallic compounds, steroids, fullerenes, retinoids, carotenoids and polyaromatic hydrocarbons.
  • mass-labels of the present invention also include mixed mass labels containing a mass-variable polymeric component and a nonpoiymeric mass static component.
  • a representative example includes a set of mass labels with a polymeric component where the number of repeat units within the set is a range from about 10 to 100, and on each polymer is a compound with a fixed large mass.
  • the mass labels within a set all contain the same mass static component.
  • this preferred set of compounds only the length of the polymer is changed to provide a set of mass labels with incremental increases in mass and a relatively uniform signal between mass labels.
  • the range of mass labels used for a given analysis may have a mass range where no multiply charged or dimer species can interfere with the detection of all mass labels, for example, the mass labels may have a range of masses wherein the smallest mass-label is more than half the mass of the largest mass label.
  • the mass label is typically attached to a reactive group.
  • the reactive groups of the present invention may be any biomolecule capable of specific molecular recognition.
  • the reactive group may form a specific interaction with the target molecule. This interaction may be noncovalent, or covalent such as crosslinking.
  • Representative reactive groups of the present invention include polypeptides, antibodies, enzymes, lipids, steroids, antibiotics and compounds such as neocarzinostatin which have a preference for certain DNA sequences.
  • Representative steroid hormones include estrogens, progestins and androgens.
  • Representative reactive group-target molecule interactions include, enzyme-substrate or substrate analog/intermediate interactions, polypeptide-nucleic acid interactions, protein-ligand interactions, receptor-ligand interactions, lipid-lipid interactions, polypeptide-metal interactions, or antigen-antibody interactions.
  • Representative examples of a covalent interaction between a reactive group and a target include proteins as reactive groups activated with crosslinkers to form conjugates with the target molecule, such as antibody-antigen interactions, enzyme-substrate interactions, receptor-ligand interactions, receptor-nembrane interactions or a protein-nucleic acid interaction.
  • Representative crosslinking reagents include chemically activated crosslinkers such as EDC or MBS and photoreactive crosslinkers such as SADP or PNP-DTP.
  • a release group is desirable.
  • a number of means may effectuate the release, including a labile chemical linkage between the mass label and the reactive group.
  • a labile chemical linkage as used herein is any moiety which upon treatment with a second chemical agent, light, enzyme or heat will cleave the moiety and release the mass label. These linkages may include chemically cleavable groups incorporated within the phosphate backbone linkage (e.g.
  • oligonucleotide primer e.g., a modified base or sugar, such as a more labile glycosidic linkage.
  • Such chemically cleavable groups would be apparent to one of skill in the art in light of the present disclosure and include, for example, dialkoxysilane, 3'-(S)-phosphorothioate, 5'-(S)-phosphorothioate, 3'-(N)-phosphoroamidate, 5'-(N)-phosphoroamidate, and ribose.
  • labile chemical, linkers consist of groups cleavable by oxidation such as dialkyl tartrate, base cleavable groups such as bis[2(alkoxycarbonyloxy)ethyl]sulfone, silyl ethers and ketals which will cleave upon treatment with fluoride ion or acid, ortho-nitrobenzyl ethers which will cleave upon irradiation with light, and groups cleavable by reduction such as dialkyl disulfides.
  • a preferred labile chemical linkage includes a disulfide bond which upon treatment with a sulfhydryl reagent, such as 2-mercaptoethanol, reduces the disulfide bond into two -SH groups.
  • a sulfhydryl reagent such as 2-mercaptoethanol
  • release group may be contained within the reactive group.
  • Released mass labels therefore, may contain none, a portion, or the whole of the reactive group still attached to the specific mass label.
  • Representative examples of release groups contained within a reactive group include the endogenous peptide linkages between amino acids in a polypeptide and the endogenous phosphodiester bond linkages between bases in a polynucleotide. These endogenous linkages may also be modified to target a specific sequence within the reactive group. Examples include modified phosphodiester bonds such as phosphorothioates, phosphoramidates and dialkylsilyl ketals.
  • Nucleotide sequences may also be introduced for recognition by an endonuclease (restriction enzyme) such as Type II or Type IIS restriction endonucleases.
  • endonuclease restriction enzyme
  • a phosphodiester bond will be the release group as recognized by an exonuclease enzyme.
  • Temperature labile release is also contemplated. Representative examples include thermal melting of a hybridized oligonucleotide from a DNA target or temperature dependent denaturation of a protein to release a bound molecule.
  • Specific peptide linkages may also be introduced within a polypeptide reactive group. Examples include peptide linkages which are specifically cleaved by chemicals such as a methionine recognized by CNBr, or tryptophan which can be cleaved by either iodosobenzoic acid or BNPS-skatole. Peptide linkages may also be introduced for recognition by an enzyme such as trypsin.
  • endogenous bonds as release groups include chemical or enzymatic cleavage at a glycosidic bond.
  • release approaches would be within the scope of the present invention.
  • mass-labeled nucleic acid probes may depend on the selective release of certain mass-labels correlating to the occurrence of a particular event. For instance, release of a mass-label may indicate that a hybridization event has occurred between a particular mass-labeled nucleic acid probe and a nucleic acid target sequence.
  • An approach to selective release can involve targeted nuclease digestion of only hybridized probes existing in a double-stranded form as shown in FIG. 12. A number of nucleases, for example restriction endonucleases and DNase 1, only digest double-stranded nucleic acids.
  • nucleic acid probes that have successfully hybridized to a target sequence.
  • a nuclease that only recognizes a nucleic acid sequence present in single-stranded form including S1 nuclease, could be used to yield signal and identity data for probes that do not undergo hybridization.
  • a hybridization probe of at least about 10-14 nucleotides in length allows the formation of a duplex molecule that is both stable and selective.
  • Molecules having contiguous complementary sequences over stretches greater than 10 bases in length may be employed to increase the stability and selectivity of the hybrid.
  • the term "about” indicates that the nucleic acid molecule may vary from the stated length by from 1 to 4 nucleotides. For example, “about 25” may be understood to include 21, 22, 23 and 24; “about 30" may be understood to include 26, 27, 28 and 29; "about 35 may be understood to include 31, 32, 33 and 34; and so on.
  • Hybridization probes may be selected from any portion of a target sequence.
  • the choice of probe and primer sequences may be governed by various factors, such as, by way of exemplification and not limitation, one may employ primers from regions near the termini of the total sequence, or from the ends of the functional domain-encoding sequences or one may employ probes corresponding to the entire DNA.
  • Probes may be designed to identify homologous genes between species including human or one may employ wild-type and mutant probes or primers with sequences designed to identify human or other non-human subjects that carry a certain mutation and thus may be susceptible to disease or a pharmaceutical agent.
  • Hybridization is understood to mean the formation of stable, anti-parallel duplex molecules based on the specific hydrogen bonding of complementary nucleotide bases of the nucleic acid molecules.
  • Complementary bases are adenosine (A) and thymidine (T) (in DNA), or adenosine and uridine (U) (in RNA), and cytosine (C) and guanine (G) in both DNA and RNA.
  • A adenosine
  • T thymidine
  • U adenosine and uridine
  • C cytosine
  • G guanine
  • the ability of two single strands to form a stable double-stranded duplex depends on the sequence of bases in each strand being complementary to the other, such that when the strands are aligned in an antiparallel orientation, sequential juxtaposed bases are able to form hydrogen bonds.
  • hydrogen bonding between any two complementary bases provides only a weak binding energy
  • the cumulative binding energy between many sequential paired bases provides sufficient attractive forces to hold the strands together in a stable duplex. Cations enhance the tendency for complementary strands to form hydrogen bonds, by masking the negative charges of the phosphate groups in the phosphodiester linkages which form the "backbone" of the nucleic acid strands.
  • Temperature is a critical variable; as the temperature of a solution of duplex nucleic acid molecules is raised, hydrogen bonds are broken first in A-U rich regions and finally in G-C rich regions, until above a critical temperature, the complementary strands come apart.
  • the composition of the two strands. i.e., their % GC content determines the critical temperature for duplex denaturation at a given ionic strength. As a corollary, the % GC also determines the threshold concentration of Na - needed to maintain duplex stability at a given temperature.
  • duplex nucleic acid molecules in solution is also affected by the nature of the solvent. For example, duplexes are much less stable in formamide (which destabilizes hydrogen bonds) than in aqueous solution, a fact exploited by molecular biologists to achieve nucleic acid hybridization at lower temperatures than would otherwise be required.
  • Equations have been derived to relate duplex formation to the major variables of temperature, salt concentration, nucleic acid strand length and composition, and formamide concentration.
  • Tm 81.5 - 16.6 ( log [ Na + ] ) + 0.41 ( % GC ) - 600 / N
  • Tm 81.5 - 16.6 ( log [ Na + ] + 0.41 ( % GC ) - 0.63 ( % formamide ) - 600 / N
  • duplex will in theory be resistant to the nucleolytic action of enzymes (DNases and RNases) which are specific for cleavage of phosphodiester bonds in single-stranded molecules.
  • DNases and RNases enzymes
  • the RNases commonly used in RNase protection assays are specific for cleavage after particular bases in single-stranded RNA molecules. Below the threshold Na - concentration needed to maintain duplex stability, the complementary RNA strands denature into single strands, which are then substrates for degradation by the RNases. Susceptibility to digestion by RNase A is therefore a functional assay for whether complementary strands exist as single-stranded or double-stranded molecules.
  • Standard annealing or hybridization procedures are described by Sambrook et al. (1989). Generally they entail two or more nucleic acids, for example probe and test sample nucleic acids, to be mixed together, denatured and then subjected to conditions in which complementary strands anneal, or base pair by hydrogen bonding to form double strands. The annealed strands are said to be hybridized. For example, the mixture may be heated to from about 90°C to about 95°C for about three minutes and then gradually cooled to a lower temperature, 42°C for example, for a period of time sufficient to allow hydrogen bonding of the complementary strands.
  • the time required for annealing of complementary strands depends on the concentration of each strand and will vary from a few minutes (for reactions where both probe an test nucleic acids are present at high concentrations), to several hours or overnight for reactions having at least one species present at low concentration. It is therefore advantageous to use high concentrations of probe and test sample nucleic acids, such as may be generated by PCR amplification and/or transcription of PCR amplified sequences.
  • relatively stringent conditions e . g ., relatively low salt and/or high temperature conditions, such as provided by 0.02M-0.15M NaCl at temperatures of 50°C to 70°C.
  • Such selective conditions tolerate little, if any, mismatch between the probe and the template or target strand.
  • hybridization conditions may typically be employed to form the heteroduplex.
  • milder hybridization conditions such as 0.15M-0.9M salt, at temperatures ranging from 20°C to 55°C.
  • Cross-hybridizing species can thereby be readily identified as positively hybridizing signals with respect to control hybridizations.
  • conditions may be rendered more stringent by the addition of increasing amounts of formamide, which serves to destabilize the hybrid duplex in the same manner as increased temperature.
  • hybridization conditions may be readily manipulated to achieve the desired results.
  • nucleases that selectively digest mass-labeled nucleic acid probes hybridized to a target nucleic acid allows for linear amplification of signal.
  • a nuclease capable of digesting only the nucleic acid probe and not the target e.g. , a double-strand specific exonuclease to digest a short, linear probe in the presence of a circular target having no end to enable the initiation of exonuclease digestion.
  • Long linear targets may also be used in cases where the exonuclease requires a recessed or blunt double-stranded end.
  • a probe As a probe hybridizes to the target, it is digested, and the digested fragments release from the target and make room for a second copy of the probe to hybridize. The second probe is then digested, and, once again, the target is free for the next hybridization.
  • the repeated cycles of hybridization and digestion leads to a linear amplification of the amount of released mass label in solution, consequently increasing the mass spectrometric signal. It is possible to achieve a many hundredfold amplification of signal using such a system. See Okano and Kambara, 1995 (exonuclease III); Copley and Boot, 1992 (lambda exonuclease).
  • Nonselective release events may also be employed with the methods disclosed herein. For example, nonselective cleavage of a disulfide releasing group using a chemical agent such as a phosphine or a mercaptan may be used.
  • a chemical agent such as a phosphine or a mercaptan
  • detection of the desired label may depend on specific partitioning of the population of reactive groups or targets.
  • Reactive groups that recognize and bind to a particular target may, for example, be immobilized to a specific location.
  • a target sequence or sequences of nucleic acids may be attached to gridded positions on a solid support such as a filter, glass, gold or to a bead or a group of beads.
  • Mass-labeled oligonucleotides (probes) that do not hybridize to the target sequence may then be separated from probes hybridized to immobilized targets simply by washing the filter or beads.
  • Such approaches may be especially preferred for removal of unhybridized probes where a subsequent nonspecific release mechanism is to be employed.
  • the reverse case may also be employed, in which the labeled probes are immobilized, and the targets are hybridized to them.
  • Methods described herein may involve the use of a nucleic acid amplification event, such as polymerase chain reaction (referred to as PCRTM), to link a mass-labeled nucleic acid probe, used specifically as a primer, to a second primer that is capable of or presently is bound to a solid support.
  • a nucleic acid amplification event such as polymerase chain reaction (referred to as PCRTM)
  • PCRTM polymerase chain reaction
  • a second primer is one that contains a biotin moiety.
  • binding of the amplification product to the solid phase affords a mechanism to wash away unused primers and then to nonselectively release the remaining mass labels.
  • a nucleic acid amplification event involving the use of one or more different nucleic acid probes, may also be used to convert mass-labeled nucleic acid probes, used specifically as a primers, from single-stranded form to double-stranded form. This conversion allows the use of a double-strand-specific nuclease to selectively release only those mass labels that were attached to primers involved in amplification events. Unused primers remain single stranded and will not release their attached mass labels.
  • nucleic acid probes may involve the modification of a select population of probes following their hybridization to a target which would allow for the partitioning of the probe population.
  • methods include double-strand dependent addition of biotinylated nucleotides or oligonucleotides to the end of mass-labeled probes using polymerase or ligase, followed by direct capture of the biotinylated probes to a streptavidin modified surface.
  • analysis of mass-labeled nucleic acid probes by MALDI mass spectrometry may be performed using a matrix that selectively desorbs and efficiently ionizes intact released mass labels but not mass labels still coupled to their respective nucleic acid probes.
  • Nucleic acid molecules often do not desorb well in many matrices which are yet effective for the desorption of released mass labels, and this difference can be accentuated by the presence of impurities such as salts.
  • Mass-labeled nucleic acid probes may typically be analyzed by direct laser-desorption mass spectrometry without further purification if, for example, the released mass label(s) are detected much more efficiently than unreleased labels. The same holds true for other forms of mass spectrometry.
  • Mass labels may be added to the reactive group during synthesis, or the reactive group may be modified after synthesis.
  • the modification of nucleic acid or amino acid building blocks provides a convenient route for developing generalized methods of mass-labeling reactive groups during synthesis.
  • different mass-labeled nucleotides or amino acids may be added to the mixture and incorporated into the growing polymer.
  • a generalized example of a mass-labeled nucleoside triphosphate is depicted in FIG. 1A.
  • FIG. 1A One skilled in the art would in light of the present disclosure envision a variety of attachment schemes and positions of attachment.
  • the attachment of a mass label should not substantially inhibit the interaction between the reactive group and target molecule, such as the hydrogen-bonding of the mass-labeled base and the complementary target base, or disrupt the proper folding of a polypeptide to form an active protein.
  • the label should typically not inhibit polymerization by a polymerase enzyme.
  • One synthesis approach of the present invention involves the use of mass label modified nucleoside triphosphates that are incorporated by a polymerase to produce a mass-labeled polynucleotide. Using this method, it is easy to load a nucleic acid probe with many copies of a mass label. Polymerase-based methods allow for the inexpensive synthesis of very long probes hundreds to tens of thousands of bases in length by incorporation into an RNA transcript or PCRTM amplicon.
  • the mass label may be a length of amino acids forming a peptide attached to either the carboxyl or amino terminus of the protein.
  • the composition of the mass label may be coded directly into the DNA sequence immediately adjacent to the coding region of the protein that represents the reactive group. Subsequent transcription and translation of this DNA sequence yields a product whereby the peptide mass label is fused to the protein.
  • Nucleic acid amplification methods may be used to prepare mass-labeled probes or to detect the presence of a target sequence.
  • One of the best known amplification methods is the PCRTM which is described in detail in U.S. Patent 4,683,195, U.S. Patent 4,683,202, U.S. Patent 4,800,159 and in Innus et al. (1990).
  • primer sequences are typically prepared which are complementary to regions on opposite complementary strands of the target sequence.
  • the primers may hybridize to form a nucleic acid:primer complex if the target sequence is present in a sample.
  • An excess of deoxynucleoside triphosphates are also added to a reaction mixture along with a DNA polymerase, e.g., Taq polymerase, that facilitates template-dependent nucleic acid synthesis.
  • the polymerase will cause the primers to be extended along the marker sequence by the addition of nucleotides.
  • the extended primers will dissociate from the marker to form reaction products, excess primers will bind to the marker and to the reaction products and the process is repeated.
  • cycles are conducted until a sufficient amount of amplification product is produced.
  • a reverse transcriptase PCRTM (“rtPCRTM”) amplification procedure may be performed in order to quantify the amount of mRNA amplified.
  • Methods of reverse transcribing RNA into cDNA are well known and described in Sambrook et al., 1989.
  • LCR ligase chain reaction
  • Qbeta Replicase described in PCT Patent application No. PCT/US87/00880, may also be used as still another amplification method in the present invention.
  • a replicative sequence of RNA which has a region complementary to that of a target is added to a sample in the presence of an RNA polymerase.
  • the polymerase will copy the replicative sequence.
  • An isothermal amplification method in which restriction endonucleases and ligases are used to achieve the amplification of target molecules that contain nucleotide 5'-[alpha-thio]-triphosphates in one strand of a restriction site may also be useful in the amplification of nucleic acids in the present invention.
  • Such an amplification method is described by Walker et al. (1992).
  • SDA Strand Displacement Amplification
  • RCR Repair Chain Reaction
  • Target specific sequences may also be generated using a cyclic probe reaction ("CPR").
  • CPR cyclic probe reaction
  • a probe having 3' and 5' sequences of non-specific DNA and a middle sequence of specific RNA is hybridized to DNA which is present in a sample.
  • the reaction is treated with RNase H, and the products of the probe identified as distinctive products which are released after digestion.
  • the original template is annealed to another cycling probe and the reaction is repeated.
  • nucleic acid amplification procedures include transcription-based amplification systems ("TAS”), including nucleic acid sequence based amplification (“NASBA”) and 3SR (Kwoh et al ., 1989; PCT Patent Application WO 88/10315).
  • TAS transcription-based amplification systems
  • NASBA nucleic acid sequence based amplification
  • 3SR Zaoh et al ., 1989; PCT Patent Application WO 88/10315.
  • the nucleic acids may be prepared for amplification by standard phenol/chloroform extraction, heat denaturation of a clinical sample, treatment with lysis buffer and minispin columns for isolation of DNA and RNA or guanidinium chloride target specific sequences.
  • DNA/RNA hybrids are digested with RNase H while double stranded DNA molecules are heat denatured again. In either case the single stranded DNA is made fully double stranded by addition of second target specific primer, followed by polymerization.
  • the double-stranded DNA molecules are then multiply transcribed by a polymerase such as T7 or SP6.
  • RNA's are reverse transcribed into double stranded DNA, and transcribed once again with a polymerase such as T7 or SP6.
  • a polymerase such as T7 or SP6.
  • European Patent Application No. 329,822 disclose a nucleic acid amplification process involving cyclically synthesizing single-stranded RNA (“ssRNA”), single-stranded DNA (“ssDNA”), and double-stranded DNA (“dsDNA”), which may be used in accordance with the present invention.
  • ssRNA single-stranded RNA
  • ssDNA single-stranded DNA
  • dsDNA double-stranded DNA
  • amplification products are separated by agarose, agarose-acrylamide or polyacrylamide gel electrophoresis using standard methods (Sambrook et al., 1989).
  • chromatographic techniques may be employed to effect separation.
  • chromatography There are many kinds of chromatography which may be used in the present invention: adsorption, partition, ion-exchange and molecular sieve, and many specialized techniques for using them including column, paper, thin-layer and gas chromatography (Freifelder, 1982). Separation may also be achieved using biologically based interactions such as biotinstreptavidin or antibody-antigen interactions.
  • detection of the mass labels may be used to confirm amplification.
  • amplification products should typically be visualized in order to confirm amplification of the sequences.
  • One typical visualization method involves staining of a gel with ethidium bromide and visualization under UV light.
  • the amplification products may typically be exposed to x-ray film or visualized under the appropriate stimulating spectra, following separation.
  • the mass label may be placed at one or more locations within the reactive group.
  • polypeptide compounds of the present invention may be synthesized using known methods for peptide synthesis (Atherton & Shepard, 1989). The preferred method for synthesis is standard solid phase methodology, such as that based on the 9-fluorenylmethyloxycarbonyl ("FMOC") protecting group (Barlos et al., 1989), with glycine-functionalized o-chlorotrityl polystyrene resin. Solid phase peptide synthesis allows for strategic placement of a mass label within the compound.
  • FMOC 9-fluorenylmethyloxycarbonyl
  • an oligonucleotide probe may be specifically labeled by introducing a modified mass-labeled phosphoramidite at a particular location within the sequence.
  • Chemical synthesis methods also permit the placement of mass labels at the termini of the probe or within an internal linker wherein the mass label is not directly attached to the base of a nucleotide.
  • a generalized example of a mass-labeled phosphoramidite is shown in FIG. 1B. Chemical synthesis methods for DNA are well known within the art (Agrawal, 1993)
  • probes may be made with a unique mass label signature for every gene within humans, and any other organism for that matter. Examples of enzymatic probe synthesis are shown in FIG. 4C and FIG. 4D.
  • nucleic acid probes prepared by an amplification method such as PCRTM, may utilize mixtures of primers whereby each primer contains a different mass label and the same DNA sequence.
  • a repertoire of mass labeled primers may be used to prepare many different mass signatures.
  • primers may be prepared containing several different mass labels within a single molecule.
  • a particular advantage to the solid phase method of synthesis is the modification of these compounds using combinatorial synthesis techniques.
  • Combinatorial synthesis techniques are defined as those techniques producing large collections or libraries of compounds simultaneously, by sequentially linking different building blocks. Libraries can be constructed using compounds free in solution, but preferably the compound is linked to a solid support such as a bead, solid particle or even displayed on the surface of a microorganism.
  • Several methods exist for combinatorial synthesis Holmes et al., 1995; Burbaum et al.. 1995; Martin et al., 1995; Freier et al., 1995; Pei et al., 1991; Bruce et al., 1995; Ohlmeyer et al., 1993); including split synthesis or parallel synthesis.
  • Split synthesis may be used to produce small amounts of a relatively large number of compounds, while parallel synthesis may produce larger amounts of a relatively small number of compounds.
  • compounds are synthesized on the surface of a microparticle. At each step, the particles are partitioned into several groups for the addition of the next component. The different groups are then recombined and partitioned to form new groups. The process is repeated until the compound is completed. Each particle holds several copies of the same compound allowing for facile separation and purification.
  • Split synthesis can only be conducted using a solid support.
  • parallel synthesis An alternative technique known as parallel synthesis may be conducted either in solid phase or solution. Using parallel synthesis, different compounds are synthesized in separate receptacles, often using automation. Parallel synthesis may be conducted in microtiter plate where different reagents can be added to each well in a predefined manner to produce a combinatorial library. Parallel synthesis is the preferred approach for use with enzymatic techniques. It is well understood that many modifications of this technique exist and can be adapted for use with the present invention. Using combinatorial methods, a large number of unique mass-labeled probes may be synthesized.
  • One embodiment is an approach to synthesizing all possible combinations of sequence simultaneously in such a way that each unique sequence within the pool will possess a unique mass signature.
  • the synthetic approach involves the use of a unique set of four mass-labeled nucleotides for each position within an oligonucleotide probe, i.e. , a set of four mass labels are used exclusively at position 1, while a different set of four is used exclusively at position 2, and so on.
  • the primary method of synthesizing said probes is chemical using phosphoramidite chemistry though other chemical and enzymatic methods including single base addition by polymerase may also be employed.
  • synthesis of the combinatorial set of all oligonucleotides 10 bases long would require 40 different phosphoramidites, 10 different A's with unique mass labels, 10 different C's with unique mass labels, 10 different G's with unique mass-labels, and 10 different T's with unique mass labels.
  • the scheme is illustrated in FIG. 4A.
  • Utility for the complete probe set is diverse. Applications include hybridization assays for identity of cDNAs of other sequences present in a solid phase bound array or some other format, mapping applications, and other diagnostic applications. It is also possible to use the set for random PCRTM amplification assays where the products are separated by electrophoresis and the primers that paired to form the different PCRTM products are identified. These applications also apply to the methods used to identify short sequence reads.
  • the combinatorial synthesis of probes can be performed as a single reaction in a single receptacle, or it may be performed using the split synthesis technique previously described. If the combinatorial synthesis does not utilize split synthesis techniques, there may be difficulties identifying sequence in cases where multiple probes hybridize. In cases where the full set of probes are used it may be difficult to uniquely identify the sequences of the probes if more than one probe is present at a significant level.
  • One possible approach to limiting the number of probes that hybridize to a particular target is by attaching a unique anchoring sequence to the probe set limiting the locations where the probe can hybridize. This anchoring is similar to the methods used to identify short sequence reads. As described previously, it may also be possible to add extra bases to the end of the probe to lengthen the sequence determination and improve discrimination, if necessary.
  • FIG. 4B A specific example of using the anchored, combinatorially synthesized probes is shown in FIG. 4B.
  • the anchored, invariant sequence may be used to hybridize to the know vector sequence immediately adjacent to the insert or in the specific case of a cDNA insert to the poly A/T region of the insert.
  • post-modification For addition of labels to an already synthesized probe, herein referred to as post-modification, various chemically active sites on the probe may be utilized. For example, a proper functionality of a label could be reacted with a primary amine on 5 propargyl amino deoxyuridine, a terminal amino or carboxyl linker, or an endogenous moiety, such as the exocyclic amine in cytosine, guanine, or adenine.
  • Potential linker groups include the heteobifunctional cross-linking agent mal-sac-HNSA (Bachem Inc., Torrence, CA), or any of a variety of cross-linking agents available from Pierce Chemical Company (Rockford, IL).
  • Pierce Chemical Company Pierce Chemical Company
  • the described mass-labeled nucleic acid probes have a variety of uses.
  • Labeled polypeptides may be used to detect interaction of a reactive group with a specific target.
  • Representative examples include a mass-labeled antibody to detect an antigen either in solution or on a solid support or a mass-labeled enzyme to detect a substrate.
  • One of skill in the art would recognize there are many such interactions detectable using labeled polypeptides to detect interactions with a target molecule.
  • One preferred embodiment of the invention relates to the simple detection of a specific target nucleic acid.
  • An advantage to using mass-labeled compounds that are detectable by mass spectrometry methods is the ability to simultaneously detect many target compounds at the same time. Due to broad overlapping spectrums produced by existing fluorescent chromophores, an upper limit for fluorescence multiplexing is most likely to be about ten different labels. With a matrix-assisted laser desorption/ionization time-of-flight ("MALDI-TOF") mass spectrometer or direct laser-desorption mass spectrometer or an electrospray mass spectrometer, multiplexing of tens of hundreds and perhaps even thousands of different mass labels is possible. A nonvolatile pool of labels may provide a wider range of masses and structures. Due to this multiplexing ability, not only can many labeled probes be used at the same time, any individual probe can be labeled with many different labels.
  • MALDI-TOF matrix-assisted laser desorption/ionization time-of-flight
  • Further embodiments involve the detection of single base variations. These applications will generally require a great deal of sensitivity. These applications include detection of "hot spot” point mutations and identification of the base at single nucleotide polymorphism ("SNP") sites.
  • Mass-labeled probes may be prepared that hybridize immediately adjacent to a polymorphic site and a polymerase may then be used to add one base at the site of the polymorphism. The particular base may be added to the probe by many ways. For example, in a preferred embodiment where a single probe is used, a mixture of the four chain terminating triphosphates may be added, each with a unique mass label attached.
  • the four chain-terminating nucleotides may add to the end of the probe coupling the associated mass label to the probe.
  • Several approaches may be taken in releasing the mass label from the probe. These approaches include, but are not limited to, the use of chemically labile functional groups linking the mass label to the terminating nucleotide, chemically labile functional groups within the backbone of the extended primer or the chain-termination nucleotide, or the use of an enzyme to cleave at one or more of the phosphodiester or glycosidic linkages within the primer extension product.
  • the mass label release point is within the backbone of the extension product, the released mass label may include the terminal nucleotide or some mass-modified version thereof.
  • the native chain-terminating nucleotides themselves may serve as all or a portion of the mass labels since each base possesses a unique mass. In cases where the mass label is chemically cleaved from the probe, any unincorporated nucleotides may first be removed or washed away so that they are not visualized by the mass spectrometer.
  • Partitioning of the hybridized mass-labeled chain-terminating triphosphate may be done on the basis of mass differences, as labeled triphosphate hybridized to a target-hybridized probe will have a higher molecular weight than a labeled triphosphate that is not.
  • the probe or target may also be attached to a solid-phase via a number of means including biotin/streptavidin or chemical coupling or UV cross-linking.
  • An alternative is the use of a nuclease to digest the mass-labeled probe. Using a nuclease the mass-labeled chain-terminating nucleotide will be released as a monophosphate.
  • the unincorporated mass-labeled chain-terminating nucleotides will remain as triphosphates, and the resulting mass shift to monophosphate will indicate which nucleotide was incorporated. This nuclease method relieves the necessity to remove unincorporated nucleotides prior to analysis.
  • Another embodiment encompasses the multiplexing of a large number of probes so as to detect many SNPs simultaneously.
  • Preferably mass labels may be present to uniquely tag each of the probes that comprise the pool.
  • the addition of a biotinylated chain-terminating nucleotide at the site of the point polymorphism may also be used to segregate the probe population depending on which probes incorporate a specific biotinylated chain-terminating nucleotide and which do not.
  • the pool of mass-labeled probes with target may be divided into four reactions.
  • the first reaction would contain only biotinylated dideoxy adenosine triphosphate
  • the second would contain only biotinylated dideoxy cytidine triphosphate
  • the fourth only biotinylated dideoxy thymidine triphosphate Following a single base extension polymerase-dependent reaction in the presence of the proper nucleotide, the extended products are captured, washed and the mass labels are released for mass spectrometric analysis.
  • the first reaction only those mass-labeled probes that incorporate an A will be visualized.
  • the second reaction only those mass-labeled probes that incorporated a C will be visualized.
  • For the third and fourth reactions probes that incorporated, respectively a G or a T will be visualized. It is expected that hundreds of probes could be multiplexed in this way.
  • a person skilled in the an could identify a number of variations of the single or multiplexed probe approach for reading out the SNP based on either the absence or appearance of the mass label or mass change occurring in the mass label.
  • Another example of mass change within a mass label is the case where the mass label is present at the 3' end of the probe. Following polymerase-dependent base extension, the mass label may be released, including the chain terminating base addition as well as the penultimate base.
  • a possible structure for this type of probe is shown in FIG. 2. Placement of the mass label and the release site may be at other bases with a preference of placement near the 3' end. In all cases the mass label should preferably be placed between the release group and the 3' end.
  • the mass label may be located within the primer near the 3' end which contains a chemical release group.
  • An alternative preferred embodiment to single base addition for detecting an SNP is the performance of a discriminating exonuclease event in the presence of matching and mismatching oligonucleotide probes.
  • This approach is to combine the use of releaseable mass labels with nick translation PCRTM.
  • Taq DNA polymerase has both 5' to 3' exonuclease and endonuclease activities. If a fully complementary oligonucleotide probe is placed in the path of polymerization, for example during PCRTM amplification, the polymerase will attack the 5' end of the probe with its exonuclease activity, digesting the molecule until it is too small to remain hybridized.
  • the end of the probe will fray and be attacked by the endonucleolytic activity of the polymerase rather than the exonuclease activity.
  • the nucleolytically cleaved product preferably containing the mass label, will have a different final mass depending on whether or not a mismatch was present and how the nuclease cut in response to this mismatch. It has been demonstrated that the initiation of endonucleolytic activity can be influenced by the presence and placement of a mismatch within the hybridization probe (Holland et al., 1991; Lee et al., 1993). Selective placement of a mass label within the oligonucleotide probe relative to the expected mismatch site can be used to yield a differential signal depending on whether or not an actual mismatch is present.
  • each of the probes targeting a particular SNP contains one of the four possible bases to complement the site of polymorphism.
  • the placement of the mass label is such that if the probe contains a perfect match to the template, the mass label will be released by the exonuclease activity of Taq polymerase, primarily in a form that includes a single nucleotide.
  • the other probes will create a mismatch and the endonuclease activity of the polymerase will initiate cutting of the probe in such a way that the mass label remains bound to a larger segment of the probe that includes more than one nucleotide.
  • the shift in mass of the mass label cleavage product is diagnostic of whether or not a mismatch has occurred.
  • the detection by mass spectrometry is performed using MALDI it may be possible to select a matrix that can visibly discriminate between the smaller product that results from the matching probe and the larger product that results from the mismatched probes such that the smaller product is desorbed more efficiently or selectively.
  • a matrix such as 2,5-dihydroxybenzoic acid, sinapinic acid, or ⁇ -cyano-4-hydroxycinammic acid, the signal strength decreases as more nucleotides are attached to the probe (Jensen, et al., 1996).
  • Nick translation PCRTM combined with mass-labeled probes can also be used as a generalized method for the detection and monitoring of a PCRTM amplification reaction. In this case, only matching probes are present and the mass label is released only if PCRTM of the particular region targeted by a particular probe is amplified.
  • nonvolatile releasable mass labels or involatile releasable mass labels
  • other types of labels can be used as well, such as isotopic mass labels, volatile mass labels (including electrophores), fluorescent labels, and chemiluminescent labels.
  • the mass-labeled probes may be used to identify short sequences.
  • combinations of hybridization and enzymatic (polymerase or ligase) extension can be employed with the labeled probes to identify short sequence runs adjacent to a "priming" or anchoring region.
  • the first method is illustrated in FIG. 3A.
  • a mixture of probes are synthesized containing two domains, a fixed sequence recognition domain, typically comprised of only one or a few sequences, and a randomized domain, comprising the full set (or some subset) of all possible sequences.
  • the fixed sequence of the probe is used to target hybridization of the probe to a single site within a particular target nucleic acid.
  • This target site is typically invariant.
  • the sequence adjacent to the invariant sequence is variable and, depending on the particular target, can have any one of the total combinations of sequence.
  • the second probe region is four bases in length, then 256 different probes need to be synthesized. If the second probe region is five bases in length, then 1024 different probes need to be synthesized. Six bases requires 4096, and so on.
  • the probes can be synthesized individually, each possessing a unique combination of mass labels as a releasable mass signature. Alternatively, the probes can be synthesized with unique mass signatures using a combinatorial synthesis method of the type described previously. In particular embodiments regarding diagnostic probes, it may be desirable to generate only a small number of probes, for example less than 20.
  • the two domain probes are useful for identifying the end sequence within clone inserts.
  • the fixed sequence domain would hybridize to the cloning vector sequence immediately adjacent to the insert sequence.
  • the variable sequence is then available to hybridize to the cloned insert. Only the probe that is complementary to the cloned insert sequence adjacent to the cloning vector sequence will form a perfect hybrid. The remaining two domain probes will not. Detection of the mass label signature for the probe that has hybridized using one of the methods described will identify the probe sequence and the clone insert sequence.
  • Other applications include targeting hypervariable sequence regions or mutation/polymorphism analysis at targeted sites. In all cases the fixed sequence of the probe directs the probe to a unique region within the target, essentially anchoring where the variable region will probe.
  • an enzyme such as polymerase or ligase
  • Addition of bases by either enzyme places stricter requirements on the variable region being a perfect hybrid to enable enzymatic action. Examples of how these probe additions work are shown in FIG. 3B. Note that for polymerase the addition needs to be to the 3' end of the probe while ligation can occur at either the 3' end or 5' end.
  • variable region within the probe increasing size of the addition will necessitate a larger and larger pool to represent all possible sequences.
  • Oligonucleotide additions don't necessarily need to be entirely variable. There may be cases where the variable region will contain an invariant region. Such extensions will increase the thermodynamic stability of the oligonucleotide addition and allow ligation to occur at higher temperatures. It is also possible to envision cases where invariant nucleotide sequence would be intermingled with the variable sequences described.
  • Combinatorial libraries may also be used to detect short sequences. In cases where the full set of probes are used, though, it may not be possible to uniquely identify the sequences of the probes if more than one probe is present after hybridization at a significant level.
  • One possible approach to limiting the number of probes that hybridize to a particular target is by attaching a unique anchoring sequence to the probe set limiting the locations where the probe can hybridize. This anchoring is similar to that previously described for analysis of short sequence reads. As previously described, it is also possible that extra bases could be added to the end of the probe to lengthen the sequence determination and improve discrimination, if necessary.
  • FIG. 4B A specific example of using the anchored, combinatorially synthesized probes is shown in FIG. 4B.
  • the anchored, invariant sequence is used to hybridize to the known vector sequence immediately adjacent to the insert or in the specific case of a cDNA insert to the poly A/T region of the insert.
  • nonvolatile releasable mass labels or involatile releasable mass labels
  • other types of labels can be used as well, such as isotopic mass labels, volatile mass labels (including electrophores), fluorescent labels, and chemiluminescent labels.
  • Oligonucleotide probes may be used for hybridization to a target DNA containing a single mutation within a region of interest, leading to the formation of a mismatch.
  • enzymatically synthesized mass-labeled probes blocked from double-strand-specific enzymatic digestion at the 3' end are used.
  • the 3' ends of the probes can be blocked by chemical modification or enzymatically. For example, blocking can be achieved by making the 3' terminus inaccessible to enzymatic digestion.
  • cleaving reagents include KMnO 4 and T4 endonuclease VII.
  • Subsequent treatment of the cleaved pair with a double-strand-specific 3'-5' exonuclease, such as exonuclease III, would lead to digestion of probe from the cleavage site to the 5' labeled end, thereby releasing the mass label. This method is illustrated in FIG. 5A and FIG. 5B.
  • the polarity of the system can be reversed by placement of the mass label at the 3' end of the probe and by using a double-strand-specific 5'-3' exonuclease, such as T7 gene 6 exonuclease.
  • mismatch detection involves the amplification of heterozygous target DNA using two different mass-labeled probes.
  • the difference can be a single base mutation, for example A:T to G:C.
  • Four products are produced by the PCRTM reaction, two fully homogenous products representing the original sequences, while the other two products contain a mismatch at the mutation site.
  • Treatment with terminal transferase adds long 3' overhangs to all of the products.
  • Chemical or enzymatic mismatch specific cleavage is used, affecting only the two heterogeneous pairs.
  • Exonuclease III digestion also affects only the cleaved heterogeneous pairs, releasing the mass labels without digesting the sequences blocked by the 3' overhangs. This method is shown is FIG. 5C and FIG. 5D.
  • These mismatch methods could also be combined with other labeling methods such as fluorescent tags or radiolabels.
  • nonvolatile releasable mass labels or involatile releasable mass labels
  • other types of labels can be used as well, such as isotopic mass labels, volatile mass labels (including electrophores), fluorescent labels, and chemiluminescent labels.
  • Multiplexed applications include multiple pathogen diagnostics, multigene genetic polymorphism screening, SNP genotyping, clone and gene mapping, and gene expression analysis.
  • Highly multiplexed analysis by hybridization can be categorized into one of three approaches; (A) hybridization of a library of probes with known sequence against a library of targets of unknown sequence, (B) hybridization of a library of probes with unknown sequence against a library of targets of known sequence, and (C) hybridization of a library of probes with unknown sequence against a library of targets of unknown sequence.
  • Approach (A) is beneficial for applications such as diagnostics, genotyping, expression analysis and probe mapping where it has been predetermined what sequences are to be screened. Many of the methods described above may be used in approach (A). Combinatorially synthesized probes can be used with approach (A) where the sequences of the probes (and target to which the probe is hybridized) are postdetermined, i.e. probe and then determine the sequence of which probe has hybridized. The limits as previously described for combinatorial probes apply. Use of repertoire sets of mass labeled probes, as opposed to combinatorial probes, can be used in multiplexed mixtures to detect the presence of short sequences for purposes of sequencing by hybridization or producing a probe signature for a particular target sequence.
  • Approach (B) provides a path for a number of applications where a library of different known DNA sequences, such as oligonucleotides, PCRTM products, RNA transcripts or DNA clones, have been arranged and are available for partitioning the unknown probe set. These methods often, but not always, include the use of solid phase arrays to physically partition the known sequences prior to probing. Applications include competitive hybridization for differential expression analysis and fast mapping of genes, subclones or short sequence tags (SSTs) against a master genomic clone library, multiplexed infectious agent detection or any other set of samples that need to be probed in a multiplexed fashion.
  • SSTs short sequence tags
  • Approach (C) is useful in cases where it is not necessary to know sequence but only to determine trends.
  • probes or targets that exhibit different properties, e.g. , fall into the nonhomologous category, may be taken on for further analysis to determine their sequences.
  • Such a method could be used for gene discovery.
  • a practical example employing these three approaches is in measuring gene expression profiles.
  • the most basic way to measure a gene expression profile is statistically, to count the number of message RNAs (mRNAs) produced for each particular gene within a particular cellular sample. The more mRNA copies of a particular gene, the higher its level of expression.
  • the approach commonly taken is to separate out a representative number of mRNAs through a process of copying the mRNA to complementary DNA (cDNA), and then growing up the individual clone colonies of each cDNA on culture plates.
  • cDNAs are cloned by insertion into either a plasmid or a phagemid cloning vector, and then transformed into bacteria or encapsidated into phage respectively.
  • Each clone represents an individual mRNA derived from the total population.
  • the set of clones comprises a gene expression library.
  • any particular EST may appear multiple times. The more times a particular EST appears, the higher the expression level for the gene correlating to the EST. The more clones that can be read, the more statistically representative the EST data will be to actual expression. Screening larger numbers of clones also makes it more likely that genes expressed at low levels will be identified.
  • the mass-labeled hybridization probes of the present invention could simplify and lower the cost of gene expression analysis.
  • the probe approach primarily utilizes knowledge of the genes to be analyzed. Since the vast majority of gene sequences will be known within a few years, it is not necessary to use a de novo technique. It is also possible to detect previously unknown genes with these hybridization procedures. Complete identification of new genes may require a separate DNA sequencing analysis, subsequent to a hybridization assay, to determine the sequence of any of these newly discovered genes.
  • the hybridization approaches of the current invention will usually involve convening the mRNA population to cDNA, transforming the cDNA into bacteria and growing bacterial colonies on culture plates and screening bacterially derived plasmids.
  • the clones to be screened can be spotted in a regularly spaced array or grid on a surface such as a nylon filter, glass, silicon or gold.
  • the typical process involving bacteria colonies involves lysing the bacteria cells on the grid and fixing the DNA to the surface.
  • the grid of cDNAs represent the library of tens to hundreds of thousands of expressed messages to be probed.
  • a grid can be probed with only one single probe sequence at a time, typically being radioactively labeled as shown in FIG. 9A.
  • the library cDNA array is wetted with a solution containing the labeled nucleic acid probe.
  • the grid-probe solution is incubated to allow the probe to hybridize its complement at one or more positions within the grid.
  • the grid is imaged in order to locate the probe-hybridization positions.
  • the grid needs to be replicated and a different grid is used for each probe.
  • nucleic acid probes can be synthesized using individual cDNAs with known sequence as templates. In all cases the probes may use combinations of mass labels or single mass labels. Following synthesis and mass-labeling, the different probes can be combined and used to probe a single grid in a multiplex fashion. The probing procedure is identical to that used for a single radioactively labeled probe until the imaging step is reached. Instead of using a phosphorimager or x-ray film, the grid is scanned within the mass spectrometer after release of the labels, pausing briefly at each position to detect the mass label signal that may be present.
  • the number of probes used is only limited to the number of probes one is willing to make and to the number one is interested in. As an example, one may be interested in a set of 1000 genes that may play an important role in a particular disease or one may wish to look at 50,000 different genes. In either case the probes may be individually synthesized or produced in combinations in microtiter plates using liquid handling robotics.
  • each synthesis reaction a different single or unique combination of mass-labeled nucleoside triphosphates are added which thereby incorporate a unique mass signature within each newly synthesized probe.
  • mass-labeled oligonucleotide probes it is also possible to use chemically synthesized combinatorial probes.
  • the probe set is mixed together to create a master probe mix.
  • a number of master probe mixes can be prepared to perform multiplexing if desired, where each cDNA of each master probe mix has a unique combination mass label signature.
  • the probe set or sets can then be used to probe a large number of different unknown complementary DNA gridded libraries as shown in FIG. 9C.
  • Different libraries can be prepared from a variety of samples, for example exposed to different stressor conditions and/or different test pharmaceuticals, possibly with time as an additional variable.
  • the mixture of cDNAs which reflect the relative abundance of different mRNAs from each sample, are then mixed and allowed to competitively hybridize to a gridded array of known genes present on a solid phase surface.
  • the relative fluorescence intensity for the two dyes is measured at each position in the gridded array. If the fluorescence intensity for each dye is equivalent then the corresponding mRNAs from each sample were expressed at a similar level. If the fluorescence intensity is stronger for one dye than the other at a particular position/gene in the gridded array, then that gene was expressed at a higher level in the sample whose fluorescence was stronger.
  • mass labels can be released by any of the appropriate release mechanisms described and the grid can be scanned for the mass label signal.
  • the intensity of the mass signals at a given grid position will be proportional to the level of mRNA in the original sample that corresponds to the detected cDNA on the grid.
  • the relative ratios of the competing mass labels are determined providing information about the differences in gene expression between all of the different samples for all of the genes present on the gridded array.
  • This same multiplexed mass-labeled probe methodology can be used to quickly map genes to large genomic libraries.
  • Gridded libraries of P1, PAC/BAC and YAC clones can be prepared in the same manner as cDNA filters.
  • Multiple label studies provide a means for quickly mapping genes and identifying gene clusters.
  • Probes generated from particular clone inserts or gene sequences are used to screen libraries of genomic or cDNA clones. Hybridization events indicate an overlap of insert sequence in the genomic case and the presence of a gene in the cDNA case.
  • These libraries can also be used for intergenomic probing, e.g. , probing a C . elegans library with human gene probes, and visa versa.
  • the technology for probing with and detecting mass labels within gridded arrays can also be applied to other solid phase systems where DNA probes are utilized, specifically Northern and Southern assays.
  • the initial phase is to run a polyacrylamide gel and then to transfer the DNA to a nylon membrane using a blotting procedure ( Sambrook et al. 1989).
  • mass-labeled nucleic acid probes can be prepared to hybridize to the filters.
  • mixtures of single or combinations of mass labels can be used in an effort to multiplex the detection.
  • a scan of the filter after hybridization and washing within the mass spectrometer provides the means to detect, and where necessary quantify, the amount of mass label present in a particular location.
  • An additional embodiment of the technology is the use of mass labeled protein probes, in the form of antibodies, for hybridization against one and two-dimensional protein gels.
  • mass labeled protein probes in the form of antibodies, for hybridization against one and two-dimensional protein gels.
  • One skilled in the art can also envision other combinations of mass labeled probe molecules hybridized against targets bound to a solid phase matrix. In all cases the mass label is released and either the solid phase surface analyzed using a scanning mass spectrometer, or a transfer to another surface takes place before mass analysis.
  • a mass-labeled probe set may be directly hybridized to DNA or RNA targets in solution.
  • a double-strand-specific nuclease such as exonuclease III, lambda exonuclease, T7 gene 6 exonuclease or a restriction endonuclease, or some partitioning event needs to occur wherein unhybridized probes are separated from hybridized probes.
  • an amplification event can be used to produce a significant amount of mass label.
  • Mass labels attached to a probe hybridizing downstream from one of the PCRTM primers can be released during PCRTM amplification using the nick translation 5'-3' exonuclease activity of the thermostable polymerase.
  • Mass labels within primers can be released using a 5'-3' exonuclease such as T7 gene 6 exonuclease after amplification.
  • a mass labeled primer is coupled to a biotinylated primer during amplification, or biotin is incorporated through the use of biotinylated nucleotides, and the product is partitioned away from the unincorporated primers, it is possible to use nonspecific cleavage, such as chemical cleavage methods, to the release of the mass label.
  • hybridization-specific nuclease digestion can also be used to cleave a probe containing both biotin and mass label, in an assay where solid-phase-bound steptavidin is used to remove uncleaved mass labels.
  • cleavage involve the use of a double-strand-specific nuclease such as those described above.
  • Restriction endonucleases may be used to cleave a probe that contains a restriction site in the center and a mass label and biotin at opposing ends of the probe.
  • RNA is used as a probe, involves double-strand-specific cleavage using RNase H.
  • a double-stranded probe is prepared with the mass label being attached to the strand that is homologous in sequence to the target strand.
  • the mass-labeled strand is then displaced by a competitive hybridization with target and the mass label is released by a single-strand specific exonuclease such as exonuclease VII, Mung Bean nuclease or nuclease S1.
  • An alternate method would employ the use of single-strand specific chemical cleavage reagent to release the mass label from a chemically modified probe.
  • Examples of chemical modifications that would provide single-strand specific release of mass label include cleavage of a ribonucleotide base by transesterification, a phosphoramidate cleavable by acid, and a 5' -P-S phosphorothioate cleavable by silver nitrate as described in Example 9.
  • PCRTM can also be combined with the use of a mass labeled primer and a restriction enzyme to enable release of a mass label only if amplification occurs.
  • the mass labeled PCRTM primer contains the sequence for a restriction site that becomes double-stranded only as part of the amplification process. Once the site is double stranded, it is recognized by the restriction enzyme and cleaved. The cleavage event releases the mass label from bulk of the primer and PCRTM product allowing it to be uniquely detected.
  • FIG. 14 An embodiment of the invention where mass-labeled probes can be used to measure mRNA levels in solution is shown schematically in FIG. 14.
  • a series of gene-specific, mass-labeled probes (1-100 per study) are added to the mRNA pool (or more likely, first-strand cDNAs derived from the mRNA pool) and allowed to hybridize.
  • Each gene-specific probe carries a unique mass label, and possibly multiple copies of that label to increase sensitivity.
  • the hybridized mixture is treated with a double-strand-specific exonuclease that releases the mass labels for the portion of the probe population that was hybridized to target genes. Only if the mRNA from a gene of interest is present will the corresponding mass label be released and detected.
  • the signal intensity for the particular mass label will be proportional to the relative abundance of the particular mRNA within the pool. Comparisons of the relative intensities for the different mass labels reflect the relative mRNA expression levels.
  • the relative gene expression pattern for as many as 38,400 genes could be probed for in a single 384 microtiter plate if 100 different probes per well are used. Conversely, a set of 100 genes could be examined for 384 different samples in a single microtiter plate experiment.
  • mass spectrometric sensitivity levels may be found to be insufficient to directly monitor the mRNA levels, e.g., due to small numbers of cells as a result of poor cell growth, or in animal model samples derived from very small tissue biopsies. For such samples, it may be necessary to incorporate message amplification schemes into the methodology.
  • nucleases that digest mass-labeled nucleic acid probes when they are hybridized to a target nucleic acid affords the possibility for linear amplification of signal.
  • the target DNA is single stranded and significantly longer than the probe being used, it is possible to selectively digest only the probe. Digestion of the oligonucleotide probe makes the target strand repeatedly available for multiple rounds of hybridization and digestion. This type of amplification can readily achieve 2 to 3 orders magnitude of amplification.
  • any given study may only monitor a relatively small number of genes, e.g., 20 to 100, it may be possible to use one or a few multiplexed PCRTM reactions to amplify only the targets associated with the probe set.
  • the use of PCRTM or other amplification methods may require the development of additional controls so as to reduce the influence of amplification artifacts.
  • the multiplexing ability of mass-labeled probes makes it easy to include one or more controls.
  • the use of redundant or semi-redundant primers, such as those used in differential display techniques, may also provide an effective amplification route. In all cases where a polymerase is used for amplification, such as Taq DNA polymerase, the 5' to 3' exonuclease activity can be used to digest the probe while amplification continues (Holland et al., 1991).
  • All of the solution phase methods, including methods that utilize partitioning, described above may be utilized as a means for coupling the release of a mass label to the presence of a particular mRNA sequence.
  • Other methods that may be used in amplification of the message population include ligase chain reaction, in vitro transcription of the cDNA population, and variants of methods for producing cDNA libraries, such as single-well polyclonal cDNA plasmid growth.
  • nonvolatile releasable mass labels or involatile releasable mass labels
  • other types of labels can be used as well, such as isotopic mass labels, volatile mass labels (including electrophores), fluorescent labels, and chemiluminescent labels.
  • the methods disclosed herein may also be employed in indirect schemes for identifying the presence of one or more target biomolecules.
  • Indirect schemes such as enzyme-linked immunosorbent assays (ELISAs), provide a method for utilizing substrate conversion to a product molecule via enzymatic turnover of the substrate. Enzymatic catalysis of a substrate leads to the linear amplification of the product's signal.
  • ELISAs enzyme-linked immunosorbent assays
  • the target molecules In an ELISA the target molecules, generally bound to the solid phase, are recognized by an antibody which noncovalently binds to the target.
  • the recognition antibody is conjugated to an enzyme used to catalyze substrate conversion to product.
  • Traditional ELISA techniques utilize small organic molecule substrates that when converted to product by an enzyme, such as alkaline phosphatase, horse-radish peroxidase, or urease, yield a molecule with changed optical qualities, e.g. the solution becomes colored or the product possesses strong fluorescence.
  • the conversion of substrate to product often produces a change in mass, thus the product may act as a mass label that may be detected by mass spectrometry.
  • the amount of product may be quantified either absolutely or relative to the substrate used, with knowledge of enzyme turnover rates and reaction conditions, and used to calculate the amount of a target molecule present in the assay.
  • the target biomolecule could also be a component of a cell that could be bound to the surface of the vessel.
  • the solid-phase target biomolecules are incubated with a target recognition molecule (antibody, ligand, oligonucleotide, etc.) that has a specific affinity for the target biomolecule.
  • This target recognition molecule is conjugated to an enzyme.
  • each target recognition molecule must be covalently linked to an enzyme with a unique catalytic activity for differentiation of the different targets (typical of the "direct” assay protocols).
  • These conjugated target recognition molecules are allowed to bind to the substrate; unbound molecules are removed by washing, then the enzyme substrates are added under conditions in which bound enzyme reacts with its substrate to release a product with a unique mass that is detectable using mass spectrometry.
  • Capture antibodies with high specific binding affinity for the antigens may be needed for soluble antigens.
  • Methods for preparation of specific antibodies for either capture or quantitation of antigens are well established in the literature.
  • Methods for conjugating enzymes to antibodies are also well established and may include crosslinking agents such as glutaraldehyde or conjugation via perioxidate oxidation.
  • Purified DNA restriction enzymes are commercially available. New enzymes with unique catalytic activity may also be engineered using established molecular procedures.
  • classes of enzymes that modify a class of substrates may also be multiplexed.
  • classes of enzymes all recognizing the same substrate but modifying it in different ways may be employed as may enzymes which recognize and modify particular chemically-related substrates, where the variations in structure alter the specificity of particular enzymes for the particular substrate.
  • proteases A class of enzymes all recognizing the same or a few substrates is proteases.
  • proteases recognize different amino acids or amino acid sequence motifs and cleave the amide linkage yielding two or more fragments. Examples of proteases and their specificities include: trypsin, which cleaves at the C-terminal side of both arginine and lysine residues; thrombin, which cleaves at arginine; Glu-C, which cleaves at the C-terminal side of glutamic acid residues; Lys-C, which cleaves at the C-terminal side of lysines; and Asp-N, which cleaves at the N-terminal side of aspartic acid residues.
  • Small polypeptides containing specific amino acids and/or amino acid sequence motifs may be used as substrates for proteolytic digestion.
  • the use of one or a few polypeptides that are recognized and cleaved differently by different proteases sets up a situation where there is a competition for substrate.
  • the use of competitive substrates, and measurements of the relative ratios of different products derived from the same substrate, may provide a more accurate measure of the relative quantities of different target biomolecules.
  • proteases One potential problem with the use of proteases is their possible digestion of antibodies and other proteins required for the bioassay. This problem may be overcome through a variety of means including, careful selection of proteases, selective chemical modification to block proteolysis, and use of protease inhibitors including those that can be competitively displaced by the reaction substrates.
  • proteases may be used on other nonprotein-based assays such as probing for nucleic acid using oligonucleotide probes conjugated to the proteases.
  • Other classes of enzymes that may be used instead of proteases include kinases which phophorylate their substrates and nucleases.
  • Ribonucleases and deoxyribonucleases have varying specificity. Endonucleases such as RNase T1, Rnase U2, and Rnase CL3 , target G, A, and C nucleotides, respectively.
  • small oligonucleotides may be used with nucleases. Nuclease resistant nucleotides, such as phosphorothioates, methylphosphonates, boranophosphates, and peptide nucleic acids can be incorporated into the substrates to direct the specificity of the different nucleases toward yielding unique products. Unlike peptides which can be simply and easily detected by mass spectrometry it may be prefered to modify the oligonucleotides with the addition of polypeptides or other molecules to improve and ease analysis in the mass spectrometer.
  • restriction endonucleases Another class of enzymes is restriction endonucleases.
  • Use of restriction enzymes falls under the second case described above, where substrates may be chemically related but variations in structure alter their specificity as far as to which enzyme in the class will recognize and modify it. In this case the structural alterations are changes in the sequence of the substrates.
  • the substrates themselves are small double-stranded oligonucleotides which contain one or more restriction endonuclease recognition and cleavage sites. Similar to the use of nucleases described above, and as is described in other sections of this invention, it is prefered to modify the oligonucleotides with the addition of polypeptides or other molecules to improve and ease analysis and selectivity in the mass spectrometer.
  • Antibodies are not the only possible target-recognition molecule that may be used in these assays.
  • Polypeptides derived from methods such as phage display with target binding properties, as well as a variety of native proteins that demonstrate some binding activity of interest, may be used instead.
  • Targets may also be something other than proteins and can include a variety of biologically relevant small molecules, including enzyme cofactors, hormones, neurotransmitters, and other biopolymers including polysaccharides and most importantly nucleic acids. Nucleic acid hybridization interactions may be used where both the target and the recognition molecule are comprised of nucleic acids.
  • Nucleic acids and other nonpeptide recognition molecules may be bound to the enzyme involved in substrate conversion covalently via a variety of linkage chemistries, some of which have been described here in the XXX section, or noncovalently through a biotin/avidin linkage where the avidin is conjugated to the substrate conversion enzyme.
  • linkage chemistries some of which have been described here in the XXX section, or noncovalently through a biotin/avidin linkage where the avidin is conjugated to the substrate conversion enzyme.
  • linkage chemistries some of which have been described here in the XXX section
  • avidin is conjugated to the substrate conversion enzyme.
  • One skilled in the art can identify other linking methods.
  • peptide-linked nucleoside 5'-triphosphates involves synthesis and coupling of allylamino-substituted dNTPs.
  • An example is shown in FIG. 6A.
  • 5-(3-aminoallyl)-2'-deoxyuridine 5'-triphosphate (c) was prepared according to the procedure of Langer et al. (1981).
  • Treatment of dUTP (a) with mercuric acetate at pH 5-7 provides the 5-mercurated derivative (b). Allylation in the presence of a palladium catalyst then provided c, which was coupled to the NHS-ester (d) of a suitably protected peptide (lysine and N-terminal amines blocked with FMOC groups).
  • Peptide nucleoside phosphoramidite conjugates were prepared from 5'-protected allylaminonucleosides as shown in FIG. 6B.
  • Selective dimethoxytritylation of uridine (h) provided the 5'-DMT ether (i), that was allylated via the mercurinucleoside with palladium catalyst (Dale et al., 1973; Langer et al., 1981).
  • Treatment of the NHS-ester of a suitably protected peptide and conversion of the conjugate to the phosphoramidite provided the desired compound (k).
  • Oligonucleotide g (FIG. 6C) (SEQ ID NO: 10) was prepared using standard solid-phase phosphoramidite chemistry. The 5'-amino-modification through a disulfide linkage was achieved by sequential addition of Thio-Modifier C6 S-S and Amino-Modifier C6 dT (Glen Research Inc., Sterling, VA) to the 5'-end.
  • the oligonucleotide was coupled to the heterobifunctonal reagent mal-sac-HNSA (Bachem California Inc., Torrance, CA) through the terminal primary amino group, purified by exclusion chromatography, and covalently coupled to a peptide with the sequence CGR GSG K through the N-terminal cysteine thiol.
  • the conjugate was purified by ion-exchange chromatography, and analyzed by MALDI-TOF mass spectrometry (FIG 7X). The peak at m/z 8401 in FIG 7X corresponds to the desired conjugate.
  • a 3' phosphorylated oligonucleotide with the sequence 5'-TGAGGTGCGTGTTTGTGCCTGTp-3' (SEQ ID NO: 1) was synthesized by standard phosphoramidite chemistry.
  • a MALDI mass spectrum of the unconjugated oligonucleotide is shown in FIG. 7A.
  • the 3'-terminal T residue of the oligonucleotide was modified with a primary amino-group that was incorporated during the synthesis as the modified phosphoramidite (C6-amino modifier, Glen Research Inc., Sterling, VA).
  • the oligonucleotide was coupled through the active amino group to a peptide using the hetero-bifunctional coupling reagent mal-sac-HNSA (Bachem Inc., Torrance, CA).
  • the sequence of the peptide used for coupling to the oligonucleotide was CGYGPKKKRKVGG (SEQ ID NO: 2) (Sigma Chemical Co., St. Louis, MO).
  • the reaction to couple the peptide to the oligonucleotide occurs at the reactive thiol group on the N-terminal cysteine residue.
  • the crude coupled product is purified by reversed phase HPLC.
  • oligonucleotide of the sequence 5'-GGT TTA CAT GTT CCA A(aminoT)A TGA T-3' was prepared by standard phosphoramidite chemistry using Amino-Modifier C6 dT (Glen Research Inc., Sterling, VA) to incorporate the internal amino-modification.
  • the oligonucleotide was coupled to the hetrobifunctional reagent mal-sac-HNSA (Bachem Californai Inc., Torrance. CA) through the internal primary amino group, purified by exclusion chromatography, and covalently coupled to a peptide with the sequence CGT RGS GKG TG through the N-terminal cysteine thiol.
  • the conjugate was purified by ion-exchange chromatography, and analyzed by MALDI-TOF mass spectrometry (FIG 7X). The peak at m/z 8075 in FIG 7X corresponds to the desired conjugate.
  • a model system was designed using a synthetic complementary strand as target DNA.
  • a 42-mer was synthesized as a model target, with the sequence 5'-CTCCCAGGACAGGCACAAACACGCACCTCAAAGCTGTTCCGT-3' (SEQ ID NO:3).
  • Detection of the target was based on release of the peptide mass label (SEQ ID NO: 2) from the probe by a digestion with the 3'-5' double-strand-specific exonuclease III with analysis by MALDI-MS.
  • Exonuclease III buffer 66mM Tris-HCl, pH 8.0; 5mM DTT; 6.6mM MgCl 2 ; 50 ⁇ g/mL BSA
  • Exonuclease III USB, Cleveland, OH
  • a I ⁇ L aliquot was added to the annealed target-probe solution.
  • Four controls were included and run simultaneously with the test solution.
  • Control sample A contained both target and probe but no exonuclease III
  • control sample B contained probe and Exonuclease III but no target
  • control sample C contained probe and Exonuclease III together with a random non-complementary 36-mer
  • control sample D contained only Exonuclease III.
  • the mixtures were allowed to incubate for 30 minutes at room temperature.
  • a I ⁇ L aliquot of the solution was removed and added on top of a polycrystalline spot of 2,5-dihydroxybenzoic acid on a MALDI-MS sample plate.
  • the resulting positive-ion mass spectra of the test and control samples A, B and C are shown in FIG. 8A, FIG. 8B, FIG. 8C, and FIG 8D.
  • the relative intensities of the three peaks in the mass spectrum reflect the number of basic (ionizable) functionalities in the three fragments.
  • the largest molecular weight fragment contains two moderately basic histidine residues and is therefore only modestly visible in the spectrum.
  • the middle fragment contains strongly basic lysine and arginine residues and therefore displays an intense peak.
  • the smallest fragment has only the terminal amino-group available for protonation, and is therefore barely detectable in the spectrum.
  • a pair of PCR TM primers for the ribosomal protein L7 gene was synthesized by standard phosphoramidite chemistry with a modified amino-thymidine (Glen Research, Sterlin, VA) incorporated near the 3'-end of each.
  • the sequence of the forward primer was 5'-ATCTGAAGTCAGTAAAT*GAAC-3' (SEQ ID NO:4) and the sequence for the reverse primer was 5'-ATTTACCAGAGAT*CGAG-3' (SEQ ID NO:5), where T* represents the amino-modified thymidine.
  • Each primer was mass-labeled with a unique peptide by a standard coupling reaction between the amino group of the amino-modified thymidine and a sulfhydryl group on the peptide through the heterobifunctional linker mal-SAC-HNSA (Bachem Corp., Torrance CA), and purified by ion-exchange HPLC.
  • the peptide mass label used for the forward primer had the sequence CGYGPKKKRKVGG (SEQ ID NO:2), and for the reverse primer the peptide was CKNLNKDKQVYRATHR (SEQ ID NO:6).
  • a reverse transcription reaction was performed on 10 ⁇ g of total RNA isolated from a stable cancer cell line to generate first strand cDNA.
  • the reaction was performed in a total volume of 20 ⁇ l and contained 0.5 mg of oligo dT 15 primer (SEQ ID NO:9) and 25 units of AMV reverse transcriptase.
  • a PCRTM reaction was performed on 1 ⁇ l of the first strand cDNA using 10 pmol each of the forward and reverse mass-labeled primers and 0.25 units of Taq DNA polymerase in a 10 ⁇ l reaction.
  • the rtPCRTM product was purified through a Microcon-30 ultrafiltration unit (Amicon, Inc., Beverly, MA) according to the manufacturer's directions. After collecting the DNA from the filter unit, it was evaporated to dryness in a vacuum centrifuge and resuspended in 3.5 ⁇ l H 2 O.
  • a digestion reaction using the double-strand specific 5'-3' exonuclease of T7 gene 6 was then performed.
  • To the 3.5 ⁇ l of purified PCRTM product was added 0.5 ⁇ l of 10X buffer (660 mM Tris, pH 8, 6.6mM MgCl 2 ) followed by 1 ⁇ l (5 units) of T7 gene 6 exonuclease (Amersham Inc.).
  • a control digestion was performed at the same time and contained 5 units of enzyme, 5 pmol of free forward primer in an identical buffer.
  • the digestion reactions were allowed to incubate at 37°C for 60 minutes follwed by a heat inactivation of the enzyme (85°C for 15 minutes).
  • Primer A containing a chemically-releasable mass label is synthesized and purified according to the method described in Example 1C.
  • Two synthetic template strands are also synthesized by standard solid phase synthesis techniques.
  • the sequence of Primer A is 5'-LTSS- GTGCTCAAGAACTACATGG -3' (SEQ ID NO: 16) and the sequences for the template strands are 5'-TACTCCAGTTCCATGTAGTTCTTGAGCAC-3' (Template 1T) (SEQ ID NO: 17) and 5'-TACTCCAGTACCATGTAGTTCTTGAGCAC-3' (Template 1A) (SEQ ID NO: 18), where LT indicates the mass label attached to an amino-modified thymidine, SS represents the chemically cleavable disulfide-containing group, and the boldface base designations in the template strands indicate the polymorphic sites adjacent to the 3'-end of the primer.
  • the primer is mass-labeled with a synthetic peptide possessing the sequence CGRGSGK (SEQ ID NO: 19).
  • Two cycle-sequencing reactions are performed. Each reaction contains 2 pmol of mass-labeled Primer A, 100 fmol of either Template 1T or Template 1A, 200 pmol of Biotin-ddUTP (Boehringer-Mannheim, Inc.) and 2.4 units of the thermostable DNA polymerase AmpliTaq-FS (Perkin-Elmer Inc.) in a total volume of 20 ⁇ L. Both reactions are begun using typical hot-start conditions.
  • the reactions are performed according to the following thermal cycling program: denaturing at 90 °C for 30 s, annealing at 50 °C for 10 s, extension at 65 °C for 10 s, for a total of 35 cycles.
  • the sequencing reacions are purified by capturing the extended biotinylated products on streptavidin-coated magnetic beads. The beads are washed to remove unextended primer and then the mass label released by treatment of the bead-bound product with a mild reducing agent to cleave the disulfide bond and release the mass label into solution.
  • Primer B Two primers (Primer B” and “Primer C”) each containing a unique chemically-releasable mass label are synthesized and purified according to the method described in Example 1C.
  • a synthetic template strand for each is also synthesized by standard solid phase synthesis techniques.
  • the sequence of the Primer B is 5'-LTSS-TCGGAGTCAACGGATTTG -3' (SEQ ID NO: 20) and the sequence for the corresponding template strand is 5'-TCCAGTTCTCAAATCCGTTGACTCCGA -3' ("Template 2T”) (SEQ ID NO: 21).
  • Primer C and its template strand (“Template 3T”) have the sequences 5'-LTSS-GATGTCTGTATATGTTGCACTG -3' (SEQ ID NO: 22) and 5'-AAGTTGACTCTCAGTGCAACATATACAGACATC-3' (SEQ ID NO: 23), respectively, where LT, SS, and boldface have the same meanings as described in Example 5.
  • Primer B is mass-labeled with the synthetic peptide CAGGRGGGKGGA (SEQ ID NO: 24) and Primer C with the synthetic peptide CASGRGSGKGSA (SEQ ID NO: 25).
  • a multiplexed cycle-sequencing reaction is performed with Primer A, Primer B, Primer C and each of the corresponding templates.
  • the reaction contains 2 pmol of each mass-labeled primer, 100 fmol each of Template 1T, Template 2T and Template 3T, 200 pmol of Biotin-ddATP (Clonetech, Inc.) and 2.4 units of the thermostable DNA polymerase AmpliTaq-FS (Perkin-Elmer Inc.) in a total volume of 20 ⁇ L.
  • the reaction is begun using typical hot-start conditions and is performed according to the following thermal cycling program: denaturing at 90 °C for 30 s, annealing at 50 °C for 10 s, extension at 65 °C for 10 s, for a total of 35 cycles.
  • the sequencing reaction is purified by capturing the extended biotinylated products on streptavidin-coated magnetic beads. The beads are washed to remove unextended primer and then the mass labels released by treatment of the bead-bound products with a mild reducing agent to cleave the disulfide bonds and release the mass labels into solution.
  • a 1 ⁇ L portion of the supernatant is removed and analysed by MALDI-TOF mass spectrometry (positive ions, 2,5-dihydroxy benzoic acid matrix).
  • MALDI-TOF mass spectrometry positive ions, 2,5-dihydroxy benzoic acid matrix.
  • the resulting mass spectrum showing signals for each of the expected mass-labels with peaks labeled as A, B and C referring to primers A, B, and C respectively is shown in FIG. 18. This demonstrates the potential for performing multiplex SNP analyses utilizing mass-labeled primers.
  • Two cycle-sequencing reactions are performed with primer A and one of either template 1T (SEQ ID NO: 17) or template 1A (SEQ ID NO: 18). Each reaction contains 2 pmol of mass-labeled primer and 100 fmol of template.
  • the triphosphates in each reaction consist of 200 pmol each of Biotin-dCTP (Clonetech, Inc.), dATP and ddTTP.
  • the reactions are performed with 2.4 units of the thermostable DNA polymerase AmpliTaq-FS (Perkin-Elmer Inc.) in a total volume of 20 mL.
  • the reactions are begun using typical hot-start conditions and are performed according to the following thermal cycling program: denaturing at 90 °C for 30 s, annealing at 50 °C for 10 s, extension at 65 °C for 10 s. for a total of 35 cycles.
  • the sequencing reactions are purified by capturing the extended biotinylated products on streptavidin-coated magnetic beads. The beads are washed to remove unextended primer and then the mass labels released by treatment of the bead-bound products with a mild reducing agent to cleave the disulfide bonds and release the mass labels into solution.
  • Two primers related to Primer A and differing only in the identity of the 3'-terminal base are synthesized and mass-labeled according to the method described in Example 1C.
  • the sequence of Primer D is 5'-LTSS- GTGCTCAAGAACTACATGA -3' (SEQ ID NO: 26) and the sequence of Primer E is 5'-LTSS- GTGCTCAAGAACTACATGT -3' (SEQ ID NO: 27), where LT and SS have the meanings described in Example 5.
  • a synthetic template strand (“Template 4A") is also synthesized using standard solid phase synthesis techniques.
  • the sequence of the template strand is 5'-TACTCCAGTTACATGTAGTTCTTGAGCAC-3' (SEQ ID NO: 28), where the boldface indicates the base that varies from Template 1T.
  • Primers D and E are mass-labeled with two unique synthetic peptide that differ from the peptide attached to Primer A.
  • the peptide attached to Primer D is CAGGRGGGKGGA (SEQ ID NO: 29), while the peptide attached to primerE is CASGRGSGKGSA (SEQ ID NO: 30).
  • Two cycle-sequencing reactions are performed. Each reaction contains 2 pmol each of mass-labeled Primer A, Primer D, and Primer E, 100 fmol of either Template 1T or Template 4A, 200 pmol of Biotin-ddATP (Clonetech, Inc.) and 2.4 units of the thermostable DNA polymerase AmpliTaq-FS (Perkin-Elmer Inc.) in a total volume of 20 ⁇ L. Both reactions are begun using typical hot-start conditions. The reactions are performed according to the following thermal cycling program: denaturing at 90 °C for 30 s, annealing at 60 °C for 10 s, extension at 65 °C for 10 s, for a total of 35 cycles.
  • the sequencing reacions are purified by capturing the extended biotinylated products on streptavidin-coated magnetic beads.
  • the beads are washed to remove unextended primer and then the mass label released by treatment of the bead-bound product with a mild reducing agent to cleave the disulfide bond and release the mass label into solution.
  • a 1 ⁇ L portion of the supernatant is removed and analysed by MALDI-TOF mass spectrometry (positive ions, 2.5-dihydroxy benzoic acid matrix).
  • MALDI-TOF mass spectrometry positive ions, 2.5-dihydroxy benzoic acid matrix
  • primer E When primer E is perfectly matched to the template, the predominant mass label signal seen in the mass spectrum is that from primer E. Likewise when primer A is perfectly matched to the template in the reaction, the predominant mass label signal seen in the mass spectrum is from primer A.
  • primer A When primer E is perfectly matched to the template in the reaction, the predominant mass label signal seen in the mass spectrum is from primer A.
  • a chemically-cleavable oligonucleotide probe (SEQ ID NO: 31) containing a bridging 5'-S-P phosphodiester linkage in the backbone is synthesized by standard solid phase synthesis techniques incorporating a modified phosphoramidite reagent at the site of cleavage as described in PCT Patent Application WO 96/37630.
  • the sequence of the 25-mer probe is 5'-CCTGGCAAACTCAACTAGGC(sT)GTCC-3' (SEQ ID NO: 31), where sT indicates the cleavage site.
  • a complementary 35-mer oligonucleotide with the sequence 5'-GATCCGGACAGCCTAGTTGAGTTTGC-CAGGTAAGA-3' (SEQ ID NO: 32) is likewise synthesized.
  • the probe and complement are hybridized together to form a duplex DNA in 1M triethylammonium acetate buffer by heating a mixture of 10 pmol each at 95 °C for 3 min followed by a 10 min incubation at 70 °C and a subsequent 50 °C 10 min incubation. The mixture is allowed to come to room temperature and AgNO 3 is added to a final concentration of 0.14 mM. The silver promoted cleavage reaction is allowed to proceed for 60 min at room temperature (20 °C) after which the reaction is quenched by the addition of excess dithiothreitol. After evaporation of the sample, 3-HPA MALDI matrix solution is added to redissolve the DNA.
  • the solution is spotted onto the mass spectrometer sample plate and analyzed.
  • the resulting mass spectrum and a mass spectrum of a no-complement control cleavage are shown in FIG. 21A and FIG. 21B, respectively.
  • the spectrum of the control reaction shows that under the conditions used, the single-stranded oligonucleotide goes to about 90% complete cleavage, while the spectrum of the double-stranded form shows that under identical conditions not more than about 5% cleavage occurs.
  • This demonstrates the potential use a chemical cleavage reagent to diminiscrate between hybridized and unhybridized probes for release of mass label.
  • a pair of PCR primers for the ribosomal protein L7 gene is synthesized by standard phosphoramidite chemistry.
  • the forward primer contained at the 5'-end an extension which is the promoter region of T7 RNA polymerase.
  • the sequence of the forward primer is 5'-TAATACGACTCACTATAGGGAGACTGCTGAGGATTGTA-GAGC-3' (SEQ ID NO: 33) and the sequence for the reverse primer is 5'-TCCAACAGTATAGATCTCATG-3' (SEQ ID NO: 34).
  • a pair of probes is also synthesized, each containing unique mass labels. The probes are designed such that each hybridizes to a different strand of the PCR product while only one of them hybridizes to a strand of transcribed RNA.
  • the peptide mass label used for the upper-strand probe had the sequence CGYGPKKKRKVGG (SEQ ID NO: 35), and for the lower-strand (RNA-specific) probe the peptide was CKNLNKDKQVYRATHRB (SEQ ID NO: 36).
  • the synthesis of the mass-labeled probes is described in Example 1E.
  • a reverse transcription reaction was performed on 10 ⁇ g of total RNA isolated from a stable cancer cell line to generate first strand cDNA.
  • the reaction was performed in a total volume of 20 ⁇ L and contained 0.5 ⁇ g of oligo dT0 primer and 25 units of AMV reverse transcriptase.
  • a PCR reaction was performed on 1 ⁇ L of the first strand cDNA using 10 pmol each of the T7-forward and reverse primers and 1 unit of Taq DNA polymerase in a 20 ⁇ L reaction.
  • a two microliter aliquot of the RT-PCR product is then used for a 20 microliter transcription reaction which contains 100 units of T7 RNA polymerase, 20 units of RNAsin inhibitor and 1 mM concentration of each rNTP.
  • the transcription reaction is allowed to proceed at 37 °C for 2 h.
  • One microliter of the transcription reaction product is then probed using 5 pmol each of the two strand specific probes above.
  • As a control one microliter of the RT-PCR product is used instead of the transcription reaction product.
  • the probes and targets are hybridized in 1X exonuclease III buffer by heating the mixture to 95 °C for 3 min, then incubating at 65 °C for 1 min then cooling to 37 °C.
  • Exonuclease III is then added to the mixture and the digestion is allowed to proceed at 37°C for 1 h. A 1 ⁇ L portion of the supernatant was removed and analysed by MALDI-TOF mass spectrometry (positive ions, 2,5-dihydroxy benzoic acid matrix). The resulting mass spectra of the digested RNA transcription product and control are shown in FIG. 22A and FIG. 22B respectively. Only the RNA-strand specific probe mass label signal is seen in the transcription reaction sample while both probe mass label signals are seen when the RT-PCR product is probed.
  • RNA-strand specific probe produces a signal in the mass spectrum when RNA transcript is present, together with the fact that signals from both probes should be seen if the signal were resulting only from residual RT-PCR product, shows that the enzyme exonuclease III can be used to specifically digest a probe hybridized to an RNA transcript to release a mass label.
  • a 2 pmol portion of each of the mass-labeled primers Primer A and Primer C is treated with a mild reducing agent to cleave the molecule at the disulfide bond to yield separate peptide and DNA fragments.
  • a 1 microliter portion is spotted onto the mass spectrometer sample plate with the matrix 2,5-dihydroxybenzoic acid, and a second 1 microliter portion is spotted with the matrix 3-HPA.
  • the mass spectrum for Primer C obtained with 2,5-dihydroxybenzoic acid is shown in FIG. 23A and shows a strong peptide signal with only very weak, poorly resolved signal at the expected mass of the DNA fragment. In contrast, the mass spectrum obtained with 3-HPA (FIG.
  • FIG. 23B shows a strong, sharp signal for the DNA fragment and a weaker signal for the peptide fragment.
  • the corresponding spectra obtained for primer A are shown in FIG. 23C (2,5-DHB) and FIG. 23D (3-HPA).
  • a model system based on ELISA technology was designed.
  • This assay incorporates a DNA restriction enzyme for the digestion of a mass-labeled substrate that is ultimately detected by mass spectrometry.
  • This example describes a antibody-sandwich ELISA to detect soluble antigens.
  • ELISA are described in Ausubel et al., (1997).
  • Synthesis of the probe is described in Example 1.
  • Double-stranded probe is prepared by hybridization of complementary oligonucleotides.
  • Standard solutions of antigen T are prepared for calibration of the assay (1-1000 ng/mL.
  • Anti-T Specific capture antibodies
  • Anti T-EcoRI a target recognition molecule crosslinked to the restriction enzyme EcoRI
  • compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Adhesives Or Adhesive Processes (AREA)

Claims (110)

  1. Composé pour la détection d'une molécule cible, le composé comprenant un marqueur de libération comprenant Rx, M et Re, dans lequel :
    Rx représente un groupe réactif qui interagit avec la molécule cible et qui est choisi entre une protéine, un peptide, un polypeptide, un lipide, un stéroïde, un antibiotique et la néocarzinostatine ;
    M représente un marqueur de masse non volatil, un marqueur de masse non volatil étant un composé comprenant un biopolymère qui comprend un ou plusieurs motifs monomères dont au moins l'un comprend un nucléoside, qui, lorsqu'il est présent sous sa forme pure et homogène et est chauffé, ne se sublime pas à l'état intact à un quelconque degré significatif, et qui est détectable par spectrométrie de masse ; et
    Re représente un groupe de libération qui libère le marqueur de masse du marqueur de libération.
  2. Composé suivant la revendication 1, dans lequel le biopolymère comprend une pluralité de motifs monomères comprenant chacun un nucléoside.
  3. Composé suivant la revendication 2, dans lequel le biopolymère comprend en outre un ou plusieurs motifs monomères, choisis séparément et indépendamment dans le groupe consistant en un aminoacide et un saccharide.
  4. Composé suivant la revendication 2, dans lequel le biopolymère comprend en outre une pluralité de motifs monomères comprenant chacun un aminoacide.
  5. Composé suivant la revendication 1, dans lequel le biopolymère comprend une pluralité de motifs monomères dont chacun comprend un nucléoside.
  6. Composé suivant la revendication 1, dans lequel le marqueur de masse comprend un polymère synthétique.
  7. Composé suivant la revendication 6, dans lequel le polymère synthétique comprend le polyéthylèneglycol, le polyvinylphénol, le polypropylèneglycol, le poly(méthacrylate de méthyle) et leurs dérivés.
  8. Composé suivant la revendication 7, dans lequel le polymère synthétique comprend le polyéthylèneglycol.
  9. Composé suivant la revendication 1, dans lequel le groupe de libération comprend une entité de liaison clivable chimiquement.
  10. Composé suivant la revendication 9, dans lequel l'entité de liaison clivable chimiquement comprend une liaison disulfure, un groupe clivable chimiquement incorporé à un squelette phosphate, ou un groupe de liaison clivable chimiquement.
  11. Composé suivant la revendication 10, dans lequel l'entité de liaison clivable chimiquement comprend en outre un groupement clivable par un acide, une base, une oxydation, une réduction ou la chaleur.
  12. Composé suivant la revendication 10, dans lequel le groupe clivable chimiquement est incorporé à un squelette phosphate.
  13. Composé suivant la revendication 12, dans lequel le groupe clivable chimiquement comprend un groupe phosphorothioate ou phosphoramidate.
  14. Composé suivant la revendication 10, dans lequel l'entité de liaison clivable chimiquement comprend une liaison glycosidique.
  15. Composé suivant la revendication 10, dans lequel l'entité de liaison clivable chimiquement comprend une liaison disulfure.
  16. Composé suivant la revendication 1, dans lequel le polypeptide est choisi dans le groupe consistant en une enzyme, un récepteur et une hormone.
  17. Composé suivant la revendication 16, dans lequel le polypeptide comprend une enzyme.
  18. Composé suivant la revendication 1, dans lequel Rx et Re sont identiques.
  19. Composé suivant la revendication 1, dans lequel Re est présent dans Rx.
  20. Composé suivant la revendication 1, dans lequel Re est clivable par une enzyme.
  21. Composé suivant la revendication 20, dans lequel Re représente une liaison phosphodiester ou peptidique.
  22. Composé suivant la revendication 1, dans lequel plus d'un marqueur de masse est incorporé.
  23. Composé suivant la revendication 1, dans lequel le marqueur de masse a un poids moléculaire supérieur à environ 500 Daltons.
  24. Méthode pour détecter une molécule cible, ladite méthode comprenant les étapes consistant :
    (a) à fournir une sonde comprenant un groupe réactif, un groupe de libération et une marqueur de masse non volatil, un marqueur de masse non volatil étant une molécule qui, lorsqu'elle est présente sous sa forme homogène pure et est chauffée, ne se sublime pas à l'état intact à un quelconque degré significatif ;
    (b) à amplifier une molécule d'acide nucléique cible ;
    (c) à mettre en contact la molécule d'acide nucléique cible amplifiée avec la sonde pour produire un complexe sonde:molécule d'acide nucléique cible amplifiée ;
    (d) à libérer sélectivement le marqueur de masse du complexe sonde: molécule d'acide nucléique cible amplifiée ; et
    (e) à déterminer la masse du marqueur de masse par spectrométrie de masse MALDI.
  25. Méthode suivant la revendication 24, dans laquelle le groupe réactif et le groupe de libération sont identiques.
  26. Méthode suivant la revendication 24, dans laquelle le groupe de libération est présent dans le groupe réactif.
  27. Méthode suivant la revendication 24, dans laquelle la sonde comprend au moins deux marqueurs de masse ayant des masses différentes.
  28. Méthode suivant la revendication 24, dans laquelle la molécule d'acide nucléique cible amplifiée comprend une molécule bicaténaire, chaque brin ayant une extrémité 3' et une extrémité 5', ladite molécule bicaténaire contenant un mésappariement et les extrémités 3' n'étant pas capables d'être dirigées par une exonucléase.
  29. Méthode suivant la revendication 28, comprenant en outre : le clivage d'au moins un brin de la molécule bicaténaire au niveau du mésappariement ; et la libération sélective du marqueur de masse par digestion du brin clivé avec une exonucléase 3' à 5'.
  30. Méthode suivant la revendication 29, dans laquelle le mésappariement est clivé par une enzyme.
  31. Méthode suivant la revendication 30, dans laquelle l'enzyme comprend l'endonucléase VII de T4.
  32. Méthode suivant la revendication 29, dans laquelle le mésappariement est clivé par un agent chimique.
  33. Méthode suivant la revendication 32, dans laquelle l'agent chimique comprend KMnO4.
  34. Méthode suivant la revendication 29, dans laquelle l'exonucléase 3' à 5' comprend l'exonucléase III.
  35. Méthode suivant la revendication 24, dans laquelle le marqueur de masse est libéré sélectivement par une enzyme.
  36. Méthode suivant la revendication 35, dans laquelle l'enzyme comprend une nucléase.
  37. Méthode suivant la revendication 36, dans laquelle la nucléase comprend une endonucléase de restriction.
  38. Méthode suivant la revendication 36, dans laquelle la nucléase comprend une exonucléase.
  39. Méthode suivant la revendication 38, dans laquelle l'exonucléase est choisie dans le groupe consistant en l'exonucléase III et l'endonucléase VII de T4.
  40. Méthode suivant la revendication 38, dans laquelle l'exonucléase est spécifique d'un ADN bicaténaire.
  41. Méthode suivant la revendication 40, dans laquelle la libération sélective du marqueur de masse se produit par hybridation de la sonde à la molécule cible amplifiée et digestion par une nucléase du complexe sonde:molécule d'acide nucléique cible amplifiée.
  42. Méthode suivant la revendication 38, dans laquelle l'exonucléase est spécifique de l'ADN monocaténaire.
  43. Méthode suivant la revendication 24, dans laquelle le groupe de libération comprend une entité de liaison clivable chimiquement.
  44. Méthode suivant la revendication 43, dans laquelle l'entité de liaison clivable chimiquement comprend une liaison disulfure, un groupe clivable chimiquement incorporé à un squelette phosphate, ou un groupe de liaison clivable chimiquement.
  45. Méthode suivant la revendication 44, dans laquelle l'entité de liaison clivable chimiquement comprend en outre un groupement clivable par un acide, une base, une oxydation, une réduction ou la chaleur.
  46. Méthode suivant la revendication 45, dans laquelle l'entité de liaison clivable chimiquement comprend une liaison disulfure.
  47. Méthode suivant la revendication 24, dans laquelle le groupe de libération est situé dans un groupe réactif et le groupe réactif est un oligonucléotide.
  48. Méthode suivant la revendication 47, dans laquelle la libération sélective du marqueur de masse est inhibée par la présence d'un oligonucléotide bicaténaire au niveau dudit groupe de libération.
  49. Méthode suivant la revendication 48, dans laquelle la mise en contact de la sonde avec la molécule d'acide nucléique cible amplifiée a pour résultat la présence du groupe de libération dans une région monocaténaire.
  50. Méthode suivant la revendication 49, dans laquelle le groupe de libération comprend un groupe de libération clivable chimiquement.
  51. Méthode suivant la revendication 50, dans laquelle le groupe de libération clivable chimiquement comprend un groupe phosphorothioate ou phosphoramidate.
  52. Méthode suivant la revendication 49, dans laquelle le groupe de libération est clivable par une nucléase spécifique des brins simples.
  53. Méthode suivant la revendication 24, dans laquelle la molécule d'acide nucléique cible comprend un groupe fonctionnel capable d'être immobilisé sur un support solide.
  54. Méthode suivant la revendication 53, dans laquelle le groupe fonctionnel comprend la biotine.
  55. Méthode suivant la revendication 53, dans laquelle la molécule d'acide nucléique cible amplifiée est immobilisée sur le support solide et n'importe quelle sonde ne faisant pas partie d'un complexe sonde:molécule d'acide nucléique cible amplifiée est éliminée par lavage.
  56. Méthode suivant la revendication 24, dans laquelle le groupe réactif comprend un polynucléotide ou oligonucléotide.
  57. Méthode suivant la revendication 56, dans laquelle le groupe réactif comprend en outre un nucléotide ou un oligonucléotide ajouté après hybridation à la molécule d'acide nucléique cible amplifiée.
  58. Méthode suivant la revendication 57, dans laquelle le nucléotide est ajouté par une polymérase.
  59. Méthode suivant la revendication 57, dans laquelle l'oligonucléotide est ajouté par une ligase.
  60. Méthode suivant la revendication 57, dans laquelle le nucléotide ou l'oligonucléotide comprend en outre un groupe fonctionnel capable d'être immobilisé sur un support solide.
  61. Méthode suivant la revendication 60, dans laquelle le groupe fonctionnel comprend la biotine.
  62. Méthode suivant la revendication 60, comprenant en outre :
    (a) l'immobilisation du groupe réactif sur le support solide après addition du nucléotide ou de l'oligonucléotide ; et
    (b) l'élimination de n'importe quelle sonde ayant des groupes réactifs non liés avant la libération de leurs marqueurs de masse.
  63. Méthode suivant la revendication 24, dans laquelle la molécule d'acide nucléique cible amplifiée est mise en contact avec une pluralité de sondes.
  64. Méthode suivant la revendication 63, dans laquelle chaque groupe réactif est associé à un marqueur de masse unique.
  65. Méthode suivant la revendication 63, dans laquelle chaque groupe réactif est associé à une série unique de marqueurs de masse.
  66. Méthode suivant la revendication 64, dans laquelle le marqueur de masse de libération comprend une série unique de marqueurs de masse.
  67. Méthode suivant la revendication 65, dans laquelle chaque marqueur de masse dans la série de marqueurs de masse est fixé à la même sonde.
  68. Méthode suivant la revendication 65, dans laquelle chaque marqueur de masse dans la série de marqueurs de masse est fixé à une sonde différente.
  69. Méthode suivant la revendication 65, dans laquelle la molécule d'acide nucléique cible amplifiée est immobilisée sur un support solide.
  70. Méthode suivant la revendication 68, dans laquelle une pluralité de molécules d'acide nucléique cible amplifiées est immobilisée sur le support solide à des emplacements espacés.
  71. Méthode suivant la revendication 70, dans laquelle le groupe réactif comprend un polynucléotide ou un oligonucléotide.
  72. Méthode suivant la revendication 66, dans laquelle les acides nucléiques cibles comprennent de l'ARNm ou de l'ADNc de premier brin.
  73. Méthode suivant la revendication 66, dans laquelle les acides nucléiques cibles comprennent des produits acides nucléiques amplifiés.
  74. Méthode suivant la revendication 73, dans laquelle les produits acides nucléiques amplifiés sont produits par PCR, rtPCR, LCR, Qbeta Replicase, SDA, CPR, TAS, NASBA ou des cycles multiples de transcription d'ARN ou une certaine de leurs combinaisons.
  75. Méthode suivant la revendication 66, dans laquelle la pluralité d'acides nucléiques cibles est obtenue par amplification d'une sous-catégorie d'un ensemble d'ARNm.
  76. Méthode suivant la revendication 75, dans laquelle au moins une sonde est capable d'être immobilisée sur un support solide.
  77. Méthode suivant la revendication 75, dans laquelle au moins un produit acide nucléique amplifié est capable d'être immobilisé sur un support solide.
  78. Méthode suivant la revendication 24, dans laquelle le marqueur de masse libéré est désorbé sélectivement d'une matrice organique pour produire des marqueurs de masse désorbés.
  79. Méthode suivant la revendication 78, dans laquelle la matrice organique comprend l'acide 2,5-dihydroxybenzoïque.
  80. Méthode suivant la revendication 24, dans laquelle la sonde est incorporée au produit acide nucléique amplifié au cours du procédé d'amplification pour produire des molécules de marqueur de masse incorporées et des molécules de marqueurs de masse non incorporées.
  81. Méthode suivant la revendication 80, dans laquelle les molécules sont des amorces oligonucléotidiques.
  82. Méthode suivant la revendication 80, dans laquelle les molécules sont des nucléoside-triphosphates.
  83. Méthode suivant la revendication 80, dans laquelle les produits acides nucléiques amplifiés sont produits par PCR, rtPCT, LCR, Qbeta Replicase, SDA, CPR, TAS, NASBA ou des cycles multiples de transcription d'ARN ou une certaine de leur combinaisons.
  84. Méthode suivant la revendication 83, dans laquelle les produits nucléiques amplifiés sont produits par PCR ou rtPCR.
  85. Méthode suivant la revendication 80, dans laquelle le marqueur de masse est libéré par une enzyme.
  86. Méthode suivant la revendication 85, dans laquelle l'enzyme comprend une nucléase.
  87. Méthode suivant la revendication 86, dans laquelle la nucléase comprend une endonucléase de restriction.
  88. Méthode suivant la revendication 86, dans laquelle la nucléase comprend une exonucléase.
  89. Méthode suivant la revendication 88, dans laquelle l'exonucléase est spécifique de l'ADN bicaténaire.
  90. Méthode suivant la revendication 89, dans laquelle l'exonucléase est choisie dans le groupe consistant en l'exonucléase III et l'endonucléase VII de T4.
  91. Méthode suivant la revendication 80, dans laquelle le groupe de libération comprend une entité de liaison clivable chimiquement.
  92. Méthode suivant la revendication 91, dans laquelle l'entité de liaison clivable chimiquement comprend une liaison disulfure, un groupe clivable chimiquement incorporé à un squelette phosphate, ou un groupe de liaison clivable chimiquement.
  93. Méthode suivant la revendication 92, dans laquelle l'entité de liaison clivable chimiquement comprend en outre un groupement clivable par un acide, une base, une oxydation, une réduction ou la chaleur.
  94. Méthode suivant la revendication 93, dans laquelle le groupement clivable chimiquement est incorporé à un squelette phosphate.
  95. Méthode suivant la revendication 94, dans laquelle le groupement clivable chimiquement comprend un groupement phosphorothioate ou phosphoramidate.
  96. Méthode suivant la revendication 93, dans laquelle l'entité de liaison clivable chimiquement comprend une liaison glycosidique.
  97. Méthode suivant la revendication 93, dans laquelle l'entité de liaison clivable chimiquement comprend une liaison disulfure.
  98. Méthode suivant la revendication 24, dans laquelle le complexe sonde:molécule d'acide nucléique cible amplifiée est soumis à une modification de masse en fixant un nucléotide ou oligonucléotide à la sonde pour produire un marqueur de masse à masse modifiée.
  99. Méthode suivant la revendication 24, dans laquelle le groupe réactif est capable de s'hybrider à un acide nucléique cible contenant un site de polymorphisme de nucléotide unique et, dans laquelle l'identité du nucléotide au niveau du site de polymorphisme de nucléotide unique correspond à la masse du marqueur de masse libéré.
  100. Méthode suivant la revendication 99, dans laquelle la sonde est obtenue par hybridation du groupe réactif à l'acide nucléique cible pour produire un complexe groupe réactif:acide nucléique cible et extension du groupe réactif par addition d'un ou plusieurs nucléotides ajoutés.
  101. Méthode suivant la revendication 100, dans laquelle au moins un nucléotide ajouté est soumis à un marquage de masse.
  102. Méthode suivant la revendication 99, comprenant en outre une série de sondes comprenant une région invariante et une région variante, dans laquelle la région invariante est capable de s'hybrider à une région immédiatement adjacente à un site de polymorphisme de nucléotide unique et dans laquelle au moins un membre de la série de sondes contient une région variable complémentaire du nucléotide au niveau du site de polymorphisme de nucléotide unique.
  103. Méthode suivant la revendication 99, dans laquelle une pluralité de sondes, chacune comprenant un groupe réactif capable de s'hybrider à un acide nucléique cible contenant un site de polymorphisme de nucléotide unique, est obtenue.
  104. Méthode suivant la revendication 103, dans laquelle la pluralité de sondes est hybridée à une pluralité d'acides nucléiques cibles.
  105. Méthode suivant la revendication 103, dans laquelle une ou plusieurs sondes sont obtenues par hybridation d'un groupe réactif à un acide nucléique cible pour produire un complexe groupe réactif:acide nucléique cible et extension du groupe réactif par addition d'un ou plusieurs nucléotides ajoutés.
  106. Méthode suivant la revendication 105, dans laquelle au moins un nucléotide ajouté est soumis à un marquage de masse.
  107. Méthode suivant la revendication 103, comprenant en outre une série de sondes ayant une région invariante et une région variante, dans laquelle la région invariante est capable de s'hybrider à une région immédiatement adjacente à un site de polymorphisme de nucléotide unique et dans laquelle au moins un membre de la série de sondes contient une région variable complémentaire du nucléotide au niveau du site de polymorphisme de nucléotide unique.
  108. Méthode suivant la revendication 24, dans laquelle la sonde comprend un acide nucléique bicaténaire avec un brin complémentaire et un brin à masse marquée, et dans laquelle le brin à masse marquée comprend en outre le marqueur de masse et le groupe de libération ;
    la molécule d'acide nucléique cible amplifiée est une cible monocaténaire qui, par contact avec la sonde bicaténaire, produit un complexe brin complémentaire:molécule d'acide nucléique cible et un brin monocaténaire à masse marquée ; et
    l'acide nucléique cible monocaténaire correspond à la masse du marqueur de masse libéré.
  109. Méthode suivant la revendication 108, dans laquelle la molécule d'acide nucléique cible monocaténaire est mise en contact avec une pluralité de sondes bicaténaires et, dans laquelle chaque groupe réactif de la sonde bicaténaire est associé à une série unique de marqueurs de masse.
  110. Composé suivant la revendication 16, dans lequel l'hormone comprend un oestrogène, une hormone progestative ou un androgène.
EP97954072A 1996-12-10 1997-12-10 Molecules d'etiquetage massique, non volatiles et liberables Expired - Lifetime EP0963443B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3303796P 1996-12-10 1996-12-10
US33037P 1996-12-10
US4671997P 1997-05-16 1997-05-16
US46719P 1997-05-16
PCT/US1997/022639 WO1998026095A1 (fr) 1996-12-10 1997-12-10 Molecules d'etiquetage massique, non volatiles et liberables

Publications (3)

Publication Number Publication Date
EP0963443A1 EP0963443A1 (fr) 1999-12-15
EP0963443A4 EP0963443A4 (fr) 2002-03-20
EP0963443B1 true EP0963443B1 (fr) 2006-03-08

Family

ID=26709207

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97954072A Expired - Lifetime EP0963443B1 (fr) 1996-12-10 1997-12-10 Molecules d'etiquetage massique, non volatiles et liberables

Country Status (8)

Country Link
US (4) US6635452B1 (fr)
EP (1) EP0963443B1 (fr)
JP (1) JP2001524808A (fr)
AT (1) ATE319855T1 (fr)
AU (1) AU5794498A (fr)
CA (1) CA2274587A1 (fr)
DE (1) DE69735445T2 (fr)
WO (1) WO1998026095A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9714937B2 (en) 2009-10-13 2017-07-25 Nanostring Technologies, Inc. Protein detection via nanoreporters

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
US7285422B1 (en) * 1997-01-23 2007-10-23 Sequenom, Inc. Systems and methods for preparing and analyzing low volume analyte array elements
US6699668B1 (en) 1997-01-15 2004-03-02 Xzillion Gmbh & Co. Mass label linked hybridisation probes
NZ501919A (en) * 1997-07-22 2001-11-30 Qiagen Genomics Inc Methods for analyzing nucleic acid molecules utilizing mass spectroscopy readable tags
GB9718921D0 (en) 1997-09-05 1997-11-12 Brax Genomics Ltd Catalytically generated mass labels
NZ503289A (en) * 1997-09-15 2002-11-26 Xzillion Gmbh & Co Kg Characterising nucleic acid fragments by mass spectrometry
US6335432B1 (en) * 1998-08-07 2002-01-01 Bio-Red Laboratories, Inc. Structural analogs of amine bases and nucleosides
JP3345401B2 (ja) 1998-08-25 2002-11-18 ユニバーシティ オブ ワシントン 複合した混合物中のタンパク質またはタンパク質機能の迅速定量分析
US6270976B1 (en) 1998-09-15 2001-08-07 Brax Group Limited Characterizing nucleic acid by mass spectrometry
US6197510B1 (en) * 1998-10-01 2001-03-06 Bio-Id Diagnostic Inc. Multi-loci genomic analysis
DE19854196C2 (de) * 1998-11-24 2001-03-15 Xerion Pharmaceuticals Gmbh Verfahren zur Modifikation und Identifikation funktioneller Stellen in Proteinen
US6629040B1 (en) 1999-03-19 2003-09-30 University Of Washington Isotope distribution encoded tags for protein identification
US6403309B1 (en) 1999-03-19 2002-06-11 Valigen (Us), Inc. Methods for detection of nucleic acid polymorphisms using peptide-labeled oligonucleotides and antibody arrays
AU6770800A (en) * 1999-08-13 2001-03-13 Yale University Analysis of sequence tags with hairpin primers
GB0006141D0 (en) 2000-03-14 2000-05-03 Brax Group Ltd Mass labels
WO2001073118A2 (fr) * 2000-03-29 2001-10-04 Lgc (Teddington) Limited Balise d'hybridation et methode de detection et discrimination rapides de sequences
US7998673B2 (en) * 2000-03-29 2011-08-16 Lgc Limited Hybridisation beacon and method of rapid sequence detection and discrimination
CA2302827A1 (fr) * 2000-04-12 2001-10-12 Michelle Furtado Denaturation de l'hybridation d'oligonucleotides et d'adn sur des surfaces
AU6689401A (en) 2000-06-12 2001-12-24 Univ Washington Selective labeling and isolation of phosphopeptides and applications to proteomeanalysis
AU2001283056A1 (en) * 2000-07-27 2002-02-13 California Institute Of Technology A rapid, quantitative method for the mass spectrometric analysis of nucleic acids for gene expression and genotyping
CA2419159A1 (fr) 2000-08-11 2002-02-21 Agilix Corporation Systemes de detection ultrasensibles
JP2004506897A (ja) * 2000-08-14 2004-03-04 アイシス　イノベーション　リミティド 質量分析
WO2002018632A2 (fr) 2000-09-01 2002-03-07 Epigenomics Ag Procede de determination du degre de methylation de cytosines determinees d'adn genomique dans le contexte sequentiel 5'-cpg-3'
US20060057565A1 (en) * 2000-09-11 2006-03-16 Jingyue Ju Combinatorial fluorescence energy transfer tags and uses thereof
US9708358B2 (en) 2000-10-06 2017-07-18 The Trustees Of Columbia University In The City Of New York Massive parallel method for decoding DNA and RNA
JP2004510433A (ja) 2000-10-06 2004-04-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Ｄｎａおよびｒｎａを解読するための大量並行方法
WO2002034948A2 (fr) * 2000-10-25 2002-05-02 City Of Hope Analyse du mesappariement dans une region candidate dans le genotypage et la detection de mutations
AU2002245047A1 (en) * 2000-10-30 2002-07-24 Sequenom, Inc. Method and apparatus for delivery of submicroliter volumes onto a substrate
US20020090652A1 (en) * 2000-12-22 2002-07-11 Fu Emil Wei-Ming Inverse labeling method for the rapid identification of marker/target proteins
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
US20030027135A1 (en) 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US20040121311A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in livestock
US20030036057A1 (en) * 2001-03-09 2003-02-20 Andreas Braun Genes and polymorphisms associated with cardiovascular disease and their use
US20040038206A1 (en) * 2001-03-14 2004-02-26 Jia Zhang Method for high throughput assay of genetic analysis
EP1950305A1 (fr) 2001-05-09 2008-07-30 Monsanto Technology, LLC Gènes tyr et utilisations associées
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
AU2002319613A1 (en) * 2001-07-19 2003-03-03 Signet Laboratories, Inc. Human tissue specific drug screening procedure
JP4290003B2 (ja) * 2001-09-14 2009-07-01 エレクトロフォレティクス リミテッド 質量標識体
US8154093B2 (en) 2002-01-16 2012-04-10 Nanomix, Inc. Nano-electronic sensors for chemical and biological analytes, including capacitance and bio-membrane devices
US8152991B2 (en) 2005-10-27 2012-04-10 Nanomix, Inc. Ammonia nanosensors, and environmental control system
US20080193490A1 (en) * 2002-02-14 2008-08-14 Andreas Hirsch Use of Carbon Nanotube for Drug Delivery
US20040241173A1 (en) * 2002-02-14 2004-12-02 William Marsh Rice University Fullerene (C60) vancomycin conjugates as improved antibiotics
TW200307563A (en) * 2002-02-14 2003-12-16 Sixty Inc C Use of BUCKYSOME or carbon nanotube for drug delivery
US20040166152A1 (en) * 2002-02-14 2004-08-26 Andreas Hirsch Use of buckysome or carbon nanotube for drug delivery
US7714398B2 (en) * 2002-09-05 2010-05-11 Nanomix, Inc. Nanoelectronic measurement system for physiologic gases and improved nanosensor for carbon dioxide
EP1501863A4 (fr) * 2002-05-03 2007-01-24 Sequenom Inc Muteines de proteines d'ancrage de kinase, leurs peptides, et procedes associes
US20030215816A1 (en) * 2002-05-20 2003-11-20 Narayan Sundararajan Method for sequencing nucleic acids by observing the uptake of nucleotides modified with bulky groups
US7948041B2 (en) 2005-05-19 2011-05-24 Nanomix, Inc. Sensor having a thin-film inhibition layer
US7074597B2 (en) * 2002-07-12 2006-07-11 The Trustees Of Columbia University In The City Of New York Multiplex genotyping using solid phase capturable dideoxynucleotides and mass spectrometry
JP2006516193A (ja) 2002-12-06 2006-06-29 アイシス・ファーマシューティカルス・インコーポレーテッド ヒトおよび動物における病原体の迅速な同定方法
WO2004055160A2 (fr) * 2002-12-13 2004-07-01 The Trustees Of Columbia University In The City Of New York Methodes de couplage biomoleculaire par cycloaddition 1,3-dipolaire
CN101245376A (zh) 2003-01-17 2008-08-20 香港中文大学 作为妊娠相关病症的诊断标志物的循环mRNA
US7195751B2 (en) 2003-01-30 2007-03-27 Applera Corporation Compositions and kits pertaining to analyte determination
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
WO2004109254A2 (fr) * 2003-06-06 2004-12-16 Ionwerks Matrices maldi a base de fullerene pour peptides et proteines
US20120122101A1 (en) 2003-09-11 2012-05-17 Rangarajan Sampath Compositions for use in identification of bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
JP2007505323A (ja) * 2003-09-12 2007-03-08 ナノミックス・インコーポレーテッド 二酸化炭素用ナノ電子センサー
FR2860006B1 (fr) * 2003-09-24 2006-12-22 Commissariat Energie Atomique Dispositif pour separer et/ou analyser plusieurs cibles moleculaires en solution dans un melange complexe
JP2005140755A (ja) * 2003-11-10 2005-06-02 Japan Science & Technology Agency 質量分析用プローブ及びそれを用いた質量分析方法
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US20050148087A1 (en) 2004-01-05 2005-07-07 Applera Corporation Isobarically labeled analytes and fragment ions derived therefrom
US20050178959A1 (en) * 2004-02-18 2005-08-18 Viorica Lopez-Avila Methods and compositions for assessing a sample by maldi mass spectrometry
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US7595155B2 (en) 2004-02-27 2009-09-29 Hitachi Chemical Research Center Multiplex detection probes
WO2005084367A2 (fr) * 2004-03-03 2005-09-15 The Trustees Of Columbia University In The City Of New York Nucleotides fluorescents photoclivables destines a sequencer de l'adn sur une puce construite par chimie de couplage specifique au site
WO2006073436A2 (fr) * 2004-04-29 2006-07-13 The Trustees Of Columbia University In The City Of New York Pcr a marqueur de masse permettant de proceder a un diagnostic multiplex
US20080206737A1 (en) * 2004-05-19 2008-08-28 Hunter Christie L Expression quantification using mass spectrometry
US20070054345A1 (en) * 2004-05-19 2007-03-08 Hunter Christie L Expression quantification using mass spectrometry
EP1756307A1 (fr) * 2004-05-20 2007-02-28 Trillion Genomics Limited Utilisation de sondes a etiquettes de masse aux fins de detection d'acides nucleiques cibles au moyen de la spectrometrie de masse
ES2641832T3 (es) 2004-05-24 2017-11-14 Ibis Biosciences, Inc. Espectrometría de masas con filtración de iones selectiva por establecimiento de umbrales digitales
US20050266411A1 (en) 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
US7785843B2 (en) 2004-06-23 2010-08-31 Sequenom, Inc. Target-specific compomers and methods of use
US7928207B2 (en) * 2004-06-28 2011-04-19 Roche Molecular Systems, Inc Synthesis and compositions of nucleic acids comprising 2′-terminator nucleotides
US20070048752A1 (en) 2004-07-12 2007-03-01 Applera Corporation Mass tags for quantitative analyses
US20060172319A1 (en) * 2004-07-12 2006-08-03 Applera Corporation Mass tags for quantitative analyses
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
DK2299275T3 (en) 2004-07-30 2018-05-07 Adeza Biomedical Corp Classification of oncofetal fetronectin level for pregnancy-related indications
JP5249581B2 (ja) 2004-08-09 2013-07-31 ジェネレイション バイオテック リミテッド ライアビリティ カンパニー 核酸の単離および増幅方法
US20060183238A1 (en) 2005-02-09 2006-08-17 Applera Corporation Amine-containing compound analysis methods
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US8182992B2 (en) 2005-03-03 2012-05-22 Ibis Biosciences, Inc. Compositions for use in identification of adventitious viruses
US20070020650A1 (en) * 2005-04-01 2007-01-25 Avak Kahvejian Methods for detecting proteins
US7326772B2 (en) * 2005-05-12 2008-02-05 Penta Biotech, Inc. Peptide for assaying hERG channel binding
ATE528644T1 (de) * 2005-06-07 2011-10-15 Centre Nat Rech Scient Verwendung ionischer matrizen zur analyse von gewebeabschnitten durch maldi-massenspektrometrie
US9169510B2 (en) * 2005-06-21 2015-10-27 The Trustees Of Columbia University In The City Of New York Pyrosequencing methods and related compositions
US8785130B2 (en) 2005-07-07 2014-07-22 Bio-Id Diagnostic Inc. Use of markers including nucleotide sequence based codes to monitor methods of detection and identification of genetic material
EP1904655A2 (fr) 2005-07-21 2008-04-02 Isis Pharmaceuticals, Inc. Procedes pour l'identification et la quantification rapide de variants d'acide nucleique
GB0515323D0 (en) 2005-07-26 2005-08-31 Electrophoretics Ltd Mass labels
CA2630544A1 (fr) * 2005-11-21 2007-05-31 The Trustees Of Columbia University In The City Of New York Immunocapture numerique multiplex utilisant une bibliotheque de marqueurs de masse photoclivable
US8460879B2 (en) 2006-02-21 2013-06-11 The Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution
US11237171B2 (en) 2006-02-21 2022-02-01 Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution
EP2007379A4 (fr) * 2006-04-04 2009-12-09 Nanomix Inc Detection nanoelectronique de biomolecules en employant l'amplification des analytes et des rapporteurs
US8088582B2 (en) 2006-04-06 2012-01-03 Ibis Biosciences, Inc. Compositions for the use in identification of fungi
US9150906B2 (en) 2006-06-28 2015-10-06 Bio-Id Diagnostic Inc. Determination of variants produced upon replication or transcription of nucleic acid sequences
US20090002703A1 (en) * 2006-08-16 2009-01-01 Craig Edward Parman Methods and systems for quantifying isobaric labels and peptides
AU2007353877B2 (en) 2006-09-14 2012-07-19 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
GB2457402B (en) 2006-12-01 2011-10-19 Univ Columbia Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators
US7902345B2 (en) * 2006-12-05 2011-03-08 Sequenom, Inc. Detection and quantification of biomolecules using mass spectrometry
US8133701B2 (en) * 2006-12-05 2012-03-13 Sequenom, Inc. Detection and quantification of biomolecules using mass spectrometry
WO2008086813A2 (fr) * 2007-01-19 2008-07-24 Kobenhavns Universitet Peptides dérivés de protéines de la superfamille de l'insuline
WO2008104002A2 (fr) 2007-02-23 2008-08-28 Ibis Biosciences, Inc. Procédé d'analyse d'adn médico-légale rapide
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use
GB0709799D0 (en) * 2007-05-22 2007-06-27 Micromass Ltd Mass spectrometer
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US20090097022A1 (en) * 2007-08-24 2009-04-16 Dynamic Throughput Inc. Discovery tool with integrated microfluidic biomarker optical detection array device and methods for use
US7952705B2 (en) * 2007-08-24 2011-05-31 Dynamic Throughput Inc. Integrated microfluidic optical device for sub-micro liter liquid sample microspectroscopy
US9404150B2 (en) 2007-08-29 2016-08-02 Sequenom, Inc. Methods and compositions for universal size-specific PCR
EP2201374B1 (fr) * 2007-08-30 2015-10-07 Trustees Of Tufts College Procédés pour déterminer la concentration d'un analyte dans une solution
US8278057B2 (en) 2007-09-14 2012-10-02 Nestec S.A. Addressable antibody arrays and methods of use
WO2009039122A2 (fr) 2007-09-17 2009-03-26 Sequenom, Inc. Dispositif de transfert d'échantillon robotique intégré
EP2940029B1 (fr) 2007-10-19 2023-11-29 The Trustees of Columbia University in the City of New York Conception et synthèse de nucléotides fluorescents clivables comme terminateurs réversibles pour le séquençage de l'adn par synthèse
EP2209911B1 (fr) 2007-10-19 2013-10-16 The Trustees of Columbia University in the City of New York Séquençage d'adn avec des terminateurs réversibles nucléotidiques non fluorescents et des terminateurs nucléotidiques modifiés par un marqueur séparable et un composé de déoxyinosine contenant un terminateur réversible
JP2011511933A (ja) * 2008-01-07 2011-04-14 ダイナミック スループット インコーポレイテッド 一体型マイクロ流体バイオマーカー光学検出アレイデバイスを用いた発見ツールおよび使用方法
GB0809488D0 (en) 2008-05-23 2008-07-02 Electrophoretics Ltd Mass spectrometric analysis
EP2347254A2 (fr) 2008-09-16 2011-07-27 Ibis Biosciences, Inc. Unités de traitement d'échantillons, systèmes et procédés associés
EP2349549B1 (fr) 2008-09-16 2012-07-18 Ibis Biosciences, Inc. Cartouches de mélange, postes de mélange et kits, et système associé
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US20100075862A1 (en) * 2008-09-23 2010-03-25 Quanterix Corporation High sensitivity determination of the concentration of analyte molecules or particles in a fluid sample
US20100075439A1 (en) * 2008-09-23 2010-03-25 Quanterix Corporation Ultra-sensitive detection of molecules by capture-and-release using reducing agents followed by quantification
US8222047B2 (en) 2008-09-23 2012-07-17 Quanterix Corporation Ultra-sensitive detection of molecules on single molecule arrays
EP2180065A1 (fr) * 2008-10-24 2010-04-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Procédé pour la réduction du poids moléculaire d'au moins un produit de PCR pour sa détection tout en conservant son identité
US20120046178A1 (en) * 2008-10-30 2012-02-23 Sequenom, Inc. Products and processes for multiplex nucleic acid identification
US8158936B2 (en) 2009-02-12 2012-04-17 Ibis Biosciences, Inc. Ionization probe assemblies
US9719083B2 (en) 2009-03-08 2017-08-01 Ibis Biosciences, Inc. Bioagent detection methods
EP2409150B1 (fr) * 2009-03-18 2016-09-14 Nestec S.A. Réseaux d'anticorps adressables et procédés d'utilisation
WO2010114842A1 (fr) 2009-03-30 2010-10-07 Ibis Biosciences, Inc. Systèmes, dispositifs et procédés de détection d'agent biologique
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
EP2454000A4 (fr) 2009-07-17 2016-08-10 Ibis Biosciences Inc Systèmes pour l'identification d'un bioagent
US9416409B2 (en) 2009-07-31 2016-08-16 Ibis Biosciences, Inc. Capture primers and capture sequence linked solid supports for molecular diagnostic tests
EP3098325A1 (fr) 2009-08-06 2016-11-30 Ibis Biosciences, Inc. Compositions de base déterminée sans masse pour la détection d'acide nucléique
JP2013501921A (ja) 2009-08-07 2013-01-17 ナノミックス・インコーポレーテッド 磁性炭素ナノチューブに基づく生体検出
US8810417B2 (en) * 2009-08-28 2014-08-19 The Invention Science Fund I, Llc Beverage immersate with detection capability
US9024766B2 (en) * 2009-08-28 2015-05-05 The Invention Science Fund, Llc Beverage containers with detection capability
EP2957641B1 (fr) 2009-10-15 2017-05-17 Ibis Biosciences, Inc. Amplification de déplacement multiple
CA2791655C (fr) 2010-03-01 2014-11-04 Quanterix Corporation Procedes et systemes pour etendre la plage dynamique dans des dosages pour la detection de molecules ou de particules
US8415171B2 (en) 2010-03-01 2013-04-09 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
US8236574B2 (en) 2010-03-01 2012-08-07 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US9678068B2 (en) 2010-03-01 2017-06-13 Quanterix Corporation Ultra-sensitive detection of molecules using dual detection methods
WO2011115840A2 (fr) 2010-03-14 2011-09-22 Ibis Biosciences, Inc. Recherche de parasites par le biais de la recherche d'endosymbiotes
ES2676183T3 (es) 2010-07-02 2018-07-17 Ventana Medical Systems, Inc. Detección de dianas usando marcas de masa y espectrometría de masas
US9952237B2 (en) 2011-01-28 2018-04-24 Quanterix Corporation Systems, devices, and methods for ultra-sensitive detection of molecules or particles
WO2012142301A2 (fr) 2011-04-12 2012-10-18 Quanterix Corporation Procédé de détermination d'un protocole de traitement et/ou d'un pronostic de rétablissement d'un patient à la suite d'un traumatisme cérébral
WO2012143010A1 (fr) 2011-04-19 2012-10-26 Dako Denmark A/S Nouveau procédé d'amplification de signal à médiation enzymatique
CN103717751A (zh) 2011-05-19 2014-04-09 塞昆纳姆股份有限公司 用于多重核酸鉴定的产品和方法
US9624539B2 (en) 2011-05-23 2017-04-18 The Trustees Of Columbia University In The City Of New York DNA sequencing by synthesis using Raman and infrared spectroscopy detection
US20140305230A1 (en) * 2011-11-22 2014-10-16 Purdue Research Foundation Sample deposition chamber for laser-induced acoustic desorption (liad) foils
WO2013130683A2 (fr) 2012-02-27 2013-09-06 Amunix Operating Inc. Compositions de conjugués xten et leurs procédés de préparation
US9932626B2 (en) 2013-01-15 2018-04-03 Quanterix Corporation Detection of DNA or RNA using single molecule arrays and other techniques
WO2014144883A1 (fr) 2013-03-15 2014-09-18 The Trustees Of Columbia University In The City Of New York Molecules marquees par des amas de raman destinees a l'imagerie biologique
US10281468B2 (en) * 2014-02-28 2019-05-07 Dh Technologies Development Pte. Ltd. Microbial identification and quantitation using MS cleavable tags
US10656157B2 (en) * 2014-09-24 2020-05-19 Purdue Research Foundation Rare event detection using mass tags
DE112015005283B4 (de) 2014-12-29 2023-02-02 Hitachi High-Tech Corporation Analysenverfahren und Analysenvorrichtung
CN104845967B (zh) 2015-04-15 2020-12-11 苏州新海生物科技股份有限公司 寡聚核苷酸片段及使用其的选择性扩增目标核酸序列变异体的方法及应用
EP3286328B1 (fr) 2015-04-24 2020-10-21 Agena Bioscience, Inc. Méthodes multiplex pour la detection et la quantification de variants mineurs
US10233489B2 (en) 2015-04-24 2019-03-19 Agena Bioscience, Inc. Multiplexed method for the identification and quantitation of minor alleles and polymorphisms
GB201510850D0 (en) 2015-06-19 2015-08-05 Cambridge Molecular Diagnositcs Ltd Nucleic acid amplification and detection assays
KR20230132628A (ko) 2015-07-07 2023-09-15 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
EP3325650B1 (fr) 2015-07-17 2024-01-03 Nanostring Technologies, Inc. Quantification simultanée de l'expression génique dans une région définie par l'utilisateur d'un tissu en coupe transversale
ES2975361T3 (es) 2015-07-17 2024-07-04 Nanostring Technologies Inc Cuantificación simultánea de una pluralidad de proteínas en una región definida por el usuario de un tejido seccionado transversalmente
WO2017139419A1 (fr) * 2016-02-11 2017-08-17 Qiagen Waltham, Inc. Additifs polyphénoliques dans le séquençage par synthèse
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
KR102443358B1 (ko) 2017-12-06 2022-09-14 어비디티 바이오사이언시스 인크. 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
SG11202007501SA (en) 2018-02-12 2020-09-29 Nanostring Technologies Inc Biomolecular probes and methods of detecting gene and protein expression
WO2020131759A1 (fr) 2018-12-19 2020-06-25 Roche Diagnostics Gmbh Nucléotides protégés en 3'
CA3172111A1 (fr) 2020-03-19 2021-09-23 Barbora MALECOVA Compositions et methodes de traitement d'une dystrophie musculaire facio-scapulo-humerale
JP2024535797A (ja) 2021-09-16 2024-10-02 アビディティー バイオサイエンシーズ，インク． 顔面肩甲上腕型筋ジストロフィーを処置する組成物および方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027327A2 (fr) * 1996-01-23 1997-07-31 Rapigene, Inc. Procedes et compositions permettant de detecter la fixation de deux elements d'une paire de ligands par marquage non fluorescent

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3553452A (en) 1969-02-17 1971-01-05 Us Air Force Time-of-flight mass spectrometer operative at elevated ion source pressures
CH543306A (de) 1971-10-13 1973-10-31 Hoffmann La Roche Mikropipettiergerät
US3776700A (en) 1971-12-08 1973-12-04 Linbro Chem Co Inc Serial dilution apparatus
US3931516A (en) 1974-08-30 1976-01-06 Nasa Moving particle composition analyzer
CH583460A5 (fr) 1974-09-30 1976-12-31 Balzers Patent Beteilig Ag
US4230797A (en) 1975-04-28 1980-10-28 Miles Laboratories, Inc. Heterogenous specific binding assay employing a coenzyme as label
US4178359A (en) 1976-10-12 1979-12-11 Hoffmann-La Roche Inc. Immunoassay method
SE404553B (sv) 1977-03-04 1978-10-09 Pharmacia Diagnostics Ab Sett vid bestemningsmetoder involverande biospecifika affinitetsreaktioner
US4139346A (en) 1977-11-28 1979-02-13 Enzo Bio Chem Incorporated Nucleic acid and protein binding paper
US4218539A (en) 1978-03-24 1980-08-19 Weltman Joel K Enzyme conjugates and method of preparation and use
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4461328A (en) 1982-06-04 1984-07-24 Drummond Scientific Company Pipette device
US5198540A (en) 1982-10-28 1993-03-30 Hubert Koster Process for the preparation of oligonucleotides in solution
US5059654A (en) 1983-02-14 1991-10-22 Cuno Inc. Affinity matrices of modified polysaccharide supports
US4515781A (en) 1983-02-23 1985-05-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 2',5'-Riboadenylate-morpholinoadenylate nucleotides
JPS59161398A (ja) 1983-03-02 1984-09-12 Mitsui Toatsu Chem Inc デオキシリボ核酸の切断処理方法及び装置
US4554839A (en) 1983-10-14 1985-11-26 Cetus Corporation Multiple trough vessel for automated liquid handling apparatus
JPS60119067A (ja) 1983-11-30 1985-06-26 Shimadzu Corp 飛行時間型質量分析装置
US4733073A (en) 1983-12-23 1988-03-22 Sri International Method and apparatus for surface diagnostics
US4582789A (en) 1984-03-21 1986-04-15 Cetus Corporation Process for labeling nucleic acids using psoralen derivatives
US4957858A (en) 1986-04-16 1990-09-18 The Salk Instute For Biological Studies Replicative RNA reporter systems
US4849077A (en) 1984-08-06 1989-07-18 Akademie Der Wissenschaften Der Ddr Process for solid phase-sequencing of nucleic acid fragments
US4629689A (en) 1984-08-29 1986-12-16 Allied Corporation Binding assay with amplified read-out and gas-phase detection
US4594506A (en) 1984-09-10 1986-06-10 Nicolet Instrument Corporation Gas chromatograph/mass spectrometer interface
US4952518A (en) 1984-10-01 1990-08-28 Cetus Corporation Automated assay machine and assay tray
US4775619A (en) 1984-10-16 1988-10-04 Chiron Corporation Polynucleotide determination with selectable cleavage sites
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5118605A (en) * 1984-10-16 1992-06-02 Chiron Corporation Polynucleotide determination with selectable cleavage sites
US4604363A (en) 1984-10-18 1986-08-05 Analytical Bio-Chemistry Laboratories Inc. Automatic evaporator system
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US5221518A (en) 1984-12-14 1993-06-22 Mills Randell L DNA sequencing apparatus
US5064754A (en) * 1984-12-14 1991-11-12 Mills Randell L Genomic sequencing method
US4818681A (en) 1985-02-22 1989-04-04 Molecular Diagnostics, Inc. Fast and specific immobilization of nucleic acids to solid supports
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8515276D0 (en) 1985-06-17 1985-07-17 Amersham Int Plc Nucleic acid sequencing
US4663944A (en) 1985-07-12 1987-05-12 Cornell Research Foundation, Inc. Cryogenic sample stage for an ion microscope
US4806546A (en) 1985-09-30 1989-02-21 Miles Inc. Immobilization of nucleic acids on derivatized nylon supports
US4935357A (en) 1986-02-05 1990-06-19 New England Biolabs, Inc. Universal restriction endonuclease
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5108703A (en) 1986-03-26 1992-04-28 Beckman Instruments, Inc. Automated multi-purpose analytical chemistry processing center and laboratory work station
US5000921A (en) 1986-10-24 1991-03-19 Hanaway Richard W Multiple pipette samples
US4877745A (en) 1986-11-17 1989-10-31 Abbott Laboratories Apparatus and process for reagent fluid dispensing and printing
US5175209A (en) 1987-01-06 1992-12-29 Baylor College Of Medicine Porous wafer for segmented synthesis of biopolymers
US4779467A (en) 1987-01-28 1988-10-25 Rainin Instrument Co., Inc. Liquid-end assembly for multichannel air-displacement pipette
US5149625A (en) 1987-08-11 1992-09-22 President And Fellows Of Harvard College Multiplex analysis of DNA
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
CA1323293C (fr) 1987-12-11 1993-10-19 Keith C. Backman Essai utilisant la reorganisation d'une sonde a l'acide nucleique dependant d'une matrice
US5670381A (en) 1988-01-29 1997-09-23 Abbott Laboratories Devices for performing ion-capture binding assays
CA1340807C (fr) 1988-02-24 1999-11-02 Lawrence T. Malek Procede d'amplification d'une sequence d'acide nucleique
SE8801070D0 (sv) 1988-03-23 1988-03-23 Pharmacia Ab Method for immobilizing a dna sequence on a solid support
US5174962A (en) 1988-06-20 1992-12-29 Genomyx, Inc. Apparatus for determining DNA sequences by mass spectrometry
US5003059A (en) 1988-06-20 1991-03-26 Genomyx, Inc. Determining DNA sequences by mass spectrometry
US4925629A (en) 1988-07-28 1990-05-15 Bioquant, Inc. Diagnostic device
FR2636738B1 (fr) 1988-09-20 1992-12-11 Commissariat Energie Atomique Procede et installation de sequencage de l'adn
SE464595B (sv) 1988-09-29 1991-05-13 Ffv Aerotech Ab Saett att med ett peltier-element med tvaa ytor bestaemma den ena eller baada ytornas temperatur
US5496562A (en) 1988-10-05 1996-03-05 Flinders Technologies Pty Ltd Solid medium and method for DNA storage
US5766847A (en) 1988-10-11 1998-06-16 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Process for analyzing length polymorphisms in DNA regions
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5237016A (en) 1989-01-05 1993-08-17 Siska Diagnostics, Inc. End-attachment of oligonucleotides to polyacrylamide solid supports for capture and detection of nucleic acids
EP0378384B1 (fr) 1989-01-13 1993-05-26 Hitachi, Ltd. Assemblages de combustibles nucléaires
US4920264A (en) 1989-01-17 1990-04-24 Sri International Method for preparing samples for mass analysis by desorption from a frozen solution
ES2083978T3 (es) 1989-02-01 1996-05-01 Asahi Glass Co Ltd Mezcla azeotropica o similar a una mezcla azeotropica a base de hidrocarburos hidrogenados, clorados y fluorados.
US5075217A (en) 1989-04-21 1991-12-24 Marshfield Clinic Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences
US5582979A (en) 1989-04-21 1996-12-10 Marshfield Clinic Length polymorphisms in (dC-dA)n.(dG-dT)n sequences and method of using the same
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
GB2233654A (en) 1989-07-07 1991-01-16 Nat Res Dev Immobilised polynucleotides
GB2236186B (en) 1989-08-22 1994-01-05 Finnigan Mat Gmbh Process and device for laser desorption of analyte molecular ions, especially of biomolecules
US5262128A (en) 1989-10-23 1993-11-16 The United States Of America As Represented By The Department Of Health And Human Services Array-type multiple cell injector
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
CA2036946C (fr) 1990-04-06 2001-10-16 Kenneth V. Deugau Molecules de liaison pour indexation
HU218095B (hu) 1990-05-01 2000-05-28 Amgen Inc. Eljárás átvitt szennyeződések csökkentésére, amplifikációs eljárásokban
US5135870A (en) 1990-06-01 1992-08-04 Arizona Board Of Regents Laser ablation/ionizaton and mass spectrometric analysis of massive polymers
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
TW221493B (fr) 1990-07-10 1994-03-01 Cardiovascular Diagnostics Inc
CA2027714C (fr) 1990-07-13 2003-01-28 Kenneth W. Turtletaub Methode de mesure pour les systemes biologiques
DE4024545A1 (de) 1990-08-02 1992-02-06 Boehringer Mannheim Gmbh Verfahren und vorrichtung zum dosierten zufuehren einer biochemischen analysefluessigkeit auf ein target
GB2250858B (en) 1990-10-22 1994-11-30 Kratos Analytical Ltd Charged particle extraction arrangement
DE4036115C2 (de) 1990-11-13 1997-12-11 Max Planck Gesellschaft Verfahren und Einrichtung zur quantitativen nichtresonanten Photoionisation von Neutralteilchen und Verwendung einer solchen Einrichtung
US5210412A (en) 1991-01-31 1993-05-11 Wayne State University Method for analyzing an organic sample
WO1992013629A1 (fr) 1991-01-31 1992-08-20 Wayne State University Procede d'analyse d'un echantillon organique
US5364759B2 (en) 1991-01-31 1999-07-20 Baylor College Medicine Dna typing with short tandem repeat polymorphisms and identification of polymorphic short tandem repeats
US5888819A (en) 1991-03-05 1999-03-30 Molecular Tool, Inc. Method for determining nucleotide identity through primer extension
US5762876A (en) 1991-03-05 1998-06-09 Molecular Tool, Inc. Automatic genotype determination
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US5300774A (en) 1991-04-25 1994-04-05 Applied Biosystems, Inc. Time-of-flight mass spectrometer with an aperture enabling tradeoff of transmission efficiency and resolution
US5378602A (en) 1991-05-29 1995-01-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Highly informative microsatellite repeat polymorphic DNA markers twenty-[seven]six
US5468610A (en) 1991-05-29 1995-11-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Three highly informative microsatellite repeat polymorphic DNA markers
US5853989A (en) 1991-08-27 1998-12-29 Zeneca Limited Method of characterisation of genomic DNA
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
GB2260811B (en) 1991-10-23 1995-07-05 Yorkshire Cancer Research Camp Detection of malignant tumours
US5605662A (en) 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
IL103674A0 (en) 1991-11-19 1993-04-04 Houston Advanced Res Center Method and apparatus for molecule detection
EP1086742B2 (fr) 1991-11-22 2007-03-14 Affymetrix, Inc. (a Delaware Corporation) Stratégies combinatoires pour la synthèse de polymère
DE69322266T2 (de) 1992-04-03 1999-06-02 Perkin-Elmer Corp., Foster City, Calif. Proben zusammensetzung und verfahren
US5325021A (en) 1992-04-09 1994-06-28 Clemson University Radio-frequency powered glow discharge device and method with high voltage interface
US5412083A (en) * 1992-04-16 1995-05-02 Northeastern University Carbohydrate heterobifunctional cross-linking reagent
JPH05308999A (ja) 1992-05-08 1993-11-22 Sumitomo Metal Ind Ltd Ｂ型肝炎ウイルスｐｒｅ−Ｃ変異の判定法
US5710028A (en) 1992-07-02 1998-01-20 Eyal; Nurit Method of quick screening and identification of specific DNA sequences by single nucleotide primer extension and kits therefor
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
DE69304292T2 (de) 1992-11-17 1997-01-02 Univ New York Tetracycline inclusive nicht antimicrobiel wirksame, chemisch modifizierte Tetracycline hemmende exzessive Kollagenquervernetzung bei Diabetes
US5436143A (en) 1992-12-23 1995-07-25 Hyman; Edward D. Method for enzymatic synthesis of oligonucleotides
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US6194144B1 (en) 1993-01-07 2001-02-27 Sequenom, Inc. DNA sequencing by mass spectrometry
CA2115811A1 (fr) 1993-02-17 1994-08-18 Claus Krebber Methode de selection in vivo de proteines fixatrices de ligands
GB9304462D0 (en) 1993-03-04 1993-04-21 Kore Tech Ltd Mass spectrometer
AU687801B2 (en) * 1993-03-19 1998-03-05 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US6074823A (en) 1993-03-19 2000-06-13 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US5399857A (en) * 1993-05-28 1995-03-21 The Johns Hopkins University Method and apparatus for trapping ions by increasing trapping voltage during ion introduction
JPH08501882A (ja) 1993-07-09 1996-02-27 マイクロスキャン、インコーポレイテッド 液体分注装置および方法
GB9315847D0 (en) * 1993-07-30 1993-09-15 Isis Innovation Tag reagent and assay method
RU2041263C1 (ru) 1993-08-11 1995-08-09 Геннадий Моисеевич Ершов Способ микродозирования водных растворов веществ на носитель и устройство для его осуществления
JP3620120B2 (ja) 1995-10-27 2005-02-16 株式会社日立製作所 溶液の質量分析に関する方法と装置
US5439649A (en) 1993-09-29 1995-08-08 Biogenex Laboratories Automated staining apparatus
US5464985A (en) 1993-10-01 1995-11-07 The Johns Hopkins University Non-linear field reflectron
WO1995009688A1 (fr) 1993-10-04 1995-04-13 Hewlett-Packard Company Systeme et procede de preparation d'echantillons
US6017693A (en) 1994-03-14 2000-01-25 University Of Washington Identification of nucleotides, amino acids, or carbohydrates by mass spectrometry
JP3385707B2 (ja) 1994-03-17 2003-03-10 株式会社日立製作所 質量分析装置
US5599666A (en) 1994-03-28 1997-02-04 Promega Corporation Allelic ladders for short tandem repeat loci
US5976798A (en) 1994-03-30 1999-11-02 Mitokor Methods for detecting mitochondrial mutations diagnostic for Alzheimer's disease and methods for determining heteroplasmy of mitochondrial nucleic acid
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5498545A (en) 1994-07-21 1996-03-12 Vestal; Marvin L. Mass spectrometer system and method for matrix-assisted laser desorption measurements
GB9417211D0 (en) 1994-08-25 1994-10-12 Solicitor For The Affairs Of H Nucleotide sequencing method
DE4431174A1 (de) 1994-09-01 1996-03-07 Deutsches Krebsforsch Nachweisverfahren für tumorspezifische mRNA
US6121048A (en) 1994-10-18 2000-09-19 Zaffaroni; Alejandro C. Method of conducting a plurality of reactions
US5985356A (en) 1994-10-18 1999-11-16 The Regents Of The University Of California Combinatorial synthesis of novel materials
DE4438630A1 (de) 1994-10-28 1996-05-02 Katharina Dr Pachmann Selfpriming - ein einfaches und schnelles Verfahren zur Amplifikation von nicht charakterisierten DNA-Abschnitten
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US5688642A (en) 1994-12-01 1997-11-18 The United States Of America As Represented By The Secretary Of The Navy Selective attachment of nucleic acid molecules to patterned self-assembled surfaces
US5601982A (en) 1995-02-07 1997-02-11 Sargent; Jeannine P. Method and apparatus for determining the sequence of polynucleotides
US5609907A (en) 1995-02-09 1997-03-11 The Penn State Research Foundation Self-assembled metal colloid monolayers
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
US5770272A (en) * 1995-04-28 1998-06-23 Massachusetts Institute Of Technology Matrix-bearing targets for maldi mass spectrometry and methods of production thereof
US5625184A (en) 1995-05-19 1997-04-29 Perseptive Biosystems, Inc. Time-of-flight mass spectrometry analysis of biomolecules
US5869240A (en) 1995-05-19 1999-02-09 Perseptive Biosystems, Inc. Methods and apparatus for sequencing polymers with a statistical certainty using mass spectrometry
US5830655A (en) 1995-05-22 1998-11-03 Sri International Oligonucleotide sizing using cleavable primers
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
GB9510699D0 (en) 1995-05-26 1995-07-19 Fisons Plc Apparatus and method for surface analysis
US5654150A (en) 1995-06-07 1997-08-05 President And Fellows Of Harvard College Method of expression cloning
US5589136A (en) 1995-06-20 1996-12-31 Regents Of The University Of California Silicon-based sleeve devices for chemical reactions
US5872010A (en) 1995-07-21 1999-02-16 Northeastern University Microscale fluid handling system
US5626184A (en) 1995-08-24 1997-05-06 Abb Air Preheater, Inc. Sootblower
US6146854A (en) 1995-08-31 2000-11-14 Sequenom, Inc. Filtration processes, kits and devices for isolating plasmids
US5869242A (en) 1995-09-18 1999-02-09 Myriad Genetics, Inc. Mass spectrometry to assess DNA sequence polymorphisms
US5661028A (en) * 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
US5994065A (en) 1995-10-18 1999-11-30 Rapigene, Inc. Methods for preparing solid supports for hybridization and reducing non-specific background
US5716825A (en) 1995-11-01 1998-02-10 Hewlett Packard Company Integrated nucleic acid analysis system for MALDI-TOF MS
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
US6027890A (en) 1996-01-23 2000-02-22 Rapigene, Inc. Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
US5580434A (en) 1996-02-29 1996-12-03 Hewlett-Packard Company Interface apparatus for capillary electrophoresis to a matrix-assisted-laser-desorption-ionization mass spectrometer
EP0886681A1 (fr) 1996-03-04 1998-12-30 Genetrace Systems, Inc. Methodes de criblage des acides nucleiques par spectrometrie de masse
DE19617011C2 (de) 1996-04-27 2000-11-02 Bruker Daltonik Gmbh Matrixkomponentengemisch für die matrixunterstützte Laserdesorption und Ionisierung sowie Verfahren zur Zubereitung eines Matrixkomponentengemisches
DE19618032C2 (de) 1996-05-04 2000-04-13 Bruker Daltonik Gmbh Lagerfähig vorpräparierte Maldi-Probenträger
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6022688A (en) 1996-05-13 2000-02-08 Sequenom, Inc. Method for dissociating biotin complexes
US6083762A (en) 1996-05-31 2000-07-04 Packard Instruments Company Microvolume liquid handling system
DE19628178C1 (de) 1996-07-12 1997-09-18 Bruker Franzen Analytik Gmbh Verfahren zum Beladen von Probenträgern für Massenspektrometer
US5743960A (en) 1996-07-26 1998-04-28 Bio-Dot, Inc. Precision metered solenoid valve dispenser
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5965363A (en) 1996-09-19 1999-10-12 Genetrace Systems Inc. Methods of preparing nucleic acids for mass spectrometric analysis
US5777324A (en) 1996-09-19 1998-07-07 Sequenom, Inc. Method and apparatus for maldi analysis
US5864137A (en) 1996-10-01 1999-01-26 Genetrace Systems, Inc. Mass spectrometer
US5885775A (en) 1996-10-04 1999-03-23 Perseptive Biosystems, Inc. Methods for determining sequences information in polynucleotides using mass spectrometry
US6024925A (en) 1997-01-23 2000-02-15 Sequenom, Inc. Systems and methods for preparing low volume analyte array elements
US6140053A (en) 1996-11-06 2000-10-31 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US7285422B1 (en) * 1997-01-23 2007-10-23 Sequenom, Inc. Systems and methods for preparing and analyzing low volume analyte array elements
US6133436A (en) 1996-11-06 2000-10-17 Sequenom, Inc. Beads bound to a solid support and to nucleic acids
US5900481A (en) 1996-11-06 1999-05-04 Sequenom, Inc. Bead linkers for immobilizing nucleic acids to solid supports
US5854486A (en) 1996-12-27 1998-12-29 R. T. Hodgson Method and apparatus for MALDI mass spectrometry
US5812272A (en) 1997-01-30 1998-09-22 Hewlett-Packard Company Apparatus and method with tiled light source array for integrated assay sensing
US6006171A (en) 1997-07-28 1999-12-21 Vines; Caroline J. Dynamic maintenance management system
US6275231B1 (en) * 1997-08-01 2001-08-14 American Calcar Inc. Centralized control and management system for automobiles
US6207370B1 (en) 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
WO1999014375A2 (fr) 1997-09-19 1999-03-25 Genetrace Systems, Inc. Recherche de type de genes par spectrometrie de masse avec marqueurs de sequences repetees d'adn polymorphes
DE19754978C2 (de) 1997-12-11 2000-07-13 Bruker Daltonik Gmbh Probenträger für die MALDI-Massenspektrometrie nebst Verfahren zur Herstellung der Platten und zum Aufbringen der Proben
US6268131B1 (en) 1997-12-15 2001-07-31 Sequenom, Inc. Mass spectrometric methods for sequencing nucleic acids
US5969350A (en) 1998-03-17 1999-10-19 Comstock, Inc. Maldi/LDI time-of-flight mass spectrometer
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
US6104028A (en) 1998-05-29 2000-08-15 Genetrace Systems Inc. Volatile matrices for matrix-assisted laser desorption/ionization mass spectrometry
US6225061B1 (en) 1999-03-10 2001-05-01 Sequenom, Inc. Systems and methods for performing reactions in an unsealed environment
US20020009394A1 (en) * 1999-04-02 2002-01-24 Hubert Koster Automated process line
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
JP4178359B2 (ja) 2001-05-01 2008-11-12 株式会社ディーエイチシー 美白化粧料

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027327A2 (fr) * 1996-01-23 1997-07-31 Rapigene, Inc. Procedes et compositions permettant de detecter la fixation de deux elements d'une paire de ligands par marquage non fluorescent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9714937B2 (en) 2009-10-13 2017-07-25 Nanostring Technologies, Inc. Protein detection via nanoreporters
US9995739B2 (en) 2009-10-13 2018-06-12 Nanostring Technologies, Inc. Protein detection via nanoreporters

Also Published As

Publication number Publication date
US7132519B2 (en) 2006-11-07
AU5794498A (en) 1998-07-03
CA2274587A1 (fr) 1998-06-18
WO1998026095A1 (fr) 1998-06-18
US6635452B1 (en) 2003-10-21
EP0963443A4 (fr) 2002-03-20
JP2001524808A (ja) 2001-12-04
DE69735445T2 (de) 2006-08-10
ATE319855T1 (de) 2006-03-15
EP0963443A1 (fr) 1999-12-15
US20120046180A1 (en) 2012-02-23
US20040033525A1 (en) 2004-02-19
US20030022225A1 (en) 2003-01-30
US8486623B2 (en) 2013-07-16
DE69735445D1 (de) 2006-05-04

Similar Documents

Publication Publication Date Title
EP0963443B1 (fr) Molecules d'etiquetage massique, non volatiles et liberables
JP6768547B2 (ja) 試験試料の多重化分析
US6436640B1 (en) Use of LNA in mass spectrometry
US7618780B2 (en) Use of mass labelled probes to detect target nucleic acids using mass spectrometry
US6051378A (en) Methods of screening nucleic acids using mass spectrometry
JP2825976B2 (ja) 均質検定システム
US6811977B2 (en) Rapid, quantitative method for the mass spectrometric analysis of nucleic acids for gene expression and genotyping
WO2001059161A2 (fr) Dosages d'analytes utilisant des reseaux universels
JP2002505116A (ja) 機能的アンチセンス因子のスクリーニング
JP2002542838A (ja) 特異的切断および質量分析法の組合せによる診断的配列決定
EP4060053A1 (fr) Procédés hautement sensibles pour la quantification parallèle précise d'acides nucléiques
US20050214796A1 (en) Compositions, methods and detection technologies for reiterative oligonucleotide synthesis
JP5128941B2 (ja) 標的特異的コンポマー及び使用法
WO2007010998A1 (fr) Procédé de détection extrêmement sensible pour molécule cible exploitant une liaison spécifique et kit pour le procédé
US20220025430A1 (en) Sequence based imaging
KR100607901B1 (ko) 분자비콘을 이용한 특정물질의 동정 및 분석방법
US20050239078A1 (en) Sequence tag microarray and method for detection of multiple proteins through DNA methods
WO2000057180A2 (fr) Utilisation d'analogues nucleosidiques bloques en spectrometrie de masse

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990712

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020206

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEQUENOM, INC.

17Q First examination report despatched

Effective date: 20020704

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060308

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20060308

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060308

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060308

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/04 20060101ALI20060116BHEP

Ipc: H01J 49/00 20060101ALI20060116BHEP

Ipc: B01D 59/44 20060101ALI20060116BHEP

Ipc: C12M 1/00 20060101ALI20060116BHEP

Ipc: C12P 19/34 20060101ALI20060116BHEP

Ipc: G01N 33/542 20060101ALI20060116BHEP

Ipc: G01N 33/53 20060101ALI20060116BHEP

Ipc: G01N 15/06 20060101ALI20060116BHEP

Ipc: C12Q 1/68 20060101AFI20060116BHEP

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

REF Corresponds to:

Ref document number: 69735445

Country of ref document: DE

Date of ref document: 20060504

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060608

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060608

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060619

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060808

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20061211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060609

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061210

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: SEQUENOM, INC.

Free format text: SEQUENOM, INC.#3595 JOHN HOPKINS COURT#SAN DIEGO, CALIFORNIA 92121 (US) -TRANSFER TO- SEQUENOM, INC.#3595 JOHN HOPKINS COURT#SAN DIEGO, CALIFORNIA 92121 (US)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20141210

Year of fee payment: 18

Ref country code: DE

Payment date: 20141202

Year of fee payment: 18

Ref country code: CH

Payment date: 20141212

Year of fee payment: 18

Ref country code: IE

Payment date: 20141209

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20141208

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20141211

Year of fee payment: 18

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69735445

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20151210

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20160831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151210

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160701

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151210

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231